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Kraussianone 1 and kraussianone 2 were previously isolated as active compounds from the
roots of Eriosema kraussianum Meisn., a plant used for the treatment of male impotence
and urinary complaints in KwaZulu-Natal. The objectives of this study were firstly, to
develop a method for the analysis of metabolites from E. kraussianum and other Eriosema
plants that are used for erectile dysfunction and secondly, to develop synthetic methods for
kraussianone 1 and structurally related compounds.
A reversed-phase HPLC-PDA method was developed for the analysis of the extracts of
plants from different sources, two of which were authentic E. kraussianum collected from
the Drakensberg and Pietermaritzburg. The roots of other Eriosema species called
ubangalala and uqonsi in Isizulu were also analysed. These plants were bought from the
local herbal traders. The extracts of the two E. kraussianum plants and one uqonsi sample
showed a similar chemical profile, even though there were variations in the relative
concentrations of the metabolites within each plant. In these three plants, kraussianone 1,
the most active metabolite of E. kraussianum, occurred in relatively low quantities,
whereas kraussianone 2 was one of the major constituents.  The other commercial plants
that were analysed contained different compounds from those found in E. kraussianum.
The HPLC method developed herein facilitates rapid identification and relative
quantification of metabolites from E. kraussianum.
Strategies based on semi-synthesis and total synthesis were employed for the preparation
of kraussianone 1. The semi-synthetic route was based on the transformation of the prenyl
side chain of kraussianone 2 into a linear dimethylpyran scaffold fused to the A-ring. Two
routes were investigated for the semi-synthesis of kraussianone 1 from kraussianone 2. In
the first route, the dimethylchromene ring was to be prepared by the acid-catalysed
cyclisation of the prenyl group of kraussianone 2, followed by dehydrogenation of the
resulting dimethylchroman chromophore. This route was abandoned due to poor
regioselectivity of the cyclisation reaction and the difficulty of oxidising the
dimethylchroman scaffold on the phloroglucinol moiety into a dimethylchromene. The
second strategy involved selective protection of the OH-2', followed by DDQ-mediated
iii
oxidative cyclisation of the prenyl group to OH-7. This was the most viable route and
kraussianone 1 was prepared in an overall yield of 54% from kraussianone 2.
The total synthesis of kraussianone 1, on the other hand, employed the Suzuki-Miyaura
reaction for the construction of the isoflavone nucleus and the regioselective introduction
of the dimethylpyran scaffolds to the A- and B-rings. The key precursors in this synthesis
were 3-iodo-5,7-dimethoxymethoxychromone and a boronic acid coupling partner, 7-
benzyloxy-2,2-dimethylchromene-6-boronic acid, already bearing the prerequisite
chromene scaffold attached to the B-ring. The isoflavones genistein, 2-hydroxygenistein,
eriosemaone D and a geranyl analogue of kraussianone 1 were prepared via the route
developed for the total synthesis of kraussianone 1 by structural modifications of rings A
and B.  Furthermore, this synthetic approach was expanded to the synthesis of the
coumarochromones lupinalbin A and lupinalbin H.
The development of the feasible semi-synthetic and total synthetic routes described herein
for kraussianone 1 is of importance for the production of material for an in depth study of
the pharmacological activities and the structure-activity relationship studies of
kraussianone 1 and related compounds.
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A number of important medicinal drugs are derived from natural sources. These include
the antitumour drug taxol from the yew tree (Taxus brevifolia), huperzine A from Qian
Ceng Ta (Huperzia serrata) used for treatment of Alzheimer’s disease and an antimalarial
drug artemisinin from qinghao (Artemisia annua).1 However, the supply of compounds
from their natural sources is often limited and not enough material for intensive tests and
clinic trials is available. Total synthesis, semi-synthesis and structural modification of the
biologically-active compounds from plants play a vital role in the studies of biological
activities of the compounds. It makes structure-activity relationship studies possible,
which in turn lead to the development of compounds with higher activity, improved
physical properties, bioavailability, specificity and lower toxicity.1,2
Our interest is centred on the synthesis of biologically-active isoflavonoids. Isoflavonoids
are secondary metabolites, which occur mostly in leguminous plants.3-6 They consist of
two phenolic rings (A-ring and B-ring), which are linked by a three carbon heterocyclic
ring (C-ring).3-5  They are distinguished from other classes of flavonoids by the position of
attachment of the phenolic B-ring at C-3.3-5 The isoflavonoid framework is established by
enzyme-mediated migration of the aryl B-ring of flavanones.3-5 Further biochemical
transformations of the isoflavone skeleton lead to the formation of advanced subclasses of
isoflavonoids such as pterocarpanoids, coumaronochromones, rotenoids as well as
coumestans as illustrated in Figure 1.1.3,7-9 More complex natural isoflavonoid structures
are attained by the incorporation of additional substituents by C- or O- alkylation and/or
alkenylation (e.g. methylation, prenylation and geranylation), cyclisation of alkyl and
alkenyl side chains to adjacent hydroxy groups and oxidation of additional substituents as
















































Figure 1.1. Major isoflavonoid classes and their biosynthetic precursors3,4,7
The isoflavonoids are frequently referred to as phytoestrogens,10,11 because they are non-
steroidal plant-derived compounds which have the ability to bind to estrogen receptors and
modulate estrogenic responses.10-14 The estrogenic properties of isoflavonoids, particularly
isoflavones, have been extensively studied with regards to health benefits.6,11,12,15 The
consumption of phytoestrogen-rich food has been linked to protection against hormone-
dependent breast cancer and prostate cancer, alleviation of postmenopausal disorders,
osteoporosis as well as cardiovascular protection.11-16 Besides hormonal action, the health
benefits of isoflavonoids have also been attributed to their antioxidant properties, which
involve scavenging of reactive oxygen species and metal chelating capabilities.13,16 Thus,
isoflavonoids have been implicated in protection against neurodegenerative diseases.11-13
Contrary to the health benefits which have been reported in favour of isoflavonoids, some
reports have indicated their potential to trigger adverse health effects, especially when
consumed in large quantities.12-14
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1.2 AIMS AND OBJECTIVES
The aims of this study were:
o To investigate the chemical profile of Eriosema kraussianum Meisn. and other
plants from different sources, which are used for the treatment of male impotence.
o The second objective was to synthesise the pyranoisoflavone kraussianone 1 (1)
and structurally related compounds, for investigation of their pharmacological
properties.
Kraussianone 1 (1) and other related pyranoisoflavonoids were first isolated by Drewes
and co-workers from E. kraussianum, a plant used in a traditional remedy for male
impotence and urinary complaints in KwaZulu-Natal.17 Preliminary studies on the
biological activities of the isolated compounds revealed that 1 and kraussianone 2 (2)
respectively, possess 85% and 65% erectile dysfunction activity compared to sildenafil
(Viagra) (3) (Figure 1.2).17 Moreover, the compounds were determined to exhibit
significant hypoglycaemic and secondary vasorelaxant effects.18 In addition, they
demonstrated improved foetal weights and decreased foetal absorption in a study carried
out on pregnant rats.19 However, the mode of action of the compounds for these activities
is still unknown.17,18 Further biochemical investigations of 1 were limited by the small





















Figure 1.2. Compounds with erectile dysfunction activity
The successful synthesis of kraussianone 1 (1) and related isoflavonoids would enable us
to perform studies leading to the determination of the molecular basis of action of 1 for
erectile dysfunction activity, test the synthesised compounds for other important biological
4
activities as well as unwanted cytotoxicity, and establish structure-activity relationships of
the synthesised compounds.
1.3 ORGANISATION OF THESIS
Following Chapter 1, this thesis is organised into five more chapters. Chapter 2 examines
the HPLC profile of some plants used as aphrodisiacs in KwaZulu-Natal. Chapter 3
presents the synthetic routes employed for the semi-synthesis of kraussianone 1 (1). This is
followed by Chapters 4 and 5, which deal with the development of a strategy for the total
synthesis of pyranoisoflavonoids and its application to the synthesis of natural and
unnatural isoflavonoids. These include the total synthesis of 1 and structural analogues,
discussed in Chapter 4 and the total synthesis of a pyranocoumaronochromone lupinalbin
H and related isoflavonoids in Chapter 5. The overall conclusions drawn from the different
chapters are given in Chapter 6.
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CHAPTER 2
HPLC PROFILE OF PLANTS USED FOR TREATMENT OF ERECTILE
DYSFUNCTION
2.1 INTRODUCTION
Chemical studies on plants used traditionally for treatment of male impotence have
revealed several compounds that offer potential leads for the development of drugs for
erectile dysfunction and associated ailments.1-7 As a result of growing scientific evidence
on potency of plants as aphrodisiacs,2-4,8 there is great interest on commercialisation of
these plants, and formulations of some of the extracts are already on the market as “over-
the-counter” products. However, it has been reported that the relative composition of the
active ingredients vary greatly among plant sources.9,10 These variations are influenced
amongst others by the regions where the plants are grown, the period of harvesting and the
age of the plant.10 Moreover, the metabolites within a plant can manifest synergistic or
antagonist effects.11-15 Therefore, knowledge of the nature, levels and distribution of
compounds within a plant is of outmost importance. Several analytical techniques have
been employed for qualitative and quantitative analysis of plant metabolites to facilitate the
safe and best use of the plant material for medicinal purposes and to guide selection of the
optimal material for commercialisation.9,10,16-18 Furthermore, knowledge of the identity and
content of the plant metabolites helps to ensure consistency of the phytotherapeuticals and
aids in identification of adulterants.10,17
Previous phytochemical studies on the roots of E. kraussianum led to the isolation of seven
prenylated isoflavonoids (1, 2, 4-8) (Figure 2.1).11,19 The stereochemistry of compounds 4-
8 has not been defined. These compounds were tested for erectile dysfunction activity. The
assay was based on the ability of the compounds to relax the corpus cavernosum of rabbits
relative to Viagra.11,19 Two compounds, kraussianone 1 (1) and kraussianone 2 (2), were
found to be the most active compounds, whereas kraussianone 3 (4) and kraussianone 5 (6)
manifested the opposite effect, by contracting muscles.11,19 Our aim was to develop an
analytical method that would facilitate rapid identification and relative quantification of
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metabolites from E. kraussianum. The developed method would then be employed for the
analysis of extracts of E. kraussianum plants from different origins. This would aid in






















































Figure 2.1. Compounds isolated from E. kraussianum
The second objective was to analyse other plants which are also used traditionally for
treatment of male impotence and urinary complaints in KwaZulu-Natal. There are several
plants that are used for male impotence in KwaZulu-Natal. The most common ones are
called iqonsi or uqonsi, uqontsi and ubangalala in Isizulu.20-22 However, there is
considerable overlap in their scientific names. For instance, the name ubangalala is given
to three species of the genus Eriosema, which are E. cordatum E. Mey,21 E. salignum E.
Mey22 and E. distictum N.E.Br. (also called ubangalala omkhulu, meaning large
ubangalala).22 Iqonsi/uqonsi, on the other hand, refers to E. salignum20-22 and uqontsi
refers to E. cordatum (also called uqontsi olukhulu, meaning large uqontsi)20-22 or E.
salignum (uqontsi olucane, meaning small uqontsi).20,22 The roots of these plants are sold
commercially and ubangalala is sold in the form of tablets called Erex™ u'Bangalala.23-25
E. kraussianum is also marketed as a tincture and capsules called Pro-Erex.26
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2.2 IMPOTENCE
Impotence, or erectile dysfunction (ED), refers to the failure to achieve or maintain
erection for satisfying sexual activity. Chronic ED is often associated with health disorders
such as diabetes mellitus, hormonal imbalances, cardiovascular diseases, hypertension,
neurological disorders, disseminated sclerosis, Alzheimer’s disease and dyslipidemia.27,28
Selective phosphodiesterase-5 (PDE-5) inhibitors, sildenafil (Viagra) (3), vardenafil
(Levitra), and tadalafil (Cialis) are currently used as oral anti-impotence drugs.27,29
They manifest this activity via the nitric oxide/cyclic guanosine monophosphate
(NO/cGMP) pathway, which commences with the release of NO from the parasynthetic
nerve endings. The released NO activates the production of cGMP, causing relaxation of
the arteries of the Corpus cavernosum while simultaneously preventing the venous
backward flow of the blood. These result in the increased influx of blood into the penile
tissue and increased pressure that effect stiffening and enlargement of the male sexual
organ. PDE enzymes impede this process by hydrolysing molecules of cGMP. PDE-5
inhibitors therefore promote accumulation of cGMP by preventing its metabolism, leading
to a prolonged erection.27,30,31 However, they cannot stimulate production of nitric oxide,
and they are reported to be incompatible with nitrate medications which are often
prescribed for patients with diabetes, hypertension, hyperlipedemia or ischemic heart
disease, conditions associated with ED.32,33 Furthermore, they are reported to cause some
side effects due to interference with other types of phosphodiesterases.32
The continuing search for anti-impotence drugs with maximal efficacy has revealed several
potential drug leads of natural origin which can overcome the shortcomings of PDE-5
inhibitors via the NO/cGMP pathway or via hormonal action. A good example is the
development of an icariin analogue 10 with enhanced PDE-5 inhibitory potency over the
parent compound icariin (9), and higher selectivity for PDE-5 enzymes than Viagra (3).1
Icariin (9) is an active component isolated from Epemedium brevicornum Maxim.1 Also,
ferutinin (11), a phytoestrogen34 from Ferula hermonis Boiss., has been reported to boost
the levels of gonadotropin in the blood stream of male rats.35 However, Zanoli and
colleagues report both positive and negative sexual effects of ferutinin (11) with respect to
duration of administration on potent rats, but most importantly, it is reported to increase
levels of testosterone in impotent rats.36 Similarly, Tribulus terrestris L., through its active













































In certain instances, the anti-impotence activity of plant extracts is attributed to the
protection and restoration of the penile vascular endothelial cells via antioxidative and
radical scavenging effects. For example, experiments on non-insulin-dependent diabetes
mellitus (NIDDM) rats suggest that Korean red ginseng restores sexual potency in NIDDM
rats via antioxidative activity.38
More recently, the human Corpus cavernosum smooth muscle tissue has been found to
produce a novel neurotransmitter H2S, which facilitates erectile function.
39,40 A statement
was made that ‘‘scientists believe that this discovery could lead to the development of a
new class of drugs to combat erectile dysfunction by affecting a different biochemical
pathway to the one targeted by Viagra’’ (Cape Times 3/5/2009).41 As a result of this
finding, H2S-donating PDE-5 inhibitors have been developed.
42 The biochemical study of
these compounds proves them to be as potent as PDE-5 inhibitors in promoting erection.
However, unlike classical PDE-5 inhibitors, these compounds have the additional effect of
preventing oxidative stress.42
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2.3 THE GENUS ERIOSEMA
The genus Eriosema DC.Desv. (Leguminosae) consists of erect or climbing subshrubs or
herbs, which occur in tropical and subtropical areas. There are 130 species belonging to
this genus and 46 of them originate from Southern Africa.43,44 The plants in this genus
possess leaves with 1 or 3 foliolate and leaflets that often have small glands underneath.
The flowers are reflexed, have 5-lobed calyx and mainly yellow corolla.43,45 Eriosema is
distinguished from other closely related genera such as Rhynchosia Gear. and Flemingia
Roxb. by the morphology of its seed.44,45
The plants of the genus Eriosema have several ethnomedical and ethnobotanical uses
besides treatment of infertility and related disorders. These include treatment of diarrhoea,
orchitis, hydrophobia, detoxification, conjuctivities, cough, emetic, and scabies.46-48 Other
Eriosema species have been found to be mildly poisonous and have been used for fish
poisoning. These include E. glomerata Guill., Perr., E. griseum Baker and E. psoraleoides
(Lam.) G.Don.49
The genus Eriosema is rich in prenylated polyphenols, which range from flavonoids,
flavonoid glycosides, chromones and chalcones.11,47,50-53 The striking feature in most
compounds isolated from different species of Eriosema is the prevalence of a
dimethylpyran ring, which results from the cyclisation of the prenyl group with the
adjacent hydroxy group. Despite the observed structural similarities, the compounds
exhibit a variety of biological activities. For example, an extract from the leaves of E.
montanum Baker F. exhibits high activity against the Semliki forest virus.48 Flavonoids 13
and 14 from E. chinense Vogel are potent antimycobacterial agents against Mycobacterium
tuberculosis H37Ra and cytotoxic against small cell lung (NCI-H187) and oral epidermal
carcinoma (KB) human cell lines.50 Awouafack et al. isolated prenylated chalcones from
E. glomerata Guill. and Perr., which manifest antimicrobial activity against Bacillus
megaterium, Escherichia coli, Chlorella fusca, and Microbotryum violaceum.51 E.
tuberosum A. Rich., which is traditionally used for treatment of diarrhoea, orchitis,
hydrophobia, and for detoxification in China, is the most studied Eriosema species.46,47
Most compounds isolated from E. tuberosum are fungitoxic, e.g. 15 – 17.47,52,54 It is
noteworthy that compound 1 (E. kraussianum) differs from 17 (E. tuberosum) only in the





















As already mentioned, metabolites from E. kraussianum manifest contradictory activities.
The kraussianones, 1 and 2, induce relaxation of Corpus cavernosum tissue; by contrast, 4
and 6 considerably contract the penile tissue regardless of the structural resemblances.11
The overall effect of E. kraussianum as a traditional remedy for male impotence and
urinary complaints in KwaZulu-Natal is therefore attributed to the kraussianones 1 and 2.11
These observations are a strong motivation to study the chemical profile of E. kraussianum
and other species of Eriosema, which are used to enhance virility.
2.4 RESULTS AND DISCUSSION
Reversed-phase HPLC coupled with a PDA detector was employed for the analysis of the
plant extracts. This technique has been used successfully for qualitative and quantitative
analysis of plant metabolites in several instances.9,10,55,56 Although HPLC-PDA does not
give detailed structural information, identification of analytes from the matrix can be
facilitated by comparison of the UV spectra as well as retention times of the eluted peaks
with those of the pure analytes ran under the same conditions.9,57,58 Furthermore, one can
have an idea of the classes of compounds present in a sample by comparing the UV spectra
of eluates with those from the literature profiles.9,59 Different classes of compounds have
















2.4.1 Analysis of E. kraussianum from the Drakensberg and Pietermaritzburg
The first step in our analysis was to develop a method that would separate the different
constituents of E. kraussianum. Kraussianone 1 (1), kraussianone 2 (2), kraussianone 3 (4),
kraussianone 4 (5) and kraussianone 5 (6) were used as reference samples. These
compounds were isolated from the CH2Cl2 extract of the roots of E. kraussianum (Figure
2.2) by the procedure established by Drewes and co-workers.19
Figure 2.2. The roots of E. kraussianum from the Drakensberg
The five analytes were separated by reversed-phase HPLC by a step-wise gradient/isocratic
programme using CH3OH/ 0.02% AcOH in H2O as mobile phase. As expected for the
reversed-phase HPLC, the more polar components, kraussianone 3 (4), kraussianone 2 (2)
and kraussianone 5 (6) were eluted first and the less polar fractions kraussianone 1 (1) and
kraussianone 4 (5) were retained for a longer time as shown in Figure 2.3. To establish the
reproducibility of the retention times, the reference samples were analysed several times,
and the results were consistent.
Time
Figure 2.3. HPLC profile of the mixture of the main constituents of E. kraussianum*






















The UV spectra of the compounds displayed maximum absorbance peaks at shorter
wavelengths, characteristic for isoflavonoids. Isoflavonoids are reported to exhibit
maximum UV absorptions at shorter wavelengths than other classes of flavonoids due to
substitution of the phenyl B-ring at C-3.9,59 This is said to prevent flow of electrons
between the B-ring and the chromone (A-ring and C-ring) chromophore.9,59 The UV
spectra of kraussianone 1 (1), kraussianone 2 (2), kraussianone 3 (4) and kraussianone 4
(5) displayed two main absorbance bands at 215 - 235 nm and 260 - 280 (max) nm and a
shoulder at around 300 nm. The UV spectrum of kraussianone 5 (6), on the other hand,
showed two major absorption peaks, whereby the maximum absorbance was observed at
shorter wavelength (220 nm) and the second absorbance at 300 nm (Figure 2.4).
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Having developed a method for the separation and identification of the five analytes, the
next step was to analyse the plant extracts from different sources. Two samples of E.
kraussianum, which were identified by the curator of the Bews Herbarium (UKZN), Dr
Trevor Edwards, were investigated. These plants were collected from the Drakensberg
(Monk’s Cowl Gate) and from Pietermaritzburg (northern boundary of the National
Botanical Gardens). The peaks for all the five analytes were observed in the
chromatograms of the root extracts from Drakensberg and Pietermarizburg as shown in
Figure 2.5. The main difference observed from the chromatograms of the two samples was
in the relative amounts of the analytes. There were two main constituents in the plant from
Pietermaritzburg, kraussianone 2 (2) and kraussianone 3 (4), and the other kraussianones
occurred in comparably low amounts. Conversely, the sample from the Drakensberg








The variations observed in the authentic E. kraussianum plants from different regions are
not unexpected. It has been reported that secondary metabolites play a vital role in the
plant physiology, and some of them are produced to help the plant adapt to the
environment.60,61 Thus, the chemical profile of the plant is influenced by its habitat.10,56,61
Other factors would include the age and the genotype of the plant.10,56 From these results, it
can be deduced that the plant from the Drakensberg provides good material for the
treatment of male impotence, as an active metabolite, kr 2 (2) was the major constituent.
Further investigations are recommended to determine the safety in using the plant from
Pietermaritzburg as kraussianone 3 (4), the metabolite that led to contraction of the corpus
cavernosum, was prevalent in relatively high quantities.
2.4.2 Analysis of Commercial Samples Uqonsi and Ubangalala
Following the successful analysis of the CH2Cl2 extracts of E. kraussianum, the chemical
compositions of other plants which are used for the treatment of urinary complaints and
male impotence in KwaZulu-Natal were examined. The plants that were investigated are
called uqonsi and ubangalala in Isizulu. The roots of the plants were purchased from street
vendors and from an herbal shop in Retief Street in Pietermaritzburg.
The CH2Cl2 extracts of root samples of uqonsi, from the street vendor (already chopped)
and from the herbal shop (Figure 2.6), were analysed with reversed-phase HPLC under the
conditions developed for E. kraussianum. As seen from Figure 2.7, the HPLC profiles of
the two samples were completely different. The retention times and the UV spectra of the
two samples did not match. There was no outstanding major component in the extract from
the street vendor and almost all the components were in relatively similar concentrations.
Figure 2.6. Roots of uqonsi from a street vendor (A) and an herbal shop (B)
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On the other hand, the chromatogram of the extract from the herbal shop displayed peaks
with retention times that corresponded to those of the five analytes, kraussianone 1 (1),
kraussianone 2 (2), kraussianone 3 (4), kraussianone 4 (5) and kraussianone 5 (6) (Figure
2.7). The identity of the compounds was confirmed by comparison of the UV spectra of the
eluted peaks with those of the pure analytes. Furthermore, 2 was found to be the major




Figure 2.7. Chromatograms of uqonsi from the street vendor (A) and the herbal shop (B)
The similarities observed in the chemical composition of the uqonsi from the herbal shop
and E. kraussianum suggest that the two plants may be the same. Uqonsi normally refers to
E. salignum. There is a possibility that some commercial suppliers may fail to make a clear
distinction between the two species, and market both E. kraussianum and E. salignum as
uqonsi. Nevertheless, the species of Eriosema investigated so far contain mostly prenylated
flavonoids,46,47,50-54 thus, it is also probable that E. kraussianum and E. salignum contain
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similar metabolites. However, no compounds have been isolated from E. salignum up to
date, thus it would be essential to conduct phytochemical studies of an identified authentic
E. salignum plant in order to clear this controversy. Although uqonsi from the herbal shop
cannot be unambiguously identified as E. kraussianum or E. salignum at this stage, it was
interesting to note that its extract had the same metabolites as E. kraussianum, and that
kraussianone 2 (2), one of the two compounds that are believed to be responsible for
erectile dysfunction activity in E. kraussianum, was the major constituent.
The second commercial plant that was studied was ubangalala. The roots of ubangalala
were also bought from the street vendor and the herbal shop. The physical appearance of
the roots was similar, except that those from the herbal shop were smaller than those from
the street vendor, and both gave an intensely orange extract (Figure 2.8). Judging from the
physical appearance, one would expect the two samples to have similar chemical profiles.
However, the similar constituents in the CH2Cl2 extracts of the two ubangalala samples
could only be observed with a close scrutiny of the chromatograms and the UV spectra of
the samples as shown in Figures 2.9 and 2.10.
Figure 2.8. Roots of ubangalala from the herbal shop (A) and the street vendor (B), and
the CH2Cl2 extract (C).
The chromatogram of the sample from the herbal shop displayed two major peaks with
retention times 27.1 and 28.8 min. The compound that eluted at 27.1 min exhibited a
maximum UV absorbance at 308 nm, indicative of a more conjugated system and the one
at 28.8 min exhibited a maximum UV absorbance at 255 nm and a shoulder at 310 nm
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of the ubangalala sample from the street vendor. The main constituent of the sample from
the vendor was eluted at a shorter retention time (15.3 min). The UV spectrum of the peak
at 15.3 min displayed four absorption bands at 240, 257 (max), 317 and 365 nm as shown
in Figure 2.10.
Time
Figure 2.9. The chromatogram and UV absorbance spectra of ubangalala from the herbal
shop
Time
Figure 2.10. The chromatogram and UV absorbance spectra of ubangalala from the street
vendor
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The differences observed in the two samples of ubangalala may be attributed to several
factors. Firstly, the name ubangalala covers a wide range of plant species under the genus
Eriosema. Thus, it may be possible that the two ubangalala plants were two different
species of Eriosema or not Eriosema species at all.21,22 It should be noted that it was not
possible to identify the plant species as the commercial samples consisted of root material
only and there were no leaves or seeds accompanying them. Secondly, it is well known
that the levels and distribution of plant metabolites vary with the age, the region from
which the plant was collected and the season of collection.9,10,56,60,61
2.5 CONCLUSION
Six plants from different sources, which were categorised as E. kraussianum, uqonsi and
ubangalala were analysed by reversed-phase HPLC-PDA. Of the six plants, three
displayed a similar chemical profile, even though there were variations in the relative
abundance of the metabolites within each plant. These were the two plants identified as E.
kraussianum and the commercial uqonsi from the herbal shop. In all three plants,
kraussianone 2 (2) was found to be the major constituent. The three other plants, uqonsi
from the street vendor and the two commercial ubangalala plants, did not contain any of
the compounds that are found in E. kraussianum. Since all six plants are claimed to be
used for the treatment of male impotence, the differences observed in their constituents
may suggest that the active metabolites in the ubangalala and uqonsi from the street
vendor are different from those identified in E. kraussianum. Several classes of
compounds, alkaloids, terpenoids, xanthones and prenylated flavonoids have been reported
as active ingredients in plants used for treatment of male impotence.1-7 Therefore,
biochemical studies are required for identification of the compounds that are responsible
for enhancing virility in the authentic plants that are used for this purpose. This will help to





Kraussianone 1 (1), kraussianone 2 (2), kraussianone 3 (4), kraussianone 4 (5) and
kraussianone 5 (6) used as reference samples were isolated from the CH2Cl2 extract of the
roots of E. kraussiaum following the procedure established by Drewes et al.19 The plant
was previously collected from the Drakensberg. E. kraussianum plants used for the
analysis were collected in October 2011 from the Drakensberg (Monk’s Cowl Gate) and
from the northern boundary of the National Botanical Gardens in Pietermaritzburg. The
commercial samples of uqonsi and ubangala were purchased from a street vendor and
from an herbal shop in Retief Street in Pietermaritburg. HPLC-grade CH3OH and AcOH
were bought from Aldrich. Ultra-pure water was obtained from a Labotec Pure LAB ultra
water purification system.
2.6.2 Sample Preparation
Reference solutions of 0.84 mg/mL kraussianone 1 (1), 0.8 mg/mL kraussianone 2 (2), 1.2
mg/mL kraussianone 3 (4), 0.82 mg/mL kraussianone 4 (5) and 0.82 mg/mL kraussianone
5 (6) were prepared in HPLC-grade CH3OH. Four μL volumes of these solutions were
analysed in multiple injections.
Approximately 2 g of ground dry root material was extracted with CH2Cl2 for 24 h. The
extract was filtered, evaporated under reduced pressure, and redissolved in 5 mL HPLC-
grade CH3OH. Four μL volumes of these samples were analysed in triplicate.
2.6.3 Chromatographic Conditions
Samples were analysed on a Shimadzu Prominence HPLC system equipped with an LC-
20AB pump, SIL-20A autosampler and an SPD-M20A PDA detector. The
chromatographic separations were achieved with 5 μm particle size, 250 mm  4.60 mm
i.d, C18 reversed-phase Phenomenex Luna column. The mobile phase consisted of solvents
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A and B, where A was 0.02% AcOH (v/v) in H2O and B was CH3OH. The following
elution programme was employed: 1-5 min linear gradient from 25 to 40% B, 5-10 min
linear gradient from 40 to 70% B, 10-20 min linear gradient from 70 to 90% B, 20-40 min
isocratic on 90%, 40-45 min linear gradient from 90 to 25%.  The flow rate was
maintained at 0.4 mL/min and the column oven temperature was adjusted to 40 oC. The
PDA detector was set to measure at the range 200 nm – 400 nm.
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CHAPTER 3
SEMI-SYNTHESIS OF KRAUSSIANONE 1
3.1 INTRODUCTION
Kraussianone 2 (2) was determined to be the major constituent of the CH2Cl2 extract of the
roots of E. kraussianum by HPLC study and also by quantitative isolation, thus appreciable
quantities of 2 can be obtained from the plant. However, kraussianone 1 (1), the most
active metabolite, occurs in relatively low concentration in the plant (See Chapter 2),
therefore isolation of large amounts of kraussianone 1 (1) from the plant would not be
sustainable. Since 2 is the major constituent in the roots of E. kraussianum and can be
readily isolated by the established procedure,1,2 it presents an ideal starting material for the
synthesis of 1. The main operation in this endeavour would involve regioselective
formation of the dimethylchromene ring by cyclisation of the prenyl side chain on the A-




































Scheme 3.1. Conversion of kraussianone 2 (2) into kraussianone 1 (1)
Studies on the chemical nature of naturally-derived and synthetic compounds have
revealed that a substantial number of bioactive compounds possess the dimethylpyran
scaffold. This qualifies the dimethylpyran moiety as a ‘‘privileged structure’’ from which
compounds with favourable bioactivities and bioavailability can be developed.3 Thus, it is
not surprising that kraussianone 1 (1) was the most active metabolite. K.C. Nicolaou has
been particularly successful in basing the synthesis of compounds with interesting
pharmacological properties on the dimethylchromene scaffold.4,5 The formation of this
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scaffold thus constitutes subsections in total and partial syntheses of a number of bioactive
compounds. As a result of the wide distribution of the scaffold in natural and synthetic
compounds, several synthetic procedures for synthesis of the dimethylpyran ring have been
developed.
In this chapter the methods for the formation of the dimethylchromene ring will be
reviewed, followed by a discussion of the results on the semi-synthesis of kraussianone 1
(1) and, finally, the conclusion and experimental procedures.
3.2 AN OVERVIEW OF METHODS FOR SYNTHESIS OF THE
DIMETHYLPYRAN MOIETY
3.2.1. Biosynthetic Pathway
The dimethylpyran ring is believed to originate biosynthetically from the enzyme-catalysed
cyclisation of a prenyl group with an adjacent hydroxy group of a phenol (Scheme 3.2).6,7
The isoprene unit is introduced onto the aromatic ring in the form of dimethylallyl











Scheme 3.2. Formation of the dimethylpyran ring
The mechanism by which the prenyl cyclisation occurs remains under debate. The
mechanism proposed initially is via an epoxide intermediate 22, followed by nucleophilic
attack of the ortho-hydroxy group,6,7 thereby forming the hydroxy-substituted
dihydrodimethylpyran 23. Dehydration of 23 under the prevailing acidic conditions results


















Scheme 3.3. Suggested mechanism for the formation of the dimethylpyran scaffold
On the other hand, Crombie and colleagues argued that the dimethylpyran ring is formed in
a single 6π-electrocyclisation step, which involves dienone 24 as an intermediate as shown
in Scheme 3.4.8-10 They proposed that the formation of the dienone 24 is intitiated by a
radical abstraction of one of the hydrogens at C-1', followed by delocalisation and finally












Scheme 3.4. Alternative mechanism for the formation of the dimethylpyran scaffold
3.2.2 Synthetic Methods
3.2.2.1 Aldol-type condensation with 3-methylbut-2-enal
The most commonly employed procedure for the synthesis of the 2,2-dimethylchromene
ring is an aldol-type condensation of a phenol with 3-methylbut-2-enal (prenal) or prenal
acetal.11-17 Different reaction conditions have been used to facilitate this reaction, and it has
been found that the regioselectivity of the reaction on substrates bearing a phloroglucinol
core greatly depends on the experimental conditions.14,15 Mondal et al. demonstrated the
exclusive formation of the linear and the angular pyranoxanthenones, osajaxanthone (25)
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Scheme 3.5. Formation of 2,2-dimethylchromenes from prenal
The reaction mechanism is envisaged to proceed via a 6π-electrocyclisation as shown in
Scheme 3.6. The first step involves the aldol-type condensation of the phenol with prenal.
Tautomerisation and dehydration of 27 give an intermediate 24, which undergoes a 6π-
electrocyclic reaction to furnish the 2,2-dimethylchromene 21. This method has an
advantage over others in that all steps involved occur in one pot.17 However, prenal is






























Scheme 3.6. Proposed mechanism for the condensation of prenal with phenols
29
3.2.2.2 Harfenist-Tom rearrangement
The formation of the dimethylpyran ring by the Harfenist-Tom rearrangement proceeds in
two steps, which involve first the O-propargylation of phenol 28 to give
1,1-dimethylpropargyl ether 29, followed by a Harfenist-Tom rearrangement to give the
2,2-dimethylchromene 30 (Scheme 3.7).17,19  Other than the conditions shown in Scheme
3.7, propargyl halides can also be used with potassium carbonate as a base in refluxing
acetone to furnish propargyl ethers.12 The drawback of this method is the poor











29 30     74% over two steps
28
Scheme 3.7. Formation of dimethylchromenes by the Harfenist-Tom rearrangement
The conversion of the propagyl ether 29 into the dimethylchromene 30 is proposed to
follow a Claisen-type rearrangement to give an intermediate diene 31, followed by










Scheme 3.8. Proposed mechanism for the cyclisation of the propagyl ether 29 into
dimethylpyran 30
30
3.2.2.3 2,2-Dimethylchromenes from 3-methylbut-2-enoic acid.
To circumvent the regioselectivity problem inherent to the procedures described above, 6-
and 7-alkoxy or hydroxy-2,2-dimethylchromenes have been synthesised elegantly  from
the corresponding 2,2-dimethylchromanones.21-23 This is illustrated in the synthesis of 7-
hydroxy-2,2-dimethylchromene (35) from resorcinol (32) (Scheme 3.9).23  The formation
of 2,2-dimethylchromanone 33 by condensation of a resorcinol 32 with but-2-enoic acid
proceeds via a Friedel-Crafts acylation, followed  by a 1,4-addition reaction. Reduction of
the chromanone 33 to the alcohol 34 and subsequent dehydration give the 2,2-
dimethylchromene 35. Regardless of the many synthetic steps involved in this route, the



















Scheme 3.9. Regioselective synthesis of 7-hydroxy-2,2-dimethylchromene (35)
3.2.2.4 2,2-Dimethylchromene by O-cyclisation of prenyl group
Alternatively, the 2,2-dimethylchromene ring can be synthesised based on the sequence of
its biogenesis, which involves C-prenylation of phenol followed by ring closure of the
prenyl group to the ortho-hydroxy group (Scheme 3.10).24  This ring closure is often













Scheme 3.10. Synthesis of 2,2-dimethylchromenes by oxidative cyclisation of a prenylated
phenol
The major shortcomings of this procedure are incurred when base-catalysed electrophilic
aromatic substitution with prenyl halides is employed for C-prenylation. This often results
in diprenylation, O-prenylation or prenylation at an unwanted position.24,28 The
regioselective methodologies developed for C-prenylation proceed via multiple steps such
as Mitsunobu coupling followed by Claisen-Cope rearrangement, and regioselective
iodination followed by Pd-catalysed coupling reactions.29-32
3.3 RESULTS AND DISCUSSION
3.3.1 Introduction
As seen from Scheme 3.1, the main step in the synthesis of kraussianone 1 (1) from
kraussianone 2 (2) is oxidative cyclisation of the prenyl chain at C-6 to OH-7 to give the
dimethylpyran scaffold on the A-ring. This step can be facilitated by quinone-based
reagents such as DDQ and chloranil or by an Ullmann-type coupling reaction.25-27 This
method has advantages over other procedures in that the dimethylchromene ring is formed
in one step. However, kraussianone 2 (2) possesses a hydroxy group at C-2', which is
prone to cyclisation with the C-ring under oxidative conditions to give
coumaronochromones (see Chapter 5).33 Therefore, OH-2' would have to be selectively
protected if this route were to be followed. Nevertheless, selective protection of OH-2'
would not be an easy endeavour in the presence of the hydroxy group at C-7 and would
require multiple protection and deprotection steps.  It was essential to devise a synthetic
route that would effect transformation at the targeted positions, and leave the rest of the
molecule intact. Two synthetic strategies for the conversion of 2 into 1 were investigated.
32
3.3.2 The First Synthetic Approach
In order to avoid several protection and deprotection steps, we initially envisaged to
transform 2 into 1 as shown in Scheme 3.11. We planned to convert the prenyl group on 2
into a dimethylchroman ring to give 36. This would allow protection of OH-2' and OH-5
without interference of OH-7. Dehydrogenation of the dimethylchroman ring into the
dimethylchromene scaffold and subsequent deprotection of 38 would render 1. Although
there are two hydroxy groups adjacent to the prenyl chain in 2, it was anticipated that
cyclisation would occur favourably at OH-7 to give 36. It is well established that the
carbonyl oxygen forms a hydrogen bond with ortho-hydroxy groups, thus we expected




























Scheme 3.1. Proposed synthetic route for kraussianone 1 (1)
Cyclisation of the prenyl group to an adjacent hydroxy group to give a chroman ring has
been reported to occur under acidic conditions.34-37 The mechanism involves a standard
acid-catalysed addition of an alcohol to an alkene. Therefore, 2 was dissolved in HCO2H
(98-100%) and stirred in an ultrasonic bath for 45 min (Scheme 3.12). The reaction gave
two compounds, which were identified as the linear isomer 36 and the angular isomer 39 in


















36    20%
39    63%
2
Scheme 3.12. Cyclisation of prenyl group under acidic conditions
The structures of the two compounds were derived from NMR data. The 1H NMR
spectrum of the linear isomer 36 displayed a one-proton singlet at δH 12.59 (Plate 1a),
indicative of the presence of a hydrogen-bonded hydroxy group (OH-5). The signal of OH-
2' appreared as a singlet at δH 8.39. The aromatic protons of rings A and B were displayed
as singlets, at δH 6.41 (1H, H-8), 6.53 (1H, H-3), and 6.76 (1H, H-6). The signals for the
dimethylchromene scaffold attached to the B-ring were displayed as a six-proton singlet at
δH 1.44 (H-7'' and H-8'') and two cis-olefinic doublets at δH 5.52 (J = 9.8 Hz, H-5'') and
6.28 (J = 9.8 Hz, H-4'') and those for the dimethylchroman ring attached to ring A
appeared at δH 1.38 (6H, s, H-7''' and H-8'''), 1.86 (2H, t, J = 6.8 Hz, H-5''') and 2.75 (2H, t,
J = 6.8 Hz, H-4'''). The 1H NMR spectrum of compound 39 showed similar signals to those
of 36 (Plate 2a), except for the absence of the signal for OH-5, confirming cyclisation at
that position. The structure of 39 was further confirmed by HRMS, which gave an m/z of
443.1460 [M + Na]+ in agreement with the calculated formula weight of 443.1471 for
C25H24NaO6.
These results are not in accordance with our initial hypothesis, as the unexpected isomer
was the major constituent of the reaction mixture. Since the reaction was carried out under
acidic conditions, it is postulated that the carbonyl oxygen was protonated by the acid,
thereby preventing the formation of the hydrogen bond with the OH-5. The two hydroxy
groups on the A-ring were therefore equally available for cyclisation. The reaction was
repeated with 1:1 THF/HCO2H. This left 2 untouched after stirring in an ultrasonic bath for
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12 h at rt. Refluxing the mixture gave multiple products. Other acids, p-TSOH and HCl,
were tested under different conditions, but in vain.36,37
Because the targeted isomer 36 was obtained in low yields, we decided to test the
feasibility of the main subsequent step, which was dehydrogenation. A model reaction was
performed with chroman 40. As shown in Scheme 3.13, chroman 40 was prepared by
reduction of the available chromanone 33 with LiAlH4 followed by acetylation.
38 The
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Scheme 3.13. Model reaction for dehydrogenation of chromans into chromenes.
The 1H NMR spectrum of 40 showed an ABX spin system for the aromatic protons at δH
7.03 (1H, d, J = 8.3 Hz, H-5), 6.56 (1H, dd, J = 2.5 and 8.3 Hz, H-6), 6.53 (1H, d, J = 2.5
Hz, H-8), and the signals for the dimethylchroman ring were displayed as a pair of triplets
integrating for two protons each at δH 2.75 (H-4) and 1.79 (H-3), and a six-proton singlet at
δH 1.33 (2   CH3). The resonance for the acetate group appeared as a singlet at δH 2.26.
Two oxidising agents, chloranil and DDQ were employed for the dehydrogenation of
chroman 40 into chromene 41. The best results were obtained from the DDQ reaction,
whereby 41 was prepared in 78% yield, Scheme 3.13.39 Chloranil afforded 10% of
chromene 41, and most of the starting material was recovered.  The formation of the
dimethylchromene moiety was confirmed by the appearance of the two doublets with
coupling constant of 10.0 Hz, indicative of the cis-double bond in the 1H NMR spectrum of
41, and the absence of the two triplets observed in the 1H NMR of 40.
The optimum conditions were applied to the isoflavone 42, prepared by acetylation of 39,
Scheme 3.14. DDQ was added to a solution of 39 in toluene, and the mixture was refluxed
for 24 h.39 Disappointingly, the starting material was left intact after 24 h reflux. Increasing
35
the reaction time to 5 days facilitated 5% conversion of the starting material into the
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39
Scheme 3.14. Dehydrogenation of the isoflavone 42
The failure to obtain good yields from the dehydrogenation of 42, prompted us to
investigate alternative methods for preparing chromenes from chromans. It has been
reported that chromans can be oxidised at the benzylic position to give chromanones using
reagents such as CAN, DDQ, PCC and IBX.40-43 Chromanones can be readily converted
into chromenes by reduction and dehydration as seen from Section 3.2.2.3. Therefore, we

























Scheme 3.15. Modified route towards the synthesis of kraussianone 1 (1)
36
Since compound 36 was obtained in a low yield, it was important to establish ideal
conditions for the oxidation of the chroman to the chromanone. Model reactions were
performed with chroman 40. A series of CAN oxidation reactions were set under different
conditions as shown in Table 3.1. The best yield (82%) of 45 was obtained upon treatment
of a CH3CN/H2O solution of 40 with 2 eq. CAN. Addition of CH3CO2H to the reaction led
to formation of the nitrated site product 46, which was obtained in low yields when the
reaction was conducted for a shorter time (30 min) and increased with long reaction time
(12 h).


























CAN 6 CH3CN/ H2O 2 45 78%
CAN 2 CH3CN/ H2O 1 45 82%
CAN 1.5 CH3CN/ H2O 1 45 74%
CAN 1.0 CH3CN/ H2O 1 45 70%
The success of the oxidation of chroman 40 to chromanone 46 was confirmed by the
absence of a pair of triplets and the presence of a singlet integrating for two protons at  δH
2.67 (H-3) in the 1H NMR spectrum of compound 45. The 13C NMR spectrum indicated
the presence of a carbonyl functional group by displaying a signal at δC 191.2.  The 1H
NMR spectrum of compound 46 displayed similar signals to those of compound 45.
However, the aromatic protons exhibited an AX spin system at δH 8.74 (1H, s, H-5) and
37
6.60 (1H, s, H-8), instead of the ABX system observed for 45. In addition the signal for the
acetate group was absent in the 1H NMR spectrum of 46.
The oxidation of chromans into chromanones by CAN is proposed to proceed via a SET
mechanism. There are several plausible pathways by which chromans can be converted
into chomanones by a SET mechanism as illustrated in Scheme 3.16.44-46 All the probable
pathways involve formation of a radical 48.44-46 The radical 48 can be generated via two
routes. Route a involves removal of a hydrogen atom by a nitrate radical. The second route
follows two steps, which involve formation of a cationic radical 47 and subsequent
abstraction of a proton (route b-c).46 The mechanistic studies conducted by Dinctürk et al.
in CH3CN suggested the latter route to be the most probable one, whereby the loss of the
proton from the radical cation was determined to be rate-determining to a certain extend.46
The benzylic radical 48 can then be attacked by oxygen or nucleophiles,45 in the present
case, by H2O to give an alcohol 50, which is further oxidised by Ce(IV) to give the ketone
(route e-g). Alternatively, the radical 48 can be further oxidised to the cation 49,44,46 which








































Scheme 3.1. Proposed pathways for oxidation of chroman 40 to chromanone 45
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Nitration of aromatic rings with CAN is not a new phenomenon. Different mechanisms
have been suggested for the nitration of aromatic compounds with CAN.47 Dinctürk and
colleagues proposed a mechanism that involves generation of a nitronium ion (NO2
+) from
the Ce(IV) complex, whereby the aromatic substrate participates as a ‘spectator’ as shown
in Equation 3.1.47 Alternatively, Mellor et al. suggested that simple aromatic compounds
such as toluene and halobenzenes are nitrated a via simple electrophilic aromatic
substitution reaction with nitronium cation (NO2
+), whereas nitration of naphthalene
involves attack on nitronium radical (NO2•).48 Dinctürk and Mellor conducted their
mechanistic studies under different conditions, thus a conclusive remark cannot be drawn
from their arguments. In the present case, the nitrated by-product 46 was observed when
the reaction was performed in a mixture of ether/AcOH/H2O, but not in a solution of
CH3CN/H2O. Therefore, further studies are required to unravel the role of different
solvents in the nitration of aromatic compounds with CAN.
ArH. NO2
+. CeO(NO3) 5
3- ArNO2 +  Ce(OH)(NO3) 5
2- ( Equation 3.1)
Since the chroman scaffold of 36 is attached to the phloroacetophenone moiety (A-ring), it
was important to test the optimised reaction conditions for the conversion of the chroman
into the chromanone on a model compound that bears the phloroglucinol moeity. The
optimised reaction conditions were applied to compound 54 that closely resembles the
western half of 36. The model compound 54 was prepared by selective reduction of the
chromene 53 by hydrogenation as shown in Scheme 3.17. Compound 53 was in turn
prepared by condensation of the available chromone 51 (the synthesis of which is
discussed in Chapter 4) with prenal following Mondal’s protocol and subsequent
acetylation of OH-5. Treatment of a solution of 54 in CH3CN/H2O with CAN gave a
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Scheme 3.17. Attempted oxidation of chroman 54 into a diketone 55
Due to poor yields of the isomer 36, obtained by the acid-catalysed cyclisaton of prenyl
moiety of kraussianone 2 (2) and the difficulty experienced in the oxidation of the chroman
with a phloroglucinol moiety into a chromene, this route was abandoned for the
preparation of kraussianone 1 (1) from kraussianone 2 (2). Therefore, a second synthetic
approach was devised.
3.3.3 The Second Synthetic Approach
An alternative route was based on selective protection and deprotection of the hydroxy
groups and cyclodehydrogenation of the dimethylallyl chain as shown in Scheme 3.18. As
already mentioned, the main challenge in this route was to protect OH-5 and OH-2'
selectively and leave OH-7 free for cyclisation. Since most protection reactions are
conducted under basic conditions, it was envisaged that OH-7 and OH-2' would be more
susceptible to protection than OH-5. Regioselectivity between OH-7 and OH-2' could be





























Scheme 3.18. The second synthetic route
The first step involved protecting OH-7 with bulky TBDMSCl using DIEA as a base. The
reaction exclusively gave 59 in 88% yields (Scheme 3.19). The structure of the compound
was confirmed by the 1H, 13C and 2D NMR spectroscopy. The 1H and the 13C NMR
spectra of 59 showed signals similar to those of kraussianone 2 (2). In addition, signals for
the TBDMS protons resonated at δH 1.04 [9H, s, SiC(CH3)3] and 0.33 [6H, s, Si(CH3)2] in
the 1H NMR spectrum (Plate 4a) and at δC 25.6 [3  CH3, SiC(CH3)3], 18.4 [C,
SiC(CH3)3], -4.1 [2 CH3, Si(CH3)2] in the 13C NMR spectrum of compound 59 (Plate 4b).
The attachment of the TBDMS group at OH-7 was confirmed by the presence of signals













Scheme 3.19. Selective protection of kraussianone 2 (2) with TBDMS
The regiochemistry of compound 59 was further substantiated by HMBC correlations
shown in Figure 3.1. The resonances of the oxygen-linked carbons on the A- and B-rings
could be distinguished from the HMBC correlations. For instance, the proton signal at δH
6.75 (H-6') showed connections to carbon resonances at δC 157.2 (C-2') and 155.9 (C-4'),
and the hydroxy group at δH 8.32 (OH-2') correlated with C-2' at δC 157.2. From these
connections, the two oxygen-linked carbon resonances on the B-ring could be assigned,
41
and it could be deduced that the silyl protecting group was attached to the A-ring and not
the B-ring. As already mentioned, the 1H NMR spectrum of 59 exhibited a one-proton
singlet characteristic of a hydrogen-bonded hydroxy group at δH 12.43 (OH-5), thus it was
clear that the TBDMS group was attached to OH-7. Furthermore, the OH-5 signal at δH
12.43 and the methylene signal at δH 3.38 (H-1''') showed connections to the carbon signal
at δC 159.5 (C-5), and the one-proton singlet at δH 7.95 (H-2) showed a correlation to the
signal of C-8a at δC 155.5. The remaining oxygen-linked carbon resonance at δC 161.0 was
therefore assigned to C-7. The C-7 resonance correlated to the proton signals at δH 3.38 (H-
















Figure 3.1. Key HMBC correlations of 59
The subsequent step involved protection of the OH-5 and OH-2'. The choice of the second
protecting group was motivated by the ease of introduction of the group, its stability to
conditions that were to be employed for the deprotection of TBDMS and the ease of
removal of the group itself. Thus we opted for acetyl protection. Compound 59 was reacted
with acetic anhydride in the presence of pyridine as shown in Scheme 3.20. The reaction
gave a mixture of compounds identified as 60, 61 and 62 by 1H NMR experiments. The 1H
NMR spectrum of compound 60 resembled that of 59, however, the peak for the OH-2'
was no observed, instead there was a three-proton singlet at δH 2.34 for the acetate group.
On the other hand, the resonances of the TBDMS group were absent in the 1H NMR
spectra of 61 and 62, instead additional signals were observed for the acetate groups at δH
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Scheme 3.20. O-acetyl protection of 59
Owing to the instability of the TBDMS ether under the basic acetylation conditions, we
opted for the TBDPS protecting group. This silyl protecting group was chosen due to its
stability to acidic conditions, especially AcOH, which is generated during the reaction.49
Therefore, kraussianone 2 (2) was reacted with TBDPSCl in the presence of DIEA as
shown in Scheme 3.21. As anticipated, the reaction gave 63 in excellent yield. An attempt
to acetylate the two remaining hydroxy groups resulted in the formation of 64 as a sole
product, Scheme 3.21. The C-5 hydroxy group was found to be resistant to esterification.
The 1H NMR spectrum of 64 (Plate 6a) exhibited the characteristic isoflavone one-proton
singlet at δH 7.54 for H-2, a signal for OH-5 resonated further downfield at δH 12.85 and
the resonances for the aromatic hydrogens were displayed at δH  5.95 (1H, s, H-8), 6.83
(1H, s, H-6') and 6.59 (1H, s, H-3'). The signals for the dimethylpyran ring attached to ring
B were observed at δH 6.25 (1H, d, J = 9.8 Hz, H-4''), 5.58 (1H, d, J = 9.8 Hz, H-5'') and
1.42 (6H, s, H-7'' and H-8''), and those of the prenyl chain on ring A were observed at δH
5.34 (1H, t, J = 6.5 Hz, H-2'''), 3.58 (2H, d, J = 6.5 Hz, H-1'''), 1.83 (3H, s, H-4'''/H-5''') and
1.72 (3H, s, H-4'''/H-5'''). The presence of the TBDPS and the acetate protecting groups
was confirmed by resonances at δH 7.74 (4H, dd, J = 8.0 and 1.5 Hz, SiPh2), 7.50-7.40 (6H,
m, SiPh2), 1.12 [9H, s, SiC(CH3)3] and 2.09 (3H, s, COCH3). The HRMS spectrum gave an






















Scheme 3.21. Preparation of 64
Although OH-5 was not protected, we decided to proceed with the subsequent steps, with
the hope that DDQ-induced O-cyclisation of prenyl group would occur favourably at OH-
7. This was motivated by the literature reports that indicated that cyclodehydrogenation of
the prenyl chain between two hydroxy groups in phloroacetophenone-like moieties occurs
preferably at the para-hydroxy group than the ortho-hydroxy group relative to the carbonyl
moiety.25,27,35 Therefore, the TBDPS group was selectively removed with CsF in CH3CN at
rt to give 65 as shown in Scheme 3.21. The penultimate steps involved oxidation of 65
with DDQ to give 66.
The formation of compound 66 was confirmed by the absence of the signals for the
TBDPS and the prenyl groups in the 1H NMR spectrum of 66 (Plate 8a). Instead, the
resonances for the second dimethylchromene ring, comprising two olefinic doublets at δH
6.71 (1H, d, J = 10.0 Hz, H-4'''), 5.62 (1H, d, J = 10.0 Hz, H-5''') and a six-proton singlet
for the enantiotopic methyl groups at δH 1.47 (H-7''' and H-8''') were observed. The
presence of a singlet integrating for one proton at δH 13.00 in the 1H NMR spectrum of 66
showed that OH-5 was left intact during the reaction, which confirmed that cyclisation
occurred at OH-7 as anticipated. Finally, removal of the acetyl group from 66 under basic
conditions rendered the target molecule, kraussianone 1 (1).  The structure of the
compound was confirmed by the 1H NMR spectrum, which was identical to that of the


























Scheme 3.22. Synthesis of kraussianone 1 (1)
3.4. CONCLUSION
Two synthetic routes have been investigated for the synthesis of kraussianone 1 (1) from
kraussianone 2 (2). The main transformation in the two strategies involved cyclisation of
the prenyl side chain on kraussianone 2 (2) into a dimethylchromene ring. In the first
synthetic strategy, the dimethylchomene ring was to be prepared in two major steps, which
were acid-catalysed cyclisation of the prenyl group into a dimethylchroman moiety and
subsequent dehydrogenation. This route was abandoned due to poor regioselectivity of the
prenyl cycloadditon reaction under acidic conditions, and the difficulty of oxidation of the
dimethylchroman into dimethylchromene on substrates with a phloroglucinol moiety. The
second pathway was based on selective protection and deprotection of the hydroxy groups,
followed by oxidative cyclisation of the prenyl goup to OH-7 to give the
dimethylchromene scaffold. This was determined to be the most viable route for
conversion of kraussianone 2 (2) into kraussianone 1 (1). Following this route,




3.5.1 General Experiental Procedures
All reactions requiring anhydrous conditions were performed under nitrogen in oven-dried
glassware. Toluene was distilled under N2 from sodium wire and benzophenone. CH3OH
was distilled under N2 from CaO. Other anhydrous solvents were distilled under N2 from
Technologies (Newburyport, MA) Pure-Solv 800 Solvent Purification System. Hex used
for chromatographic purifications was distilled at 70 oC prior to use. Reagent grade
reagents used for syntheses were purchased from Fluka, Sigma-Aldrich or Merck and were
used without further purification unless otherwise stated. Kraussianone 2 (2) used for the
synthesis was isolated from E. kraussianum following the procedure reported by Drewes et
al.1,2
TLC was performed on Merck silica gel plates (60 F254) and visualised under UV light
(254 nm) and/or upon treatment with iodine vapour. Alternatively, detection of the TLC
spots was achieved by heating with a heat gun after treatment with a solution of
anisaldehyde in concentrated sulfuric acid and ethanol prepared in volume ratios of 1:1:18,
respectively. Column chromatography was performed on columns with 25 mm or 40 mm
column diameter using Merck Kieselgel 60 (230-400 mesh). Centrifugal chromatography
was performed on a Harrison Research Chromatotron Model 7924T on glass plates coated
with Merck silica gel with particle size 0.040-0.063 mm, 2-4 mm thick.
Synthesised compounds were characterised by mass spectrometry, infrared spectroscopy
and NMR spectroscopy. The mass spectra were recorded on an ion trap Thermo Finnigan
GC-MS using electron-impact ionization or on a time-of-flight Waters LCT Premier MS
using electrospray ionisation in the positive or negative mode, and the IR spectra on an FT-
IR Perkin Elmer spectrophotometer (Spectrum 100 and Spectrum one).
The NMR spectra were recorded on a Bruker AVANCE DPX spectrometer. The chemical
shifts from 1H NMR and 13C NMR spectra are reported in parts per million relative to the
residual protonated or deuterated solvents peaks. The chemical shifts for the solvents used
are as follows:
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The coupling constants were measured in Hz. Abbreviations used for the multiplicity of
signals are as follows:
s singlet dd doublet of doublets
d doublet br broadened
t triplet m multiplet
q quartet
The melting points of crystalline compounds were measured on a Reichert electrothermal
melting point apparatus, and were uncorrected.











A solution of kraussianone 2 (2) (50 mg, 0.119 mmol) in HCO2H (15 mL, 98%-100%) was
immersed in an ultrasonic bath fitted with a magnetic stirrer. The solution was stirred for
45 min, diluted with H2O and extracted with EtOAc. The combined organic extracts were
washed with H2O, brine and dried over anhydrous MgSO4. The solvent was evaporated
and the crude mixture was purified by column chromatography using Hex:EtOAc (3:2) to
give 36 (10 mg, 20%) and 39 (31.5 mg, 63%). Compound 39 was recrystallised from




1H NMR (CDCl3, 400 MHz) δ 12.59 (1H, s, OH-5), 8.39 (1H, s, OH-2'), 7.93 (1H, s, H-2),
6.76 (1H, s, H-6'), 6.53 (1H, s, H-3'), 6.41 (1H, s, H-8), 6.28 (1H, d, J = 9.8 Hz, H-4''), 5.52
(1H, d, J = 9.8 Hz, H-5''), 2.73 (1H, t, J = 6.8 Hz, H-4'''), 1.86 (1H, t, J = 6.8 Hz, H-5'''),
1.44 (6H, s, H-7''' and H-8'''), 1.38 (6H, s, H-7'' and H-8''); (Plate 1a)
13C NMR (DMSO-d6, 100 MHz) δ 182.0 C, C-4), 161.4 (C, C-7), 159.3 (C, C-5), 157.1 (C,
C-2'), 155.7 (C-8a), 155.5 (C, C-4'), 154.9 (CH, C-2), 128.7 (CH, C-5''), 127.1 (CH, C-6'),
122.6 (C, C-3), 121.4 (CH, C-4''), 115.2 (C, C-5'), 112.4 (C, C-1'), 107.3 (CH, C-3'), 106.1
(C, C-6), 104.4 (C, C-4a), 95.0 (CH, C-8), 76.6 (C, C-6''), 76.7 (C, C-6'''),  31.7 (CH2, C-




mp > 270 oC (decomposes)
IR (neat) vmax 3336, 2958, 2926, 1725, 1620, 1547, 1462, 1298, 1261, 1149, 1068 cm
-1;
1H NMR (DMSO-d6, 400 MHz) δ 9.67 (1H, brs, OH-2'), 7.84 (1H, s, H-2), 6.78 (1H, s,
H-6'), 6.38 (1H, s, H-8), 6.28 (1H, d, J = 9.8 Hz, H-4''), 6.24 (1H, s, H-3'), 5.52 (1H, d,
J = 9.8 Hz, H-5''), 2.52 (1H, t, J = 6.9 Hz, H-4'''), 1.70 (1H, t, J = 6.8 Hz, H-5'''), 1.32 (6H,
s, H-7'' and H-8''), 1.25  (6H, s, H-7''' and H-8'''); (Plate 2a)
13C NMR (DMSO-d6, 100 MHz) δ 174.7 (C, C-4), 160.6 (C, C-7), 157.9 (C-8a), 156.8 (C,
C-2'), 155.6 (C, C-5), 153.9 (C, C-4'), 152.4 (CH, C-2), 129.9 (CH, C-6'), 128.3 (CH,
C-5''), 123.0 (C, C-3), 120.0 (CH, C-4''), 113.5 (C, C-5'), 113.0 (C, C-1'), 108.1 (C, C-4a),
106.4 (C, C-6), 103.9 (CH, C-3'), 93.9 (CH, C-8), 76.8 (C, C-6''), 75.8 (C, C-6'''),  31.3
(CH2, C-5'''), 28.3 (2  CH3, C-7'' and C-8''), 26.8 (2  CH3, C-7''' and C-8'''), 17.3 (CH2, C-
4'''); (Plate 2b)
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A solution of 39 (20 mg, 0.0476 mmol), pyridine (0.20 mL, 2.53 mmol) and acetic
anhydride (0.16 mL, 1.65 mmol) was stirred at rt for 6 h. The reaction was quenched with
ice-water and stirred for an additional 20 min. The resulting mixture was extracted with
EtOAc, washed with H2O and brine. The organic layer was dried over anhydrous MgSO4.
The solvent was evaporated with a rotary evaporator and the crude product was purified on
a chromatotron using Hex:EtOAc (3:2) to give compound 42 (22.8 mg, 95%) as a
colourless oil.
IR (neat) vmax 2975, 2930, 1761, 1652, 1607, 1426, 1368, 1182, 1127 cm
-1;
1H NMR (CDCl3, 400 MHz) 7.65 (1H, s, H-2), 6.97 (1H, s, H-6'), 6.71 (1H, s, H-8), 6.58
(1H, s, H-3'), 6.28 (1H, d, J = 9.8 Hz, H-4''), 5.57 (1H, d, J = 9.8 Hz, H-5''), 2.62 (1H, t, J =
6.8 Hz, H-4'''), 2.36 (3H, s, OCOCH3), 2.13 (3H, s, OCOCH3), 1.82 (1H, t, J = 6.9 Hz,
H-5'''), 1.43 (6H, s, H-7'' and H-8''), 1.41  (6H, s, H-7''' and H-8'''); (Plate 3a)
13C NMR (CDCl3,100 MHz) δ 175.4 (C, C-4), 169.4 (C, OCOCH3), 168.3 (C, OCOCH3),
156.8 (C-8a), 156.1 (C, C-5), 153.8 (C, C-4'), 152.5 (C, C-7), 151.5 (CH, C-2), 149.2 (C,
C-2'), 130.3 (CH, C-5''), 129.3 (CH, C-6'), 122.3 (C, C-3), 121.5 (CH, C-4''), 119.1 (C, C-
5'), 117.0 (C, C-1'), 113.2 (C, C-4a), 110.8 (CH, C-3'), 110.6 (C, C-6), 102.0 (CH, C-8),
76.7 (C, C-6''), 75.9 (C, C-6'''),  31.0 (CH2, C-5'''), 28.3 (2  CH3, C-7'' and C-8''), 26.6 (2 
CH3, C-7''' and C-8'''), 21.0 (CH3, OCOCH3), 20.8 (CH3, OCOCH3),  17.3 (CH2, C-4''');
(Plate 3b)
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HR-ESIMS m/z [M + Na]+ 527.1672 (Calcd. for C29H28NaO8 527.1682).
3.5.4 7-Acetoxy-2,2-dimethylchroman (40)
OAcO
LiAlH4 (1.58 g, 41.6 mmol) was added portion-wise to a solution of chromanone 33 (2.01
g, 10.4 mmol) in THF (50 mL) at 0 oC. The mixture was stirred at this temperature for 10
min and then refluxed for 12 h. The reaction was quenched with H2O and filtered. The
filtrate was extracted with EtOAc, washed with brine and dried over ahydrous MgSO4. The
solvent was evaporated to give a yellow oil. Pyridine (2.03 mL, 25.3 mmol) and acetic
anhydride (1.86 mL, 19.8 mmol) were added to the oil and the mixture was stirred at rt for
6 h. Ice was added and the mixture was stirred for an additional 20 min, after which a
white solid precipitated. The solid was filtered and washed with H2O to render 40 (1.95 g,
83%). The compound was recrystallised from Hex to give colourless needles.
mp 56.6 – 57.2 oC
IR (neat) vmax 2972, 1755, 1498, 1201, 1142, 771 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 7.03 (1H, d, J = 8.3 Hz, H-5), 6.56 (1H, dd, J = 2.5 and 8.3
Hz, H-6), 6.53 (1H, d, J = 2.5 Hz, H-8), 2.75 (2H, t, J = 6.8,  H-4), 2.26 (3H, s,  OCOCH3),
1.79 (2H, t, J = 6.8,  H-3), 1.33 (6H, s, 2   CH3);
13C NMR (CDCl3, 100 MHz) δ 169.3 (C, OCOCH3), 154.5 (C, C-8a), 149.6 (C, C-7),
129.6 (CH, C-5), 118.4 (C, C-4a), 112.7 (CH, C-6), 110.2 (CH, C-8), 74.3 (C, C-2), 32.5
(CH2, C-3), 26.8 (2  CH3), 22.0 (CH2, C-4), 20.9 (CH3, OCOCH3);




To a solution of 40 (52.0 mg, 0.236 mmol) in toluene (5.00 mL), was added DDQ (0.161 g,
0.708 mmol) under N2. The mixture was refluxed for 24 h. The solid was filtered and the
filtrate was extracted with EtOAc, washed with brine and dried over anhydrous MgSO4.
The solvent was evaporated and the crude product was purified by column chromatography
using Hex:EtOAc (8:2) to give chromene 41 as a yellow oil (40 mg, 78%).
IR (neat) vmax 2976, 1759, 1610, 1494, 1368, 1195, 1115, 990 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 6.94 (1H, d, J = 8.2 Hz, H-5), 6.57 (1H, dd, J = 2.3 and 8.2
Hz, H-6), 6.52 (1H, d, J = 2.3 Hz, H-8), 6.29 (1H, d, J = 10.0 Hz,  H-4), 5.57 (1H, d, J =
10.0 Hz,  H-3), 2.26 (3H, s,  OCOCH3), 1.43 (6H, s, 2   CH3);
13C NMR (CDCl3, 100 MHz) δ 169.2 (C, OCOCH3), 153.8 (C, C-8a), 151.1 (C, C-7),
130.1 (CH, C-3), 126.6 (CH, C-5), 121.6 (CH, C-4), 119.0 (C, C-4a), 113.6 (CH, C-6),
109.9 (CH, C-8), 76.5 (C, C-2), 28.1 (2  CH3), 21.1 (CH3, OCOCH3);
EIMS m/z 218 (10%), 203 (20), 161 (100).
3.5.6 7-Acetoxy-2,2-dimethylchroman-4-one (46)
CAN (0.248 g, 0.454 mmol) was added to a solution of chroman 40 (50.0 mg, 0.227 mmol)
in CH3CN/H2O (3:1, 8 mL). The mixture was stirred for 3 h at rt, H2O and EtOAc were
added and the two phases were partitioned. The organic phase was washed with brine and




purified by column chromatography using Hex:EtOAc (7:3) to give chromanone 46 as a
white solid (43.6 mg, 82%). Recrystallisation of the solid from EtOH gave colourless
crystals.
mp 78.3 – 79.8 oC;
IR (neat) vmax 2983, 1685, 1659, 1606, 1219, 1150, 772 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 7.84 (1H, d, J = 8.5 Hz, H-5), 6.67-6.69 (2H, m, H-6 and H-
8), 2.67 (2H, s, H-3), 2.26 (3H, s,  OCOCH3), 1.42 (6H, s, 2  CH3);
13C NMR (CDCl3, 100 MHz) δ 191.3 (C, C-4), 168.5 (C, OCOCH3), 161.0 (C, C-8a),
156.7 (C, C-7), 127.9 (CH, C-5), 118.0 (C, C-4a), 114.6 (CH, C-6), 111.2 (CH, C-8), 79.9
(C, C-2), 48.6 (CH2, C-3), 26.6 (2  CH3), 21.1 (CH3, OCOCH3);
















To a solution of 51 (50.2 mg, 0.282 mmol) in CH3OH (15 mL) was added Ca(OH)2  (42.0
mg, 0.564 mmol) followed by prenal (0.12 mL, 1.41 mmol). The mixture was stirred under
an N2 atmosphere for 3 days at rt, the CH3OH evaporated and the reaction mixture diluted
with EtOAc and 1 M HCl. The two phases were partitioned and the aqueous phase was
extracted with EtOAc. The combined organic extracts were washed with H2O and brine
and dried over anhydrous MgSO4. The solvent was evaporated and the crude product
purified by column chromatography using Hex:EtOAc (3:2) to give 52 as a cream white
solid (53.7 mg, 78%).
52
1H NMR (CDCl3, 400 MHz) δ 12.9 (1H, s, OH-5), 7.69 (1H, d, J = 6.0 Hz, H-2), 6.70 (1H,
d, J = 10.0 Hz, H-4'), 6.30 (1H, s, H-8), 6.18 (1H, d, J = 6.0 Hz, H-3), 5.61 (1H, d, J = 10.0
Hz, H-5'), 1.47 (6H, s, 2   CH3);
13C NMR (CDCl3, 100 MHz) δ 181.9 (C, C-4), 159.6 (C, C-7), 157.4 (C, C-8a), 156.5 (C,
C-5), 155.4 (CH, C-2), 128.3 (CH, C-5'), 115.4 (CH, C-4'), 111.2 (CH, C-3), 106.6 (C,





Compound 53 was prepared from 52 (50 mg, 0.205 mmol) according to the procedure
given in 3.5.3. The crude product was purified on a chromatotron using Hex:EtOAc (3:1)
to give compound 53 (56.3 mg, 96%) as a colourless oil, which solidified on cooling.
IR (neat) vmax 3064, 2989, 1765, 1640, 1620, 1609, 1293, 1190, 1114, 780 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 7.63 (1H, d, J = 6.0 Hz, H-2), 6.68 (1H, s, H-8), 6.48 (1H,
d, J = 10.0 Hz, H-4'), 6.10 (1H, d, J = 6.0 Hz, H-3), 5.75 (1H, d, J = 10.0 Hz, H-5'), 2.45
(3H, s, OCOCH3), 1.47 (6H, s, 2   CH3);
13C NMR (CDCl3, 100 MHz) δ 175.8 (C, C-4), 169.3 (C, OCOCH3), 158.2 (C, C-8a),
157.8 (C, C-7), 153.5 (CH, C-2), 144.6 (C, C-5), 132.0 (CH, C-5'), 115.1 (CH, C-4'), 113.7
(CH, C-3), 113.0 (C, C-6), 112.1 (C, C-4a), 102.3 (CH, C-8), 78.1 (C, C-6'), 28.4 (2 






To a solution of 53 (20.0 mg, 0.070 mmol) in EtOAc (15 mL) was added 10% Pd(C) (11.2
mg, 15 mol%). The mixture was purged with H2 at 60 kPa with stirring for 15 min. The
Pd(C) was filtered off and washed with EtOAc and the filtrate was evaporated to give a
yellow oil. The oil was purified on a chromatotron using Hex:EtOAc (7:3) to give 54 as a
white solid (17 mg 84%).
IR (neat) vmax 2985, 2936, 1761, 1626, 1456, 1280, 1198, 1154, 1087 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 7.63 (1H, d, J = 6.0 Hz, H-2), 6.71 (1H, s, H-8), 6.09 (1H,
d, J = 6.0 Hz, H-3), 2.68 (2H, brs, H-4'), 2.44 (3H, s, OCOCH3), 1.84 (2H, t, J = 6.9 Hz, H-
5'), 1.36 (6H, s, 2   CH3);
13C NMR (CDCl3, 100 MHz) δ 176.0 (C, C-4), 169.2 (C, OCOCH3), 159.0 (C, C-7), 156.9
(C, C-8a), 153.6 (CH, C-2), 147.7 (C, C-5), 113.7 (C, C-6), 113.4 (CH, C-3), 111.3 (C,
C-4a), 102.6 (CH, C-8), 76.2 (C, C-6'), 31.6 (CH2, C-5'), 26.7 (2  CH3), 21.0 (CH3,
OCOCH3), 16.9 (CH2, C-4');








To a solution of kraussianone 2 (2) (50 mg, 0.119 mmol) in CH2Cl2 (15 mL) was added
DIEA (0.02 mL, 0.119 mmol) and TBDMSCl (21.4 mg, 0.142 mmol) under N2. The
solution was stirred at rt for 3 h, H2O added and the two phases partitioned. The aqueous
phase was extracted with CH2Cl2 and the combined organic extracts were washed with
H2O, brine and dried over anhydrous MgSO4. The crude product was purified on a
chromatotron using Hex:EtOAc (4:1) to afford 59 (56.0 mg, 88%) as a yellow oil.
1H NMR (CDCl3, 400 MHz) 12.42 (1H, s, OH-5 ), 8.32 (1H, s, OH-2'), 7.95 (1H, s, H-2),
6.74 (1H, s, H-6'), 6.53 (1H, s, H-3'), 6.43 (1H, s, H-8), 6.28 (1H, d, J = 9.9 Hz, H-4''), 5.52
(1H, d, J = 9.9 Hz, H-5''), 5.17 (1H, t, J = 6.7 Hz, H-2'''), 3.38 (2H, d, J = 6.7 Hz, H-1'''),
1.78 (3H, s, H-4''' or H-5'''), 1.68 (3H, s, H-4''' or H-5'''), 1.44 (6H, s, H-7'' and H-8''), 1.04
[9H, s, SiC(CH3)3], 0.33 [6H, s, Si(CH3)2]; (Plate 4a)
13C NMR (CDCl3,100 MHz) δ 180.1 (C, C-4), 161.0 (C, C-7), 159.5 (C-5), 157.2 (C, C-2'),
155.6 (C, C-4'), 155.5 (C, C-8a), 154.7 (CH, C-2), 132.2 (C, C-3'''), 128.7 (CH, C-5''),
127.1 (CH, C-6'), 123.1 (C, C-3), 121.9 (CH, C-2'''), 121.4 (CH, C-4''), 117.0 (C, C-6),
115.2 (C, C-5'), 112.3 (C, C-1'), 107.3 (CH, C-3'), 105.8 (C, C-4a), 96.7 (CH, C-8), 76.6
(C, C-6''), 28.1 (2  CH3, C-7'' and C-8''), 25.7 (CH3, C-4''' or C-5'''), 25.6 [3  CH3,
SiC(CH3)3], 22.0 (CH2, C-1'''), 18.4 [C, SiC(CH3)3], 18.0 (CH3, C-4''' or C-5'''), -4.1 [2 
CH3, Si(CH3)2]. (Plate 4b)
















Compound 59 (50 mg, 0.0935 mmol) was acetylated according to the procedure given in




1H NMR (CDCl3, 400 MHz) 13.16 (1H, s, OH-5 ), 7.90 (1H, s, H-2), 6.95 (1H, s, H-6'),
6.72 (1H, s, H-3'), 6.38 (1H, s, H-8), 6.27 (1H, d, J = 9.8 Hz, H-4''), 5.50 (1H, d, J = 9.8
Hz, H-5''), 5.16 (1H, t, J = 6.8 Hz, H-2'''), 3.33 (2H, d, J = 6.8 Hz, H-1'''), 2.34 (3H, s,
COCH3), 1.78 (3H, s, H-4''' or H-5'''), 1.68 (3H, s, H-4''' or H-5'''), 1.44 (6H, s, H-7'' and H-
8''), 0.83 [9H, s, SiC(CH3)3], 0.13 [6H, s, Si(CH3)2].
2',7-Diacetoxy-5-hydroxy-6-prenyl-[6'',6''-dimethylpyrano(2'',3'':4',5')] isoflavone (61)
1H NMR (CDCl3, 400 MHz) 12.98 (1H, s, OH-5 ), 7.82 (1H, s, H-2), 6.91 (1H, s, H-6'),
6.71 (1H, s, H-3'), 6.64 (1H, s, H-8), 6.30 (1H, d, J = 9.8 Hz, H-4''), 5.61 (1H, d, J = 9.8
Hz, H-5''), 5.14 (1H, t, J = 7.0 Hz, H-2'''), 3.32 (2H, d, J = 7.0 Hz, H-1'''), 2.35 (3H, s,
COCH3), 2.14 (3H, s, COCH3), 1.78 (3H, s, H-4''' or H-5'''), 1.68 (3H, s, H-4''' or H-5'''),
1.45 (6H, s, H-7'' and H-8'').
2',5,7-Triacetoxy-6-prenyl-[6'',6''-dimethylpyrano(2'',3'':4',5')]isoflavone (62)
1H NMR (CDCl3, 400 MHz) 7.75 (1H, s, H-2), 7.19 (1H, s, H-6'), 6.85 (1H, s, H-3'), 6.63
(1H, s, H-8), 6.27 (1H, d, J = 9.8 Hz, H-4''), 5.58 (1H, d, J = 9.8 Hz, H-5''), 5.02 (1H, t, J =
6.7 Hz, H-2'''), 3.29 (2H, d, J = 6.7 Hz, H-1'''), 2.40 (3H, s, COCH3), 2.35 (3H, s, COCH3),









To a solution of 2 (50 mg, 0.119 mmol) in CH2Cl2 (15 mL) was added DIEA (0.024 mL,
0.142 mmol) and TBDPSCl (0.033 mL, 0.142 mmol) under N2. The solution was stirred at
rt for 3 h. H2O was added and the two phases were partitioned. The aqueous phase was
extracted with CH2Cl2 and the combined organic extracts were washed with H2O, brine
and dried over anhydrous MgSO4. The crude product was purified on a chromatotron using
Hex:ether (4:1) to afford 63 (72 mg, 92%) as a yellow solid.
IR (neat) vmax 2931, 2859, 1649, 1639, 1574, 1472, 1108, 820 cm
-1;
1H NMR (CDCl3, 400 MHz) 12.46 (1H, s, OH-5 ), 8.26 (1H, s, OH-2'), 7.75-7.74 (5H, m,
H-2, SiPh2), 7.50-7.40 (6H, m, SiPh2), 6.64 (1H, s, H-6'), 6.49 (1H, s, H-3'), 6.22 (1H, d,
J = 9.8 Hz, H-4''), 6.02 (1H, s, H-8), 5.49 (1H, d, J = 9.8 Hz, H-5''), 5.33 (1H, t, J = 6.6 Hz,
H-2'''), 3.60 (2H, d, J = 6.7 Hz, H-1'''), 1.85 (3H, s, H-4''' or H-5'''), 1.73 (3H, s, H-4''' or
H-5'''), 1.42 (6H, s, H-7'' and H-8''), 1.13 [9H, s, SiC(CH3)3]; (Plate 5a)
13C NMR (CDCl3,100 MHz) δ 182.0 (C, C-4), 160.6 (C, C-7), 159.3 (C-5), 157.2 (C, C-2'),
155.6 (C, C-4'), 155.1 (C, C-8a), 154.7 (CH, C-2), 135.3 (4  CH, SiPh2), 132.2 (C, C-3'''),
131.5 (2  C, SiPh2), 130.4 (2  CH, SiPh2), 128.7 (CH, C-5''), 128.1 (4  CH, SiPh2),
127.1 (CH, C-6'), 123.0 (C, C-3), 122.0 (CH, C-2'''), 121.3 (CH, C-4''), 116.6 (C, C-6),
115.2 (C, C-5'), 112.3 (C, C-1'), 107.3 (CH, C-3'), 105.8 (C, C-4a), 97.6 (CH, C-8), 76.6
(C, C-6''), 28.1 (2  CH3, C-7'' and C-8''), 26.3 [3  CH3, SiC(CH3)3 ], 25.8 (CH3, C-4''' or
C-5'''), 22.0 (CH2, C-1'''), 19.5 [C, SiC(CH3)3], 18.0 (CH3, C-4''' or C-5'''); (Plate 5b)








Compound 63 (65.0 mg, 0.0987 mmol) was acetylated according to the procedure given in
3.5.3 to afford 64 (61.5 mg, 89%) as a white solid after purification on a chromatotron
using Hex:ether (4:1).
IR (neat) vmax 2932, 2854, 1757, 1651, 1469, 1281, 1887, 1107, 824, 701 cm
-1;
1H NMR (CDCl3, 400 MHz) 12.85 (1H, s, OH-5 ), 7.74 (4H, dd, J = 8.0 and 1.5 Hz,
SiPh2), 7.54 (1H, s, H-2), 7.50-7.40 (6H, m, SiPh2), 6.83 (1H, s, H-6'), 6.59 (1H, s, H-3'),
6.25 (1H, d, J = 9.8 Hz, H-4''), 5.95 (1H, s, H-8), 5.58 (1H, d, J = 9.8 Hz, H-5''), 5.34 (1H,
t, J = 6.5 Hz, H-2'''), 3.58 (2H, d, J = 6.5 Hz, H-1'''), 2.09 (3H, s, COCH3), 1.83 (3H, s,
H-4''' or H-5'''), 1.72 (3H, s, H-4''' or H-5'''), 1.42 (6H, s, H-7'' and H-8''), 1.12 [9H, s,
SiC(CH3)3]; (Plate 6a)
13C NMR (CDCl3,100 MHz) δ 180.2 (C, C-4), 169.0 (C, COCH3 ), 159.7 (C, C-7), 159.5
(C-5), 155.1 (C, C-8a), 154.1 (C, C-4'), 153.8 (CH, C-2), 149.3 (C, C-2'), 135.3 (4  CH,
SiPh2), 132.4 (C, C-3'''), 131.7 (2  C, SiPh2), 130.5 (CH, C-5''), 130.3 (2  CH, SiPh2),
128.7 (CH, C-6'), 128.1 (4  CH, SiPh2), 122.4 (CH, C-2'''), 121.2 (CH, C-4''), 120.3 (C, C-
3), 119.2 (C, C-5'), 115.89 (2  C, C-6, C-1'), 111.1 (CH, C-3'), 106.2 (C, C-4a), 97.6 (CH,
C-8), 76.9 (C, C-6''), 28.3 (2  CH3, C-7'' and C-8''), 26.3 [3  CH3, SiC(CH3)3], 25.8 (CH3,
C-4''' or C-5'''), 22.0 (CH2, C-1'''), 21.0 (CH3, COCH3), 19.5 [C, SiC(CH3)3], 18.0 (CH3, C-
4''' or C-5'''); (Plate 6b)
















To a stirred solution of 64 (50 mg, 0.0713 mmol) in CH3CN (5 mL) was added CsF (21.7
mg, 0.143 mmol). The mixture was stirred at rt for 12 h and then diluted with H2O and
EtOAc. The two phases were partitioned and the aqueous phase was extracted with EtOAc.
The organic layers were combined, washed with H2O, brine and dried over anhydrous
MgSO4. The crude product was purified on a chromatotron using Hex:EtOAc (3:2) for
afford 65 as  a cream white solid (28.7 mg, 87%).
IR (neat) vmax 3208, 2971, 2925, 2950,1762, 1641, 1281, 1196, 1130 cm
-1;
1H NMR (CDCl3, 400 MHz) 13.08 (1H, s, OH-5 ), 7.82 (1H, s, H-2), 6.92 (1H, s, H-6'),
6.64 (1H, s, H-3'), 6.38 (1H, s, H-8), 6.29 (1H, d, J = 9.9 Hz, H-4''), 5.60 (1H, d, J = 9.9
Hz, H-5''), 5.28 (1H, t, J = 7.0 Hz, H-2'''), 3.46 (2H, d, J = 7.0 Hz, H-1'''), 2.12 (3H, s,
COCH3), 1.84 (3H, s, H-4''' or H-5'''), 1.78 (3H, s, H-4''' or H-5'''), 1.45 (6H, s, H-7'' and H-
8''); (plate 7a)
13C NMR (CDCl3, 100 MHz) δ 180.3 (C, C-4), 169.1 (C, COCH3 ), 161.5 (C, C-7), 159.6
(C-5), 156.2 (C, C-8a), 154.2 (C, C-4'), 154.0 (CH, C-2), 149.4 (C, C-2'), 136.2 (C, C-3'''),
130.6 (CH, C-5''), 128.7 (CH, C-6'), 121.2 (CH, C-4''), 121.0 (CH, C-2'''), 120.4 (C, C-3),
119.3 (C, C-5'), 115.8 (C, C-1'), 111.2 (CH, C-3'), 110.1 (C, C-6), 105.6 (C, C-4a), 94.1
(CH, C-8), 77.2 (C, C-6''), 28.3 (2  CH3, C-7'' and C-8''), 25.8 (CH3, C-4''' or C-5'''), 21.5
(CH2, C-1'''), 21.0 (CH3, COCH3), 17.9 (CH3, C-4''' or C-5'''); (Plate 7b)



























DDQ (17.7 mg, 0.0778 mmol) was added to a solution of 65 (30.0 mg, 0.0649 mmol) in
toluene (20 mL). The mixture was refluxed under an N2 atmosphere for 4 h. A solution of
10% NaHCO3 was added and the mixture was extracted with EtOAc. The organic layer
was washed with H2O, brine and dried over anhydrous MgSO4. The crude product was
purified by column chromatography using Hex:EtOAc (7:3) to afford 66 as a cream white
solid (23.6 mg, 79%)
IR (neat) vmax 2975, 2919, 1764, 1650, 1617, 1184, 1130 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 13.00 (1H, s, OH-5), 7.73 (1H, s, H-2), 6.92 (1H, s, H-6'),
6.71 (1H, d, J = 10.0 Hz, H-4'''), 6.64(1H, s, H-3'), 6.33 (1H, s, H-8), 6.29 (1H, d, J = 9.8
Hz, H-4''), 5.62 (1H, d, J = 10.0 Hz, H-5'''), 5.60 (1H, d, J = 9.8 Hz, H-5''), 2.13 (3H, s,
COCH3),  1.47 (6H, s, H-7''' and H-8'''), 1.45 (6H, s, H-7'' and H-8''); (Plate 8a)
13C NMR (CDCl3, 100 MHz) δ 180.3 (C, C-4), 169.0 (C, COCH3 ), 159.6 (C, C-7), 157.3
(C-8a), 156.8 (C, C-5), 154.2 (C, C-4'), 153.9 (CH, C-2), 149.3 (C, C-2'), 130.6 (CH,
C-5''), 128.6 (CH, C-6'), 128.2 (CH, C-5'''), 121.2 (CH, C-4''), 120.6 (C, C-3), 119.3 (C, C-
5'), 115.7 (C, C-1'), 115.4 (CH , C-4'''), 111.2 (CH, C-3'), 105.8 (C, C-4a), 105.7 (C, C-6),
94.9 (CH, C-8), 78.1 (C, C-6'''), 77.2 (C, C-6''), 28.3 (4  CH3, C-7''', C-8''', C-7'' and C-8''),
21.0 (CH3, COCH3); (Plate 8a)
HR-ESIMS m/z [M+Na]+ 483.1404 (Calcd. for C27H24O7NaSi 483.1420).
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To a solution of 66 (15 mg, 0.0326 mmol) in CH3OH (10 mL) was added NaOH (2 mL, 2
M). The solution was stirred at rt for 3 h. CH3OH was evaporated and crude mixture was
diluted with DCM and HCl (10 mL, 1M). The two phases were partitioned and the aqueous
phase was back-extracted with DCM. The combined organic extracts were washed with
H2O, brine and dried over anhydrous MgSO4. The product was purified on a chromatotron
using Hex:EtOAc (4:1) to give 1 as a yellow solid (13.1 mg, 96%).
IR (KBr) vmax 3336, 2975, 2872, 1649, 1615, 1460, 1132, 773 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 12.55 (1H, s, OH-5), 8.27 (1H, s, OH-2'), 7.73 (1H, s, H-2),
6.75 (1H, s, H-6'), 6.74 (1H, d, J = 10.0 Hz, H-4'''), 6.53 (1H, s, H-3'), 6.40 (1H, s, H-8),
6.28 (1H, d, J = 9.8 Hz, H-4''), 5.65 (1H, d, J = 10.0 Hz, H-5'''), 5.52 (1H, d, J = 9.8 Hz, H-
5''), 1.49 (6H, s, H-7''' and H-8'''), 1.44 (6H, s, H-7'' and H-8''); (Plate 9a)
13C NMR (CDCl3, 100 MHz) δ 182.0 (C, C-4), 160.4 (C, C-7), 157.2 (C, C-2'), 157.1 (C-
8a), 156.4 (C, C-5), 155.7 (C, C-4'), 154.7 (CH, C-2), 128.8 (CH, C-5''), 128.6 (CH, C-5'''),
127.1 (CH, C-6'), 123.1 (C, C-3), 121.3 (CH, C-4''), 115.28 (CH and C, C-4''' and C-5'),
112.1 (C, C-1'), 107.3 (CH, C-3'), 106.1 (C, C-6), 105.5 (C, C-4a), 95.0 (CH, C-8), 78.5
(C, C-6'''), 77.2 (C, C-6''), 28.4 (2  CH3, C-7''' and C-8'''), 28.2 (2  CH3, C-7'' and C-8'');
(Plate 9b)
HR-ESIMS m/z [M + Na]+ 441.1317 (Calcd. for C25H22NaO6 441.1314).
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CHAPTER 4
TOTAL SYNTHESIS OF THE PYRANOISOFLAVONE KRAUSSIANONE 1 AND
RELATED ISOFLAVONES
4.1 INTRODUCTION
Pyranoisoflavones have been isolated from different plants, mostly belonging to the
Leguminosae.1-4 This class of compounds has been reported to possess biological activities
such as cytotoxicity against cancer cell lines, hypertensive, hypoglyceamic, antifungal,
antiplasmodial, anti-inflammatory, estrogenic and antiestrogenic activities.2-4 The
pyranoisoflavones are believed to originate biosynthetically from the enzyme-catalysed
cyclisation of a prenyl group with the adjacent hydroxy group of the isoflavone.5
Prenylation can occur after the isoflavone skeleton has been assembled or during the early
stages in the biosynthetic pathway.5,6 The early formation of the dimethylpyran ring is in
part supported by the prevalence of prenylated chalcones and flavanones, which are
biosynthetic precursors of the isoflavones.6
Most synthetic routes for the pyranoisoflavones followed either the deoxybenzoin or the
chalcone route for the construction of the isoflavone core and a number of methods have
been followed for the synthesis of the dimethylpyran moeity.7-12 More recently, Zheng and
Shen synthesised a pyranoisoflavone as precursor to hirtellanine A by the Suzuki-Miyaura
reaction.13 Poor regioselectivity in the introduction of the dimethylpyran ring, which often
resulted in the formation of both the linear and angular isomers of the pyranoisoflavones,
has been a problem in most synthetic routes.7-12
In this Chapter, the methods for the synthesis of the isoflavone skeleton are reviewed,
followed by the discussion of the results on the synthesis of the pyranoisoflavone
kraussianone 1 (1) and related isoflavones. The conclusions drawn from the discussions
and the experimental procedures are given in the last sections of the chapter.
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4.2 AN OVERVIEW OF SYNTHETIC METHODS FOR THE SYNTHESIS OF
ISOFLAVONES
As a result of the wide range of important biological activities exhibited by the isoflavones,
many synthetic routes towards these compounds have been investigated since the 1950’s.14
New methods are still being developed in a quest for efficient methodologies that will
tolerate substitution patterns found in most naturally-occurring isoflavones. There are two
long-established procedures for the preparation of isoflavones which are still widely used.
These are the deoxybenzoin and chalcone routes.1,14-17 Other methods include the Suzuki-
Miyaura coupling of halochromones with arylboronic acids, reductive cleavage of
isoxazoles, intramolecular ketene cycloaddition followed by decarboxylation,
rearrangement and cyclisation of chalcone epoxides, rearrangement of flavanones and
many others.1 The methods that have been developed more recently, are the Wacker-Cook
tandem conversion of α-methylene deoxybenzoins into isoflavones and the Cu(I)-mediated
cyclisation of 3-(2-bromophenyl)-3-oxopropanal.18,19 Regardless of the many new
synthetic approaches presented, the general applicability of most of them has not been
demonstrated. This is particularly the case in the synthesis of polyhydroxyisoflavones and
isoflavones bearing other naturally-occurring substitution patterns.
The subsections that follow will review the methods that are widely employed for the
synthesis of isoflavones, i.e. the deoxybenzoin and chalcone routes. The synthesis of
isoflavones by the Suzuki-Miyaura coupling, which is now gaining acceptance, and the
newly developed methods, the Wacker-Cook and the Cu(I) catalysed intramolecular
cyclisation of oxophenylpropanal, will also be reviewed.
4.2.1 The Deoxybenzoin Route
The deoxybenzoin method involves formylation and subsequent cyclisation of
2-hydroxyphenyl benzyl ketone (deoxybenzoin) with a reagent containing an activated C-1
unit. Initial procedures employed reagents such as ethyl formate and sodium, ethyl
orthoformate with pyridine or piperidine, and ethoxalyl chloride with pyridine. The two
former conditions were reported to give poor yields of isoflavones bearing a phloroglucinol
nucleus, thus the ethoxalyl chloride procedure was developed to overcome this
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shortcoming. However, ethoxalyl chloride gives 2-carboethoxyisoflavone, which requires
subsequent decarboxylation.14,15
Pelter and Foot later developed a formylation procedure for large-scale synthesis,
employing DMF-DMA in benzene or DMF at high temperatures.20 Again, with this
method, very low yields were reported with benzyl ketones containing a phloroglucinol
moiety.20,21 Bredereck’s reagent, bis(dimethylamino)-t-butoxymethane
[HC[N(CH3)2]2O-
tBu] was employed for the synthesis of calopogonium isoflavone-B and
jamaicin.9,1 DMF has also been used as a source of an activated C-1 unit in conjunction
with the Lewis acids BF3.OEt2 and CH3SO2Cl.
22 A number of polyhydroxyisoflavones
have been successfully synthesised under these conditions at higher temperatures or under
microwave irradiation.23-25 The application of this route is demonstrated in Scheme 4.1 in

















Scheme 4.1. Preparation of an isoflavone by the deoxybenzoin route
The benzyl ketone 67 was synthesised from phloroglucinol (69) and phenylacetonitrile 70
by the Houben-Hoesch reaction using ZnCl2 and gaseous HCl. Hydrolysis of the resulting























Scheme 4.2. Preparation of a deoxybenzoin by the Houben-Hoesch reaction
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Alternatively, the deoxybenzoin can be synthesised by Friedel-Crafts acylation of an
appropriately substituted phenol with a phenylacetic acid or acyl chloride. This
condensation is facilitated by Lewis acids such as AlCl3, TiCl4 or BF3.Et2O.
1,21,22,24,27,28
A proper choice of the reagents and conditions for the preparation of isoflavones via the
deoxybenzoin route allows for the preparation of polyhydroxyisoflavones without prior
protection of the free hydroxy groups.21-23 This eliminates the protection and deprotection
steps often required when other synthetic methods are employed. However, sensitive
substituents such as dimethylchromenes and prenyls do not survive the harsh conditions
employed for the preparation of the deoxybenzoin via Friedel-Crafts acylation and
Houben-Hoesch reaction.29 As a result such functional groups are often incorporated upon
complete construction of the isoflavone skeleton, making it difficult to control the
regiochemistry of the final compound.7,23
4.2.2 The Chalcone Route
Prior to 1974, oxidative rearrangement of chalcones with TTN in CH3OH was the most
widely used method for the synthesis of isoflavones.16 However, the use of TTN made the
method unattractive due to its high cost, toxicity and adverse environmental effects.30,31
Some environmentally friendly and less toxic hypervalent iodine reagents have been
developed to facilitate the important aryl shift. They include phenyliodine(III)
bis(trifluoroacetate), (diacetoxyiodo)benzene/p-toluenesulfonic acid, [hydroxy(tosyloxy)
iodo]benzene and [bis(trifluoroacetoxy)iodo]benzene.17,30,31 Unlike deoxybenzoins,
chalcones can be readily prepared by a Claisen-Schmidt condensation of a benzylaldehyde
and an acetophenone. Good yields of the chalcones have been reported when the reaction
is performed in an alcoholic KOH solution or in piperidine and anhydrous CH3OH.
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Scheme 4.3 shows the synthesis of 2',4'-dibenzyloxy-7-methoxyisoflavone (75) by the
oxidative rearrangement of chalcone 73. The chalcone 73 was obtained by condensation of
acetophenone 71 and benzaldehyde 72 in dry CH3OH using piperidine as the base.
Treatment of the chalcone 73 with TTN gave the intermediate acetal 74, which was
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Scheme 4.3. Synthesis of isoflavone 75 by the oxidative rearrangement of chalcone 73
4.2.3 The  Suzuki-Miyaura Cross Coupling
In 1988, Suzuki et al. demonstrasted the versatility of the palladium-catalysed cross-
coupling reaction for the synthesis of isoflavones from 3-bromochromones and arylboronic
acids.33 Following this, the Suzuki-Miyaura cross-coupling reaction has been applied in
several instances for the synthesis of isoflavones in the presence of palladium(0) or
palladium(II) catalysts.34-38 Examples of catalysts which have successfully facilitated this
C-C bond formation are Pd(PPh3)4, Pd(C), trans-[PdCl2(2-ethyl-2-oxazoline-к1N)2],
benzothiozole-oxime-based Pd(II) catalyst, and Pd(OAc)2 in the presence of 2-(2,6-
dimethoxybiphenyl)dicyclohexylphosphane (SPhos) as a ligand.34-38  The mild reaction
conditions employed by the Suzuki-Miyaura coupling have the advantage of the reaction
occurring in the presence of sensitive substituents found in most isoflavones. Moreover, a
large number of isoflavones can be synthesised from a 3-halochromone precursor by
varying the substituents on the boronic acid partner. This has been well demonstrated by































Scheme 4.4. Synthesis of isoflavone glycosides by the Suzuki-Miyaura reaction
In this sequence, a 3-bromochromone 77 was coupled to different aryl boronic acids in the
presence of Pd(OAc)2 and SPhos to give the corresponding isoflavones 78. The
3-bromochromone was prepared in a sequence of steps employing the condensation of
triethyl orthoformate with an acetophenone to give chromone 76. Subsequent bromination























X = I or Br
DMF-DMA
Scheme 4.5. Preparation of 3-halochromone
More conveniently, the 3-halochromones can also be obtained by Gammill’s protocol,40
which involves condensation of an appropriately substituted 2'-hydroxyacetophenone 79
with DMF-DMA to form an enaminoketone 80. Halogen-mediated ring closure of the
enamino ketone then gives the corresponding 3-halochromone 81, Scheme 4.5.40 Good
yields of the 3-halochromones have been reported for mono- and dihydroxyacetophenones.
However, the yields drop considerably when 2',4',6'-trihydroxyacetophenone is used as the
starting material.41-43
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4.2.4 The  Wacker-Cook Synthesis
In 2009 Granados-Covarrubias and Maldonado adapted the Wacker-Cook method for the
synthesis of formononetin (85). The reaction occurred in one pot, via oxidative cyclisation
of α-methylenedeoxybenzoin 84 in the presence of a Pd(II) catalyst. The
methylenedeoxybenzoin was obtained by conjugate addition of the cyanohydrin 83 to the
























Scheme 4.6. A Wacker-Cook synthesis of formononetin
4.2.5 Cu(I)-Catalysed Intramolecular Cyclisation
Most recently (2011), Qiu-Lian Li and co-workers developed a new method for the
synthesis of isoflavones based on Cu(I)-mediated intramolecular cyclisation of 3-(2-
bromophenyl)-3-oxo-2-phenylpropanal (87), Scheme 4.7. The bromophenylpropanal 87
was prepared by formylation of bromodeoxybenzoin 86. The application of this method
was demonstrated for isoflavones 88 with various substitution patterns, however, no

























Scheme 4.7. Preparation of isoflavones 88 by Cu(I)-catalysed intramolecular cyclisation
Despite the many new synthetic methods that are being developed for the isoflavones, the
deoxybenzoin route is used most often, mainly because it involves a smaller number of
synthetic steps.22-25,27-28 As already mentioned, the isoflavones can be prepared by this
method without prior protection of the hydroxy groups.21-23 Moreover, most starting
materials (i.e. polyphenols and phenylacetic acids/phenylacetonitriles) are commercially
available. However, the reaction employs strong acidic conditions, which are incompatible
with some naturally-occuring substituents such as prenyl groups.7,21-24,27-29 Thus,
introduction of such groups is restricted to the late stages of the synthesis, when the
isoflavone nucleus has been assembled. Therefore, it becomes difficult to control the
regioselectivity in the synthesis of isoflavones bearing acid-sensitive substituents.7,23
The two newly developed methods, the Wacker-Cook synthesis and Cu(I)-catalysed
cyclisation of bromopropanals are variations of the deoxybenzoin route.18,19 The main
disadvantage of these methods is that they introduce extra synthetic steps to the original
deoxybenzoin route. Moreover, the Cu(I)-catalysed method still employs strong Lewis
acids such as POCl3 for formylation of the bromodeoxybenzoin. On the other hand, the
synthesis of isoflavones by oxidative rearrangement of chalcones has been discouraged due
to the high cost and toxicity of TTN.30,31 Even though the less toxic hypervalent iodine
reagents have been developed to facilitate aryl migration of chalcones, the rearrangement
proceeds only when the 2'-hydroxy group is protected with robust protective groups, as
most acid-sensitive protective groups do not survive.17,30,31 Furthermore, olefinic
substituents cannot withstand the conditions employed for the aryl-shift, thus such
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substituents can only be incorporated after the isoflavone skeleton has been completely
constructed.
4.3 RESULTS AND DISCUSSION
4.3.1 Introduction
Several synthetic pathways for the pyranoisoflavonoids can be designed based on the
isoflavone and the dimethylchromene synthetic methods discussed in Sections 4.2 and
3.2.2 (Chapter 3), respectively. However, a thoughtful combination of the methods for the
preparation of the isoflavone skeleton and the dimethylpyran ring is required for the
development of an ideal synthetic procedure. The choice of the methods may be guided by
a number of factors which include:
o the structural variations of the target pyranoisoflavonoids,
o the regiochemistry of the target compounds,
o the sensitivity of the functional groups on the target molecules towards the reagents
used in the method of choice, and
o the toxicity of the reagents involved
Our aims were to develop a synthetic route for the total synthesis of kraussianone 1 (1) and
to prepare other isoflavonoids, which are structurally related to kraussianone 1 (1). These
















For the syntheses of these compounds, we took advantage of the Suzuki-Miyaura
protocol.33 As already seen from the literature review, this method employs less toxic
reagents and offers access to a number of different isoflavones in the final stages of the
synthetic pathway, by using different boronic acid partners or by incorporating additional
substituents to the A-ring of the isoflavone.38,39 We also hoped that the mild conditions
often employed in the Suzuki-Miyaura protocol would permit the syntheses of the
pyranoisoflavones from precursors bearing the dimethylchromene scaffolds. This would
allow the regioselective construction of the dimethylpyran rings, which has been a problem
in several synthetic routes for the pyranoisoflavones.7,8,10
We envisaged the syntheses of the target compounds to proceed as outlined in the
retrosynthetic route (Scheme 4.8). As seen from Scheme 4.8, the precursors for all the
target compounds were 3-iodochromone 90 and arylboronic acid 91. Eriosemaone D (17)
was planned to be synthesised by the Suzuki-Miyaura cross-coupling reaction of 90 and
91, followed by deprotection. Kraussianone 1 (1) and 89 were envisaged to arise from
aldol-type condensation and subsequent 6π-electrocyclisation of eriosemaone D (17) with

























Scheme 4.8. Retrosynthetic analysis of eriosemaone D (17), kraussianone 1 (1) and the
geranyl derivative 89
74
4.3.2 Preparation of 3-Iodochromone 90
We planned to construct 3-iodochromone 90 by an aldol-type condensation of the
commercially available 2',4',6'-trihydroxyacetophenone (92) with the dimethylacetal of
dimethylformamide (DMF-DMA), followed by iodine-mediated cyclisation of the














Scheme 4.9.  The proposed synthetic pathway for the precursor 90
Although the synthesis of the 3-iodochromones via an enaminoketone intermediate is a
well-established procedure,40 there are only a few reports on its application using
phloroacetophenone as the starting material. Vasselin and colleagues attempted the
synthesis of 3-iodochromones from the corresponding 4',6'-dibenzyloxy-2'-
hydroxyacetophenone and 2'-hydroxy-4',6'-dimethoxyacetophenone.41 However, they only
managed to recover an unidentified mixture of products from the dibenzylated
acetophenone, and 29% of the 3-iodo-5,7-dimethoxychromone from the latter.41 Similarly,
low yields (34.5%) of the 3-iodo-5,7-dimethoxychromone have been obtained by
Watanabe et al.43 In both instances, the enaminoketones were obtained in good yields and
the main problem was encountered in the iodine-mediated cyclisation step.41,43
Therefore, it was required that other protecting groups be investigated for the preparation
of the 3-iodochromone. The protection of the 4'- and 6'-hydroxy groups of the
phloroacetophenone is essential for the successful condensation of the 2',4',6'-
trihydroxyacetophenone (92) with DMF-DMA, because it decreases the nucleophilicity of
the aromatic ring and prevents side reactions that may occur between the free hydroxy
groups and DMF-DMA.
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2',4',6'-Trihydroxyacetophenone (92) was regioselectively protected with MOMCl
generated from the reaction of dimethoxymethane, acetyl chloride and catalytic ZnBr2 to
give 94 (Scheme 4.10).46 The 1H NMR spectrum of compound 94 showed two meta-
coupled doublets at δH 6.24 and 6.26 arising from  the aromatic protons H-3' and H-5',
respectively, a three-proton singlet at δH 2.65 due to the C-2 methyl group, and a
characteristic hydrogen-bonded hydroxy signal at δH 13.68. The methoxymethyl ether pair




















Scheme 4.10. MOM protection of trihydroxyacetophenone 92
Condensation of 94 with DMF-DMA gave enaminoketone 93, albeit in modest yield (68%)
(Scheme 4.11).40 The structure of compound 93 was confirmed by the appearance of broad
singlets at δH 2.94 and 3.13, integrating for three protons each for the dimethylamino
protons, and two olefinic doublets, δH 6.29 and 7.92 (J = 12.0 Hz, H-2 and H-3,
respectively) in the 1H NMR spectrum of the compound (Plate 10a). The relative small
coupling constant of 12.0 Hz for the E-configuration in this case is due to the
electronegative nitrogen substituent, which weakens the through-bond interaction between
the two olefinic protons. The 13C NMR spectrum of the compound showed an upfield shift
for the carbonyl signal to δC 190.6 due to the resulting conjugation (Plate 10b), relative to
the chemical shift of δC 203.1 observed for the carbonyl signal of acetophenone 94.
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Treatment of 93 with pyridine and iodine yielded an inseparable mixture of the targeted
iodochromone 90 as the major component and the unwanted diiodinated chromone 95 as
the minor product (Scheme 4.11). The 1H NMR spectrum of the iodochromone 90
exhibited, apart from the aromatic protons and the MOM ether signals, a characteristic H-2
signal resonating as a one-proton singlet at δH 8.09 (Plate 11a). The 1H NMR spectrum of
the diiodinated chromone 95 displayed a singlet at δH 6.96 for the one aromatic proton

























Scheme 4.11. Preparation of 3-iodochromone 90 from enaminoketone 93
The cyclisation of the intermediate 93 into 3-iodochromone 90 in the presence of iodine
and pyridine, is believed to follow the mechanism depicted in Scheme 4.12. The reaction is
initiated by addition of iodine to the α-position, followed by nucleophilic attack of the
ortho-hydroxy group to the iminium moiety 96 to afford 97. Abstraction of the α-proton by
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R =  MOM
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Scheme 4.12. Proposed mechanism for the formation of 3-iodochromones
Addition of pyridine was found to be essential for the conversion of 93 to 90 in moderate
yields in the present case. It was observed that without pyridine, the reaction yielded
multiple products whereby non-iodinated chromone 99 was obtained as the major product
(Scheme 4.13). The 1H NMR spectrum of 99 showed a pair of coupled doublets at δH 6.23




























95    6% 99    29%
Scheme 4.13. Preparation of iodochromone 90 in the absence of pyridine
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The formation of 99 in the absence of pyridine may be attributed to the generation of HI in
the reaction mixture. It is known that ortho-hydroxy enaminoketones readily cyclise to
form chromones under acidic conditions.20,47 It is therefore proposed that pyridine
promotes the formation of the target 3-iodochromone by neutralising the generated HI. A
similar phenomenon has been observed by Hong et al., who established that nitrogen-
containing bases such as piperidine and pyridine promote the conversion of
enaminoketones into 3-iodochromones in good yields.48
4.3.3 Preparation of Genistein (103)
Having accomplished the synthesis of the 3-iodochromone precursor 90, we decided to
perform a model reaction for optimisation of the reaction conditions for the Suzuki-
Miyaura coupling using phenylboronic acid 102. Not only did this reaction help us to
establish the ideal conditions for the synthesis of a boronic acid from an aryl iodide and for
the Suzuki-Miyaura coupling, but it also gave access to an important phytoestrogen,
genistein (103).
Although most phenylboronic acids are commercially available, we opted to synthesise the
boronic acid 102 in order to pave the way for the synthesis of the boronic acid 91, which
was required for eriosemaone D (17), kraussianone 1 (1) and the geranyl analogue 89.
Arylboronic acids are traditionally prepared by the reaction of arylmagnesium halides or
aryllithium with trialkyl borates. Alternatively, they can be synthesised by the Pd-catalysed
cross-coupling reaction of aryl halides with alkoxydiboron or alkoxy hydroboranes.49-52
However, the boron reagents used in the latter procedure are expensive and unattractive for
large scale synthesis.53 On the other hand, the direct metal-halogen exchange reactions
involved in the former procedures, are reported to have low functional group tolerance.49
The magnesium-halogen exchange procedures reported to be applicable in the presence of
sensitive substituents, require alkylmagnesium halide reagents, such as
isopropylmagnesium chloride, to facilitate the insertion of magnesium to the aryl halide.54
We opted to synthesise the arylboronic acids from an aryllithium using the readily-
available n-BuLi to facilitate lithium-halogen exchange.
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The synthesis of 102 was initially attempted by a normal sequential procedure whereby a
solution of aryl iodide 101 in THF was successively treated with n-BuLi, then triisopropyl
borate and the resulting boronate ester hydrolysed with NH4Cl. Following this procedure, a
small amount of boronic acid 102 was obtained and an appreciable quantity of the de-
iodinated starting material was recovered. It was evident from these results that the
lithium-iodine exchange occurred rapidly as expected, and that the generated aryllithium
was very unstable. It was therefore necessary to change the reaction conditions to

















Scheme 4.14. Preparation of boronic acid 102
Optimum results were obtained by changing the solvent system to THF:diethyl ether (1:2),
and the sequence in which the reagents were added, by employing the ‘‘in situ quench’’
procedure developed by Li and co-workers.53 Therefore, the boronic acid 102 was prepared
in a one-pot sequence, which involved addition of n-BuLi to a solution of aryl iodide 101
and triisopropyl borate in THF:diethyl ether (1:2), followed by the hydrolysis of the
boronate ester with an ammonium chloride solution (Scheme 4.14). The improvement
observed with this procedure may be attributed to the immediate in situ quench of the
generated phenyllithium with triisopropyl borate thus preventing side reactions of the
phenyllithium.53 The role played by the THF:ether solvent system is not fully understood.
However, it has been reported that different coordinating solvents affect the stability, the
aggregation and the reactivity of the lithiated species.55,56
The 1H NMR spectrum of compound 102 displayed two ortho-coupled doublets, each
integrating for two protons, δH 7.15 and 8.16 (J = 8.2 Hz), and the protons of the
methoxymethyl protecting group resonating at δH 5.07 (2H, s, OCH2O) and 3.52 (3H, s
OCH3). The presence of boron in the molecule was confirmed by the disappearance of a
signal at around δC 84.3 in the 13C NMR spectrum, indicating the displacement of iodine in
the starting material. The 11B spectrum of 102 further confirmed the presence of a boronic
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acid by a resonance at δB 28.52. The IR spectrum of compound 102 displayed an OH














1. DME/H2O, Pd(C), K2CO3
2. CH3OH, HCl
103    66%
Scheme 4.15. Synthesis of genistein (103)
The Suzuki-Miyaura cross-coupling of boronic acid 102 with 3-iodochromone 90 using a
heterogeneous Pd(C) catalyst and subsequent removal of the MOM protecting groups
furnished genistein (103) in 66% yield (Scheme 4.15).35 The use of the ligandless Pd(C)
for the C-C bond formation is said to have advantages over other methods in that the
reaction is conducted successfully under hydrous conditions. Moreover, the Pd(C) can be
readily removed from the reaction mixture by filtration.35
The 1H NMR spectrum of compound 103 displayed a characteristic isoflavone one-proton
singlet at δH 8.29 for the hydrogen at C-2, two meta-coupled doublets for the aromatic
protons of the A-ring at δH 6.22 (1H, d, J = 2.1 Hz, H-8) and δH 6.38 (1H, d, J = 2.1 Hz, H-
6), and the protons of the B-ring exhibited an AA'BB' spin system at δH 6.81 (2H, d, J = 8.8
Hz, H-3' and H-5') and 7.36 (2H, d, J = 8.8 Hz, H-2' and H-6') (Plate 12). The HRMS
spectrum of the compound showed an m/z peak of 269.0452 [M-H]-, consistent with the
calculated molecular mass of 269.0450 for C15H9O5.
Using 3-iodochromone 90, the proposed mechanism for the Suzuki coupling reaction is
shown in Scheme 4.16. It involves oxidative addition of iodochromone 90 to Pd(0) to give
Pd(II) intermediate 104. The intermediate 104 undergoes transmetallation with the
arylboronic acid to afford the organopalladium species 105, which upon reductive







































Scheme 4.16. Mechanism for the Pd-catalysed C-C bond formation
Although genistein (103) was synthesised in a model reaction, this synthesis is of utmost
importance since 103 has been associated with a number of biological activities that
include inhibition of tyrosine kinase, phytoestrogenic, antioxidative, anticancer activities
and protection against cardiovascular diseases and ostereoporosis.57,58 Furthermore, it may
serve as an important precursor for a large number of biologically-active isoflavonoids by
modifications of rings A, B and C.
4.3.4 Preparation of the Boronic Acid Derivative 91
As seen from the proposed synthetic route, Scheme 4.8, the target compounds 17, 1 and 89
were planned to be prepared from 3-iodochromone 90 and the boronic acid 91. The

























Scheme 4.17. Proposed synthetic pathway for the boronic acid 91
In this synthetic route, it was envisaged that a major challenge would be encountered in the
regiospecific C-6 iodination of 7-hydroxy-2,2-dimethylchromanone 33 to form 7-hydroxy-
6-iodo-2,2-dimethylchromanone 107. Iodination of chromanone 33 has not been reported
previously. Except for the nucleophilic aromatic substitution of a diazonium salt with
iodide ion,59 most iodination protocols for electron-rich aromatic rings proceed via
electrophilic aromatic substitution. Nevertheless, there are three sites susceptible to
electrophilic substitution in compound 33, as shown in Figure 4.1, which may give






X = nucleophilic site
Figure 4.1. Active sites for electrophilic substitution
The dimethylchromanone 33 was prepared in good yields by condensation of resorcinol
(32) with 3-methylbut-2-enoic acid.60 The iodinating reagents, KIO3/KI, HIO4/I2 and ICl
were initially screened for C-6 iodination of 33 under different conditions,31,61-63 but 7-
hydroxy-8-iodo-2,2-dimethylchroman-4-one (111) and 7-hydroxy-6,8-diiodo-2,2-
dimethylchroman-4-one (112) predominated. Benzyl protection of the 7-hydroxy group of
chromanone 33, with the aim of preventing di-iodination through decreased nucleophilicity
83
of the aromatic ring, and subsequent iodination of the resulting benzyloxychromanone with
HIO3/I2,
















Figure 4.2. Unwanted iodinated chromanones
The structures of the iodinated chromanones 111, 112 and 113 were elucidated by 1H
NMR spectroscopy. The spectrum of 111 displayed two ortho-coupled doublets for the
aromatic protons at δH 6.71 and 7.83 (J = 8.4, H-6 and H-5, respectively) and two singlets
for the aliphatic protons at δH 1.55 (2 x CH3) and 2.73 (2H, H-3), while that of 112
exhibited a one-proton singlet for the aromatic proton H-5 at δH 8.26. Besides the signals
of the benzyl protecting group, the 1H NMR spectrum of 113 on the other hand, displayed
an ABX spin system in the aromatic region [δH 6.54 (1H, d, J = 1.8, H-8), 6.71 (1H, dd, J =
1.8 and 8.4, H-6 ) and 7.89 (1H, J = 8.4, H-5)]. This indicated that the aromatic ring of the
starting material was not iodinated. However, a deshielded one-proton singlet was
observed at δH 4.65 instead of the two-proton singlet at around δH 2.73, observed in the 1H
NMR spectrum of the starting material and other iodinated chromanones 111 and 112. The
resonances of the diastereotopic methyl groups in 113 gave two distinct singlets,
intergrating for three protons each at δH 1.59 and 1.67. Therefore, it was deduced that
iodination of 7-benzyloxy-2,2-dimethylchromanone occurred at C-3, giving a racemic
mixture of 113.
Promising results were obtained upon treatment of a methanolic solution of 33 with iodine
and iodic acid at 85 oC. This gave a mixture of the intended C-6 iodinated chromanone 107
as the major component and the unwanted iodochromanone 111 as a minor component,
Scheme 4.18. The two compounds were difficult to separate with column chromatography,
but could be purified based on their solubility properties. It was established that the two
isomers had different solubility properties, whereby 111 dissolved in CH2Cl2 and CHCl3,


















Scheme 4.18. Preparation of 7-hydroxy-6-iodo-2,2-dimethylchroman-4-one (107)
The 1H NMR spectrum of 107 displayed two aromatic singlets at δH 6.40 (1H, s, H-8) and
7.96 (1H, s, H-5), and the aliphatic protons resonated at δH 1.36 (6H, s, 2 x CH3) and 2.67
(2H, s, H-3). The 13C  NMR spectrum displayed a signal at δC 189.2 assigned to the
carbonyl carbon, in addition to the signals for the six aromatic carbons (δC 76.4, 102.8 –
163.1) and the four aliphatic carbons (δC 26.1, 47.4 and 79.8) with the methyl carbons
overlapping. A sharp C=O band appeared at 1641 cm-1 in the IR spectrum of the
compound.
It was necessary to synthesise 107 in larger quantities in order to continue with the steps
leading to boronic acid 91. However, scaling up to 1.5 g scale gave rise to some
reproducibility problems, whereby we obtained a mixture of 107, 111, 112 and the starting
material 33, repeatedly, the major compound being the unwanted 8-iodochromanone 111.
From these results, we suspected that the formation of 6-iodochromanone 107 by treatment
of 33 with iodine and iodic acid did not proceed via a simple electrophilic aromatic
substitution as expected. We deduced that compound 107 may be formed via migration of
I+ from C-8 of 111 to C-6 as shown in Scheme 4.19. This kind of rearrangement, also
known as the ‘‘iodine dance’’, has been reported by Thomsen and Torsell, in the























Scheme 4.19. Acid-catalysed rearrangement of 111 to 107
85
The targeted 6-iodochromanone was obtained upon treatment of a CHCl3 solution of
7-benzyloxy-2,2-dimethylchromanone (114) with silver trifluoroacetate and iodine at room
temperature. This gave 7-benzyloxy-6-iodo-2,2-dimethylchromanone (108) as the sole
product in 94% yield (Scheme 4.20).66 This procedure allowed for the large scale synthesis
of 108 in good yields. The 1H NMR spectrum of compound 108 displayed signals similar


















Scheme 4.20. Preparation of iodochromanone 108
These results support the Haszeldine and Sharpe findings, who reported that iodination of
substituted aromatic rings with silver trifluroacetate and iodine gives predominantly para-
iodinated compounds.66 Iodination with these reagents is said to be facilitated by the
generation of the electrophilic iodine trifluoroacetate, which decomposes into carbon
dioxide and trifluoroiodomethane (Scheme 4.21).66








Scheme 4.21. The generation of electropositive iodine from silver trifluoroacetate and
iodine
Reduction of 108 with sodium borohydride and the subsequent dehydration proceeded
cleanly to give 7-benzyloxy-6-iodo-2,2-dimethylchromene (110) (Scheme 4.22).67,68
Reduction of the carbonyl group was confirmed by the presence of a signal at δH 4.75 (1H,
ddd, J = 8.5, 7.3 and 6.0 Hz) for H-4, indicating a coupling to the two C-3 protons and an
adjacent OH in the 1H NMR spectrum of racemic 109. The two C-3 protons were displayed
as a pair of doublet of doublets at δH 1.80 (Jgem = 13.6 and J3,4 = 8.5 Hz) and 2.10
(Jgem = 13.6 and J3,4 = 6.0 Hz), and the OH as a broad doublet at  δH 2.17 (J = 7.3 Hz). The
86
reduction was further confirmed by the disappearance of the carbonyl absorption peak at
1641 cm-1 and the appearance of the broad OH band at 3467 cm-1 in the IR spectrum of
compound 109. The 1H NMR spectrum of chromene 110, on the other hand, exhibited
olefinic doublet signals at δH 5.48 and 6.22 (J = 9.9 Hz, H-3 and H-4, respectively). The IR































Scheme 4.22. Preparation of the boronic acid derivative 91
Boronic acid 91 was prepared from iodochromene 110 under the same reaction conditions
to those employed in the synthesis of boronic acid 102 (Scheme 4.22).53  The 1H NMR
spectrum of 91 (Plate 13a) exhibited an additional two-proton singlet at δH 5.54 (-B(OH)2)
and a slight downfield shift of the aromatic proton signals, δH 6.46 and 7.47 (H-8 and H-5,
respectively) instead of δH 6.41 and 7.37 observed in the 1H NMR spectrum of the
iodochromene 110 due to the electron-withdrawing effect of boron in the molecule. The
13C NMR spectrum confirmed the substitution of iodine by the absence of the
iodine-bearing C-6 signal at δC 74.8 (Plate 13b). The presence of the boronic acid group
was further confirmed by the IR spectrum which displayed a broad band at 3367 cm-1 due
to the OH stretches and by the appearance of a characteristic arylboronic acid signal at δB
28.74 in the 11B NMR spectrum of compound 91.
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4.3.5 Preparation of Eriosemaone D (17) and Kraussianone 1 (1)
Following the synthesis of the boronic acid 91, the next step was to couple it to the
3-iodochromone precursor 90. Thus,  Pd(C)-catalysed cross coupling of boronic acid 91
with 3-iodochromone 90 and subsequent cleavage of the MOM protecting groups with HCl
gave 2'-O-benzyleriosemaone D (115) (Scheme 4.23).35 The 1H NMR spectrum of 115
(Plate 14a) displayed the characteristic isoflavone one-proton singlet at δH 7.77 (H-2),
instead of a downfield shift δH 8.09 for H-2 observed in the spectrum of the
3-iodochromone 90. The aromatic protons of the A-ring appeared as two meta-coupled
doublets at δH 6.19 and 6.21 (J = 2.2, H-6 and H-8, respectively) and those of the B-ring
displayed an AM spin system, δH 6.50 and 6.92 (s, H-3' and H-6', respectively). The
dimethylchromene ring signals were observed at δH 1.40 (2 x CH3), 5.44 and 6.23 (d, J =
9.8 Hz, for the cis olefinic protons H-5'' and H-4'', respectively) and those of the benzyl
group at δH 5.03 (2H, s, PhCH2) and 7.22-7.34 (5H, m, PhCH2). The HRMS spectrum gave
an m/z ion at 465.1312 [M+Na]+  in agreement with the calculated pseudo molecular mass

















































Scheme 4.23. Preparation of benzyl derivatives of eriosemaone D and kraussianone 1
88
Base-catalysed condensation of the pyranoisoflavone 115 with prenal gave the benzyl
derivative of kraussianone 1 116 (Scheme 4.23).69 The structure of 116 was confirmed by
the presence of additional signals in the 1H NMR spectrum for the dimethylchromene
fused to the A-ring at δH 1.47 (2 x CH3), 5.61 and 6.73 (d, J = 10.0 Hz, H-5''' and H-4''',
respectively) (Plate 15a). The HRMS spectrum gave an m/z of 531.1782 [M+Na]+ in
agreement with the calculated pseudo molecular mass of 531.1784 for C32H28NaO6.
Three regioisomers are possible for this reaction. These are the linear 116 and the angular
isomers 117 and 118, respectively. From the 1H NMR results, it could be readily deduced
that the isomer 118 was not formed, due to the presence of the characteristic hydrogen-
bonded OH-5 resonance at δH 13.22 in the 1H NMR spectrum. Thus, the product could
























The fusion of prenal to C-6 and OH-7 of 115 to give the linear isomer 116 was confirmed
by the presence of the slight downfield H-8 signal at δH 6.31 in the 1H NMR spectrum of
compound 116, consistent with the literature results.70-72 If the angular isomer 117 was
formed, we expected a more shielded H-6 signal at around δH 6.27, which was not
observed in the present case. The structure of 116 was further corroborated by the 13C
NMR spectrum, which displayed the characteristic non-alkylated C-8 signal at δC 94.8,
instead of the C-6 signal, which would appear at around 100.3.70,71 The regiochemistry of
compound 116 was also confirmed by the NOESY experiment, which showed weak
through-space correlations between OH-5 and H-4''', and H-8 and H-2, in agreement with











Figure 4.3. Observed NOESY correlations for the linear isomer 116
The formation of the second dimethylpyran ring by the condensation of the
pyranoisoflavone 115 with prenal follows an aldol-type condensation and subsequent 6π-
electrocyclisation as discussed in Chapter 3, Section 3.2.2.1. It has been reported that the
regioselectivity in the synthesis of linear and angular isomers by condensation of prenal to
the phloroglucinol moiety of chromone-based systems depends on the reaction
conditions.69,73 Jeso and Nicolaou introduced the linear dimethylpyran scaffold on the
phloroacetophenone moiety of tovophyllin B by a CaO-induced aldol-type condensation
with prenal.73  Mondal and co-workers also reported the regioselective formation of the
linear and angular pyranoxanthones. From their investigation, the angular isomer was
formed in good yields when the reaction was performed neat at high temperatures (140-
150 oC) whereas the linear isomer was formed when the reaction was performed at rt in
CH3OH, using Ca(OH)2 as a base.
69 Therefore, we opted for the latter conditions for the
synthesis of 116 from 115. Under these conditions, it is postulated that Ca2+ chelates with
the carbonyl group and the adjacent OH-5 (Figure 4.4), thereby increasing the










Figure 4.4. Chelation of 2'-O-benzyleriosemaone D (115) with Ca2+
Furthermore, two hypothetical carbanions 119 and 120 may result from deprotonation of
the OH-7 under basic conditions as shown in Scheme 4.24. Upon keto-enol
tautomerisation, the carbanion 119 is flanked between two carbonyl systems, therefore it is
less stable and more reactive than the carbanion 120, which is stabilised by conjugation
with the α,β unsaturated carbonyl.69 The regioselective formation of the linear isomer 116
90




















































Scheme 4.24. Formation of the linear and the angular isomers via carbanions 119 and 120,
respectively
Having successfully synthesised the benzyl derivatives of eriosemaone D and kraussianone
1, we were now in a position to cleave the benzyl protecting group. A careful selection of
the debenzylating conditions was crucial for the successful conversion of 115 and 116 into
17 and 1, respectively, since the compounds possess dimethylchromene scaffolds. Thus
palladium-catalysed hydrogenation, which is often employed for cleavage of the benzyl
protecting group, could not be employed in the present case as the double bonds would be
reduced. The choice of the reagents for the debenzylation  was restricted to Lewis acids
such as TiCl4 and AlCl3, BF3.OEt2 and BCl3.
11,74,75,76,77 The successful debenzylation of
benzylpyranoisoflavones has been reported by Tsukayama and co-workers, who employed
BCl3 in CH2Cl2. Therefore, similar conditions were employed in the synthesis of
eriosemaone D (17) and kraussianone 1 (1) from 115 and 116, respectively (Scheme
4.25).11 The structures of the targeted compounds were confirmed by the absence of the




































Scheme 4.25. Synthesis of eriosemaone D (17) and kraussianone 1 (1)
4.3.6 Preparation of a Geranyl Analogue of Kraussianone 1
The geranyl moiety occurs sporadically amongst the different classes of flavonoids and is
mostly prevalent in flavanones, chalcones and other classes of polyphenolic compounds
such as xanthones,.78-82 Even though the geranylated isoflavonoids are uncommon, the few
reported ones exhibit important biological activities such as anti-inflammatory, estrogenic,
cytotoxicity against human cancer cell lines, antiviral, antimicrobial, immunosuppressive
as well as anti-oxidative activities.2-4,83,84
Following the successful synthesis of kraussianone 1 (1), eriosemaone D (17) and genistein
(103), the focus was shifted to the synthesis of 89, a derivative of kraussianone 1 with an
O-cyclised geranyl moiety attached to the A-ring. More often, prenylation of biologically-
active compounds has been determined to enhance the activity of the compounds,85,86 and
in certain instances, geranylated compounds have been found to be more active than the
prenylated ones.78,80,85-87 Therefore, we planned to prepare 89, the geranyl derivate of







As shown in Scheme 4.26, the synthesis commenced with preparation of the
dimethylchromene boronic acid 125, which would render the B-ring and the dimethylpyran
scaffold fused to it. This time, the MOM protecting group was used instead of a benzyl
group, because of the ease of cleavage of the MOM group and in order to eliminate the
debenzylation step. Chromanone 33 was thus converted into methoxymethyl ether 121,46
which was iodinated by I2 and CF3CO2Ag in CH2Cl2 to give 122. Iodochromanone 122
was reduced and dehydrated to give iodochromene 124.66 Sequential treatment of the
solution of 124 in ether:THF with triisopropylborate, n-BuLi and NH4Cl gave boronic acid
































3. NH4Cl125    79%
Scheme 4.26. Preparation of boronic acid 125
The 1H NMR spectrum of the boronic acid 125 displayed an AM spin system at δH 7.45
(1H, s, H-5) and 6.58 (1H, s, H-8) for the aromatic protons, two olefinic doublets at δH 5.50
and 6.31 (J = 9.9 Hz, H-3 and H-4, respectively) and a six-proton singlet at δH 1.43 (6H, s,
2  CH3) for the dimethylpyran scaffold. In addition, a broad singlet intergrating for two
protons was observed at δH 5.63 (B(OH)2) and the signals for the methoxymethyl
protecting group resonated at δH 5.24 (2H, s, OCH2O) and 3.50 (3H, s, OCH3) in the 1H
93
NMR spectrum of 125 (Plate 16a). The presence of the boronic acid group was further
confirmed by the IR spectrum which displayed a broad band at 3380 cm-1 due to the OH
stretches and by the appearance of a characteristic arylboronic acid signal at δB 29.06 in the
11B NMR spectrum of compound 125.
The Suzuki-Miyaura coupling of boronic acid 125 with 3-iodochromone 90 in the presence
of Pd(C) and Na2CO3 in DME:H2O gave the isoflavone 126.
35 Cleavage of the MOM
































Scheme 4. 27. Preparation of eriosemaone D (17)
Having prepared 17, the next step was to condense it with citral to give the geranyl
derivative 89. The feasibility of this reaction was first tested on chromone 51.
Condensation of 51 with citral gave racemic 127 in 64% yield as shown in Scheme 4.28.
The presence of the O-cyclised geranyl moiety was evidenced by the presence of signals at
δH 5.57 (1H, d, J = 10.0 Hz, H-5'), 6.75 (1H, d, J = 10.0 Hz, H-4'), 5.10 (1H, t, J = 7.2 Hz,
H-10'), 2.09 (2H, dd, J = 16.1 and 8.0, H-9'), 1.75-1.81 (1H, m, H-8'b), 1.62-1.69 (4H, m,
H-8'a and H-12' or 13'), 1.57 (3H, s, H-12' or 13'), 1.43 (3H, s, H-7'), indicative of the
pyran chromophore with a methyl and 4-methylpent-3-enyl substituents in the 1H NMR































Scheme 4.28. Model reaction for condensation of chromone 51 with citral
Motivated by the results from the model reaction, the condensation was performed on
eriosemaone D (17). Ca(OH)2-induced condensation of 17 with citral gave an inseparable












Scheme 4.29. Attempted synthesis of 89
In order to overcome the aforementioned problem, we opted to condense citral with 2'-O-
benzyleriosemaone D (115) as the polarity of the resulting product would be different from
that of 89. Thus, 2'-O-benzyleriosemaone D 115 was reacted with citral under similar
conditions to give racemic compound 128 in 68% (Scheme 4.30). Cleavage of the benzyl
protecting group with BCl3 in CH2Cl2 gave the targeted racemic compound 89 in a 61%
yield. The 1H NMR spectrum of 89 (Plate 21) showed signals similar to those of
kraussianone 1 (1) except for the appearance of additional signals of the 4-methylpent-3-
enyl and the methyl substituents [δH 5.09 (1H, t, J = 7.0 Hz, H-10'''), 2.11 (2H, dd, J = 15.8
and 7.9, H-9'''), 1.84 (1H, m, H-8'''b), 1.66-1.70 (4H, m, H-8'''a, H-12''' or 13'''), 1.57 (3H, s,
H-12''' or 13'''), 1.45 (3H, s, H-7''')] instead of two equivalent methyl groups on the
chromene ring attached to the A-ring. The structure was confirmed by HRMS, which gave
























Scheme 4.30. Successful synthesis of 89
4.4 CONCLUSION
In conclusion, we have successfully synthesised the two biologically-active
pyranoisoflavones, the anti-impotence pyranoisoflavone kraussianone 1 (1) and the anti-
fungal pyranoisoflavone eriosemaone D (17), the simple isoflavone genistein (103) and the
geranyl derivative of kraussianone 1 89 by application of the Suzuki-Miyaura protocol as
the key step. This route readily gave access to structurally-related isoflavones by using
different boronic acid partners or by incorporation of additional substituents to the A-ring
of the isoflavones. Secondly, it employed mild reaction conditions, which tolerated highly
sensitive functional groups, such as the dimethylpyran ring. For instance the dimethylpyran
ring constructed in the early stages of the synthetic pathway survived all the subsequent
reaction conditions leading to targeted isoflavones. Furthermore, the present synthetic
strategy allowed the regioselective introduction of the dimethylpyran scaffolds to the
resorcinol (B-ring) and the phloroglucinol (A-ring) moieties of kraussianone 1 (1) and its










ZnBr2 (13.4 mg, 0.0594 mmol) was dissolved in dimethoxymethane (2.62 mL, 29.7 mmol)
under an N2 atmosphere, and then AcCl (2.12 mL, 29.7 mmol) was added dropwise to the
stirred solution. The solution was stirred for an additional 2 h at room temperature and
transferred via a cannula to an ice-cold solution of the pre-dried phloroacetophenone (92)
(2.00 g, 11.9 mmol) and DIA (3.6 mL, 23.59 mmol) in CH2Cl2 (100 mL) under an N2
atmosphere. The mixture was stirred for 3 h, diluted with saturated NH4Cl solution and
stirred for an additional 15 min. The two phases were partitioned and the aqueous phase
was extracted with CH2Cl2. The combined organic extracts were washed with brine and
dried over anhydrous MgSO4. The solvent was evaporated to give a yellow oil which was
purified by column chromatography using Hex:EtOAc (7:3) as eluent to afford 94 as a
colourless oil (1.53 g, 50%).
IR (neat) vmax 3100, 2925, 1618 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 13.68 (1H, s, OH), 6.26 (1H, d, J = 2.4 Hz, H-3'), 6.24 (1H,
d, J = 2.4 Hz, H-5'), 5.25 (2H, s, OCH2O), 5.16 (2H, s, OCH2O), 3.52 (3H, s, OCH3), 3.47
(3H, s, OCH3), 2.65 (3H, s, COCH3);
13C NMR (CDCl3, 100 MHz) δ 203.1 (C, C-1), 167.3 (C, C-2'), 163.3 (C, C-4'), 160.5 (C,
C-6'), 107.3 (C, C-1'), 97.3 (CH, C-3'), 94.5 (CH, C-5'), 94.0 (CH2, 2  OCH2O), 56.7
(CH3, OCH3), 56.4 (CH3, OCH3), 32.9 (CH3, -COCH3);
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DMF-DMA (0.29 mL, 2.19 mmol) was added to 94 (0.28 g, 1.09 mmol) at 95 oC. The
mixture was stirred at the same temperature for 1.5 h. The volatiles in the orange oil were
evaporated on a rotary evaporator and the crude solid was subjected to flash
chromatography using Hex:EtOAc (1:1) as eluent. Evaporation of the solvent gave 93 as a
yellow oil, which solidified upon cooling (0.23 g, 68%). The solid was recrystallized to
give yellow needle-like crystals (1:1 Hex:Et2O).
mp 85-86 oC;
IR (KBr) vmax 3445, 3163, 2913, 1606, 1233 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 15.08 (1H, s, OH-2'), 7.92 (1H, d, J = 12.0 Hz, H-3), 6.29
(1H, d, J = 12.0 Hz, H-2), 6.26 (1H, d, J = 2.4 Hz, H-3'), 6.17 (1H, d, J = 2.4 Hz, H-5'),
5.20 (2H, s, OCH2O), 5.14 (2H, s, OCH2O), 3.51 (3H, s, OCH3), 3.46 (3H, s, OCH3), 3.13
[3H, brs, N(CH3)2], 2.94 [3H, brs, N(CH3)2]; (Plate 10a)
13C NMR (CDCl3, 100 MHz) δ 190.6 (C, C-1), 166.9 (C, C-2'), 161.3 (C, C-4'), 158.9 (C,
C-6'), 154.4 (CH, C-3), 107.1 (C, C-1'), 97.9 (CH, C-3'), 97.0 (CH, C-2), 95.2 (CH2,
OCH2O),  94.5(CH, C-5'),  94.1 (CH2, OCH2O), 56.7 (CH3, OCH3), 56.3 (CH3, OCH3),
45.5 [CH3, N(CH3)2], 37.2 [CH3, N(CH3)2]; (Plate 10b)







To a solution of propenone 93 (0.12 g, 0.38 mmol) in CH2Cl2 (20 mL) was added pyridine
(0.06 mL, 0.74 mmol) followed by I2 (0.11 g, 0.44 mmol). The resulting solution was
stirred at room temperature for 12 h. The reaction was quenched with saturated Na2S2O3
solution and the two phases partitioned. The aqueous phase was extracted with CH2Cl2.
The organic layers were combined, washed with H2O, brine and dried over anhydrous
MgSO4. The solvent was evaporated to give a yellow solid. The crude product was purified
on a chromatotron using Hex:EtOAc (7:3) as eluent. The solvent was evaporated to afford
a cream-white solid (94 mg), which was identified (1H NMR) as a mixture of 90 and 3,8-
diiodo-5,7-dimethoxymethoxychromone (95) in the ratio of 50:7, respectively. Therefore,
the percentage yield of compound 90 was 58%.
IR (KBr) vmax 3179, 3099, 3058, 2958, 2904, 1622, 1445, 1275, 1140, 1036, 921, 844 cm
1;
1H NMR (CDCl3, 400 MHz) δ 8.09 (1H, s, H-2), 6.75 (1H, d, J = 2.3 Hz, H-8), 6.71 (1H,
d, J = 2.3 Hz, H-6), 5.29 (2H, s, OCH2O), 5.22 (2H, s, OCH2O), 3.54 (3H, s, OCH3), 3.49
(3H, s, OCH3); (Plate 11a)
13C NMR (CDCl3, 100 MHz) δ 171.2 (C, C-4), 161.5 (C, C-7), 159.2 (C, C-5), 158.3 (C,
C-8a), 155.6 (CH, C-2), 108.8 (C, C-4a), 102.1 (CH, C-6), 96.8 (CH, C-8), 95.5 (CH2,
OCH2O), 94.4 (CH2, OCH2O), 89.4 (C, C-3), 56.7 (CH3, OCH3), 56.5 (CH3, OCH3); (Plate
11b)





AcCl (1.94 mL, 27.3 mmol) was added dropwise to the stirred solution of
dimethoxymethane (2.40 mL, 27.3 mmol) and ZnBr2 (12.3 mg, 0.0546 mmol) under N2.
The solution was stirred for an additional 2 h at room temperature and transferred via a
cannula to the ice-cold solution of 4-iodophenol (100) (2.00 g, 9.09 mmol) and DIA (4.16
mL, 27.27 mmol) in CH2Cl2 (100 mL) under an N2 atmosphere. The mixture was stirred
for 4 h, diluted with saturated NH4Cl solution and stirred for an additional 15 min. The two
phases were partitioned and the aqueous phase was extracted with CH2Cl2. The combined
organic extracts were washed with brine and dried over anhydrous MgSO4. The solvent
was evaporated and the product was purified with column chromatography using
Hex:EtOAc (8:2) to afford 101 as a colorless oil (1.8 g, 75%).
IR (neat) vmax 2954, 2901, 2825, 1585, 1483, 1231, 1147, 987, 818 cm
-1;
1H NMR (CDCl3, 400 MHz) δ  7.56 (2H, d, J = 9.0 Hz, H- 2 and H-6), 6.82 (2H, d, J = 9.0
Hz, H-3 and H-5), 5.14 (2H, s, OCH2O), 3.46 (3H, OCH3);
13C NMR (CDCl3, 100 MHz) δ 157.0 (C, C-4), 138.2 (CH, C-2 and 6), 118.5 (CH, C-3 and
C-5), 94.3 (CH2, OCH2O), 84.3 (C, C-1), 55.9 (CH3, OCH3).
4.5.5 4-Methoxymethoxyphenylboronic acid (102)
MOMO
B(OH)2
Triisopropyl borate (2.21 mL, 9.47 mmol) was added in one portion to the stirred solution
of iodobenzene 101 (1.0 g, 3.79 mmol) in THF:Et2O (60 mL, 1:2) under N2. The solution
was cooled to -100 oC using liquid N2 and a CH3OH bath, and then n-BuLi (3.79 mL of a
100
1.5 M solution in hexanes) was added with stirring over 5 min. After 1 h of stirring at a
temperature below -78 oC, saturated NH4Cl solution was added. The mixture was stirred
for an additional 1 h and the two phases were partitioned. The aqueous phase was extracted
with Et2O. The organic phases were combined, washed with H2O and brine, and dried over
anhydrous MgSO4. The solvent was evaporated to give a white solid which was subjected
to column chromatography using Hex:EtOAc (4:1) as the mobile phase. The solvent was
evaporated to give boronic acid 102 as a white solid (0.59 g, 85%).
IR (KBr) vmax 3436, 3359, 1651, 1606, 1235, 1016, 773 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 8.16 (2H, d, J = 8.6 Hz, H- 2 and H-6), 7.15 (2H, d, J = 8.6
Hz, H-3 and H-5), 5.27 (2H, s, OCH2O), 3.52 (3H, OCH3);
13C NMR (CDCl3, 100 MHz) δ 160.9 (C, C-4), 137.5 (CH, C-2 and 6), 115.6 (CH, C-3
and C-5), 94.1 (CH2, OCH2O), 56.1 (CH3, OCH3), (C-1 signal not observed);






4-Methoxymethoxyphenylboronic acid (102) (42 mg, 0.23 mmol), K2CO3 (51 mg, 0.37
mmol), and catalytic 10% Pd/C were added to a solution of 3-iodochromone 90 (50 mg,
0.13 mmol) in DME (2 mL) and H2O (2 mL). The resulting mixture was stirred at 40-45
oC
for 12 h. The catalyst was filtered and washed with H2O and Et2O. The organic solvents
were evaporated and the crude product was diluted in CH3OH (10 mL) and HCl (3 M, 5
mL). The resulting solution was refluxed for 30 min. CH3OH was evaporated and the
aqueous phase was extracted with EtOAc. The combined organic layers were washed with
H2O, brine, and dried over anhydrous MgSO4. The solvent was evaporated and the crude
101
product was purified by column chromatography using Hex:EtOAc (3:2)  and
recrystallized from EtOH to give the isoflavone 103 as a yellow crystals (23 mg, 66%).
mp 300-303 oC  (Lit.88 301-302 oC);
IR (KBr) vmax 3434, 3181, 3069, 2922, 1652, 1621, 1176, 809, 784 cm
-1;
1H NMR (DMSO-d6, 400 MHz) δ 12.93 (1H, s, OH-5), 9.65 (1H, brs, OH-4'), 8.29 (1H, s,
H-2), 7.36 (2H, d, J = 8.8 Hz, H-2' and 6'), 6.81 (2H, d, J = 8.8 Hz, H-3' and H-5'), 6.38
(1H, d, J = 2.1 Hz, H-6), 6.22 (1H, d, J = 2.1 Hz, H-8); (Plate 12)
13C NMR (DMSO-d6, 100 MHz,) δ 182.3 (C, C-4), 166.0 (C, C-7), 163.9 (C, C-5), 159.8
(C, C-4'), 158.9 (C, C-8a), 154.8 (CH, C-2), 131.2 (CH, C-2' and 6'), 124.8 (C, C-1'), 123.3
(C, C-3), 116.8 (CH, C-3'  and 5'), 106.3 (C, C-4a), 100.1 (CH, C-6), 94.8 (CH, C-8);





Resorcinol (32) (1.00 g, 9.10 mmol) and 3-methyl-2-butenoic acid (0.910 g, 9.10 mmol)
were added simultaneously under N2 to a stirred mixture of CH3SO3H (14.5 mL, 0.218
mol) and P2O5 (0.70 g, 5.10 mmol) at 70
oC. The reaction mixture was stirred at the same
temperature for 30 min, cooled to room temperature and poured into ice-water. The
aqueous phase was extracted with Et2O, and the combined organic extracts were washed
with H2O, brine, and dried over anhydrous MgSO4. The solvent was evaporated to afford a
yellow solid. The solid was purified by flash chromatography using Hex:EtOAc (3:2) as
mobile phase to give chromanone 33 as a light yellow solid (1.61 g, 92%).
Recrystallization of the solid afforded white crystals (9:1 CH2Cl2:Et2O).
mp 170.0-171.5 oC  (Lit.60 172-174 oC);
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IR (KBr) vmax 3129, 2967, 2837, 1578, 1252, 1169, 1126, 854 cm
-1;
1H NMR (DMSO-d6, 400 MHz) δ 7.58 (1H, d, J = 8.4 Hz, H-5), 6.43 (1H, dd, J = 1.9 and
8.4 Hz, H-6), 6.24 (1H, d, J = 1.9 Hz, H-8), 2.65 (2H, s, H-3), 1.36 (6H, s, 2   CH3);
13C NMR (DMSO-d6, 100 MHz) δ 190.1 (C, C-4), 164.7 (C, C-7), 161.4 (C, C-8a), 127.9
(CH, C-5), 112.8 (C, C-4a), 109.8 (CH, C-6), 102.8 (CH, C-8), 79.3 (C, C-2), 47.8 (CH2,
C-3), 26.2 (2  CH3);






A solution of chromanone 33 (0.15 g, 0.78 mmol), HIO3 (0.03 g, 0.17 mmol), and I2 (0.08
g, 0.32 mmol) in CH3OH:H2O (3:1, 10 mL) was heated to 85
oC for 12 h. The CH3OH was
evaporated to give a yellow residue, which was diluted with EtOAc and H2O. The two
phases were partitioned, and the aqueous phase was extracted with EtOAc. The combined
organic extracts were washed with saturated Na2S2O3 solution, H2O and brine, and dried
over anhydrous MgSO4. Evaporation of the solvent gave a yellow solid, which was washed
with hot CH2Cl2, cooled and filtered. The residue was recrystallized from CH2Cl2:EtOAc
(8:2) to give pure 107  (0.16 g, 65%). The mother liquor, which contained mostly 7-
hydroxy-8-iodo-2,2-dimethyl-4-chromanone (111), was evaporated to give a yellow solid
(49 mg).
mp 195-197 oC;
IR (KBr) vmax 2978, 2922, 2702, 1641, 1563, 1327, 1259, 849 cm
1;
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1H NMR (DMSO-d6, 400 MHz) δ 7.96 (1H, s, H-5), 6.40 (1H, s, H-8), 2.67 (2H, s, H-3),
1.36 (6H, s, 2  CH3);
13C NMR (DMSO-d6, 100 MHz) δ 189.2 (C, C-4), 163.1 (C, C-7), 161.1 (C, C-8a), 136.3
(CH, C-5), 114.9 (C, C-4a), 102.8 (CH, C-8), 79.8 (C, C-2), 76.4 (C, C-6), 47.4 (CH2, C-
3), 26.1 (2  CH3);





 K2CO3 (2.16 g, 15.6 mmol) and BnBr (1.20 mL, 10.4 mmol) were added under N2 to a
stirred solution of chromanone 33 (1.00 g, 5.21 mmol) in dry CH3CN (30 mL). The
reaction mixture was refluxed for 8 h under N2. The mixture was cooled to room
temperature, acidified with 2 M HCl (40 mL) and extracted with EtOAc. The organic
extracts were combined and washed with H2O, brine, then dried over anhydrous MgSO4.
The solvent was removed with a rotary evaporator and the crude product purified on a
chromatotron using Hex:EtOAc (7:3) solvent mixture. The product 114 was obtained as
white crystals after evaporation of the solvent and recrystallization from Hex (1.30 g,
88%).
mp 55-56 oC;
IR (KBr) vmax 3324, 2982, 2964, 2890, 1672, 1604, 1441, 1319, 1258, 1164, 1000, 988,
840 cm-1;
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1H NMR (CDCl3, 400 MHz) δ 7.81 (1H, d, J = 8.4 Hz, H-5), 7.32-7.43 (5H, m, PhCH2),
6.62 (1H, dd, J = 1.9 and 8.4 Hz, H-6), 6.46 (1H, d, J = 1.9 Hz, H-8), 5.08 (2H, s, PhCH2),
2.66 (2H, s, H-3), 1.45 (6H, s, 2   CH3);
13C NMR (CDCl3, 100 MHz) δ 191.2 (C, C-4), 165.7 (C, C-7), 161.8 (C, C-8a), 136.2
(PhCH2), 128.7 (PhCH2), 128.3 (CH, C-5), 128.2 (PhCH2), 127.5 (PhCH2), 113.1 (C, C-
4a), 109.8 (CH, C-6), 102.2 (CH, C-8), 79.6 (C, C-2), 70.2 (CH2, PhCH2), 48.6 (CH2, C-3),
26.7 (2  CH3);






CF3CO2Ag (94.0 mg, 0.426 mmol) was added to a solution of 114 (100 mg, 0.355 mmol)
in CHCl3 (10 mL). The mixture was stirred for 5 min, and then a solution of I2 (90.0 mg,
0.355 mmol) in CHCl3 (20 mL) was added dropwise to the stirred suspension. The
resulting mixture was stirred at room temperature for 12 h. The solution was filtered to
remove the AgI, and the filtrate was washed with 10% Na2S2O3 solution, NaHCO3
solution, H2O, and brine. The organic phase was dried over anhydrous MgSO4 and the
solvent was evaporated to give a cream-white solid. The solid was purified by flash
chromatography using Hex:EtOAc (6:4) as eluent to afford iodochromanone 108 as a white
solid (136 mg, 94%). Recrystallization of the solid from CH3OH gave colorless needles.
mp 128-130 oC;
IR (KBr) vmax 2983, 1661, 1583, 1262 cm
-1;
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1H NMR (CDCl3, 400 MHz) δ 8.28 (1H, s, H-5), 7.48 (2H, d, J = 7.5 Hz, PhCH2), 7.41
(2H, t, J = 7.5 Hz, PhCH2), 7.34 (1H, t, J = 7.3 Hz, PhCH2), 6.40 (1H, s, H-8), 5.14 (2H,
s, PhCH2), 2.65 (2H, s, H-3), 1.44 (6H, s, 2  CH3);
13C NMR (CDCl3, 100 MHz) δ 194.2 (C, C-4), 162.8 (C, C-7), 162.1 (C, C-8a), 137.3 (CH,
C-5), 135.6 (PhCH2), 128.7 (PhCH2), 128.2 (PhCH2), 127.0 (PhCH2), 116.0 (C, C-4a),
101.3 (CH, C-8), 80.1 (C, C-2), 77.2 (C, C-6), 71.1 (CH2, PhCH2), 48.2 (CH2, C-3), 26.6 (2
 CH3);






To a solution of 108 (0.295 g, 1.05 mmol) in THF (5 mL) was added NaBH4 (0.200 g, 5.25
mmol) in EtOH (20 mL). The resulting solution was refluxed for 3 h. The reaction mixture
was cooled to room temperature, quenched with saturated NH4Cl solution and extracted
with EtOAc. The organic phases were combined, washed with saturated NaHCO3 solution,
brine, H2O, and dried over anhydrous MgSO4. The organic layer was concentrated and the
product was purified by flash chromatography using Hex:EtOAc (1:1) solvent system to
afford chromanol 109 as a colorless oil ( 0.282 g, 95%), which eventually solidified. The
solid was recrystallized from Hex:Et2O (3:2) to give white crystals.
mp 90-92 oC;
IR (KBr) vmax 3782, 3467, 2982, 2929, 1579, 1460, 1278, 1163, 1129, 1035 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 7.83 (1H, s, H-5), 7.49 (2H, d, J = 7.5 Hz, PhCH2), 7.39
(2H, t, J = 7.6 Hz, PhCH2), 7.32 (1H, t, J = 7.3 Hz, PhCH2), 6.36 (1H, s, H-8), 5.07 (2H, s,
PhCH2), 4.75 (1H, ddd, J = 8.5, 7.3 and 6.0 Hz, H-4), 2.17 (1H, br d, J = 7.3 Hz, OH-4),
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2.10 (1H, dd, J = 6.0 and 13.6 Hz, H-3b), 1.80 (1H, dd, J = 8.5 and 13.6 Hz, H-3a), 1.43
(3H, s, CH3), 1.30 (3H, s, CH3);
13C NMR (CDCl3, 100 MHz) δ 157.8 (C, C-7), 154.9 (C, C-8a), 138.0 (CH, C-5), 136.6
(PhCH2), 128.5 (PhCH2), 127.9 (PhCH2), 127.0 (PhCH2), 119.5 (C, C-4a), 101.8 (CH,
C-8), 76.2 (C, C-2), 75.2 (C, C-6), 70.8 (CH2, PhCH2), 62.9 (C, C-4), 42.6 (CH, C-3), 28.8
(CH3), 25.9 (CH3);




p-TSOH (0.012 g, 0.058 mmol) was added to a solution of chromanol 109 (0.120 g, 0.290
mmol) in THF (15 mL) under N2. The resulting solution was refluxed under N2 for 2 h. A
10% NaOH solution was added to the cooled reaction mixture, and the mixture was
extracted with Et2O. The combined organic extracts were washed with H2O, brine solution,
and dried over anhydrous MgSO4. Evaporation of the solvent afforded a colourless oil,
which solidified upon cooling. The solid was successively recrystallized from Hex and
CH3OH to give iodochromene 110 as white fluffy crystals (0.112 g, 97%).
mp 63-65 oC;
IR (KBr) vmax 3032, 2972, 2924, 1713, 1602, 1480, 1454, 1358, 1158, 736 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 7.49 (2H, d, J = 7.3 Hz, PhCH2), 7.40 (2H, t, J = 7.3 Hz,
PhCH2), 7.37 (1H, s, H-5), 7.32 (1H, t, J = 7.2 Hz, PhCH2), 6.41 (1H, s, H-8), 6.22 (1H, d,
J = 9.9 Hz, H-4), 5.48 (1H, d, J = 9.9 Hz, H-3), 5.10 (2H, s, PhCH2), 1.42 (6H, s, 2  CH3);
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13C NMR (CDCl3, 100 MHz) δ 157.9 (C, C-7), 154.6 (C, C-8a), 136.5 (PhCH2), 136.0
(CH, C-5), 128.7 (CH, C-3), 128.5 (PhCH2), 127.9 (PhCH2), 127.0 (PhCH2), 120.9 (CH,
C-4), 117.0 (C, C-4a), 102.0 (CH, C-8), 76.8 (C, C-2), 74.8 (C, C-6), 70.9 (CH2, PhCH2),
28.0 (2  CH3);
HR-ESIMS m/z [M + Na]+  415.0176 (Calcd. for C18H17INaO2 415.0171).
4.5.13 7-Benzyloxy-2,2-dimethylchromene-6-boronic acid (91)
OBnO
(HO)2B
Boronic acid 91 was prepared from aryl iodide 110 (1.00 g, 2.55 mmol) according to the
procedure given in 4.5.5. The title compound was obtained as a fluffy white solid (0.55 g,
70%) after purification with column chromatography using Hex:EtOAc (4:1) as the mobile
phase.
IR (KBr) vmax 3367, 3027, 2969, 2928, 1643, 1607, 1567, 1449 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 7.47 (1H, s, H-5), 7.36-7.42 (5H, m, PhCH2), 6.46 (1H, s,
H-8), 6.32 (1H, d, J = 10.1 Hz, H-4), 5.54 (2H, s, B(OH)2),  5.49 (1H, d, J = 10.1 Hz, H-3),
5.08 (2H, s, PhCH2), 1.44 (6H, s, 2  CH3);  (Plate 13a)
13C NMR (CDCl3, 100 MHz) δ 165.6 (C, C-7), 157.4 (C, C-8a), 135.8 (PhCH2), 134.8
(CH, C-5), 128.9 (PhCH2), 128.6 (PhCH2), 127.9 (C, C-3), 127.8 (PhCH2), 121.8 (CH, C-
4), 114.9 (C, C-4a), 100.1 (CH, C-8), 77.1 (C, C-2), 70.9 (CH2, PhCH2), 28.3 (2  CH3),
(C-6 signal not observed); (Plate 13b)









Compound 115 was prepared from 3-iodochromone 90 (0.500 g, 1.28 mmol) and boronic
acid 91 (0.550 g, 1.77 mmol) according to the procedure in 4.5.6. The reaction mixture was
subjected to column chromatography using Hex:EtOAc (3:2) as eluent to give 115 as a
yellowish oil which solidified upon cooling (0.41 g, 72%). Recrystallization of the solid
from Hex:Et2O (1:1) gave white crystals.
mp 93-95 oC;
IR (KBr) vmax 3255, 2974, 2929, 1650, 1615, 1497, 1277, 1151, 1038, 832, 699 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 12.79 (1H, s, OH-5), 7.77 (1H, s, H-2), 7.22-7.34 (5H, m,
PhCH2), 6.92 (1H, s, H-6'), 6.50 (1H, s, H-3'), 6.23 (1H, d, J = 9.8 Hz, H-4''), 6.21 (1H, d, J
= 2.2 Hz, H-8), 6.19 (1H, d, J = 2.2 Hz, H-6), 5.44 (1H, d, J = 9.8 Hz, H-5''), 5.03 (2H, s,
PhCH2), 1.40 (6H, s, H-7'' and H-8''); (Plate 14a)
13C NMR (CDCl3, 100 MHz) δ 181.0 (C, C-4), 163.0 (C, C-7), 162.5 (C, C-5), 158.0 (C,
C-8a), 157.5 (C, C-2'), 154.8 (C, C-4'), 154.6 (CH, C-2), 136.6 (PhCH2), 129.2 (CH, C-6'),
128.5 (PhCH2), 128.2 (CH, C-5''), 127.9 (PhCH2), 127.3 (PhCH2), 121.5 (CH, C-4''),
120.8 (C, C-3), 114.6 (C, C-5'), 112.0 (C, C-1'), 105.8 (C, C-4a), 101.8 (CH, C-3'), 99.6
(CH, C-6), 94.1 (CH, C-8), 76.8 (C, C-6''), 70.9 (CH2, PhCH2), 28.2 (2  CH3, C-7'' and
C-8''); (Plate 14b)
HR-ESIMS m/z [M + Na]+ 465.1312 (Calcd. for C27H22NaO6 465.1314).
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3-Methyl-2-butenal (0.18 mL, 1.85 mmol) was added under an N2 atmosphere to a stirred
mixture of Ca(OH)2 (55.0 mg, 0.740 mmol) and 115 (82.0 mg, 0.185 mmol) in CH3OH (10
mL). The mixture was stirred for 3 days at room temperature. CH3OH was evaporated and
the reaction mixture was diluted with EtOAc and H2O. The two phases were partitioned
and the aqueous phase was extracted with EtOAc. The organic layers were combined,
washed with 1M HCl, H2O, brine, and dried over anhydrous MgSO4. Evaporation of the
solvent followed by column chromatography gave 116 as a yellowish oil (70 mg, 74%).
IR (KBr) vmax 3422, 3034, 2974, 2927, 1651,1615, 1496, 1463, 1287, 1146, 1058, 828, 696
cm-1;
1H NMR (CDCl3, 400 MHz) δ 13.22 (1H, s, OH-5), 7.79 (1H, s, H-2), 7.27-7.34 (5H, m,
PhCH2), 6.96 (1H, s, H-6'), 6.73 (1H, d, J = 10.0 Hz, H-4'''), 6.52 (1H, s, H-3'), 6.31 (1H, s,
H-8), 6.28 (1H, d, J = 9.8 Hz, H-4''), 5.61 (1H, d, J = 10.0 Hz, H-5'''), 5.49 (1H, d, J = 9.8
Hz, H-5''), 5.04 (2H, s, PhCH2), 1.47 (6H, s, H-7''' and H-8'''), 1.44 (6H, s, H-7'' and H-8'');
(Plate 15a)
13C NMR (CDCl3, 100 MHz) δ 180.9 (C, C-4), 159.3 (C, C-7), 157.5 (C, C-2'), 157.3 (C,
C-8a), 156.9 (C, C-5), 154.7 (C, C-4'), 154.4 (CH, C-2), 136.8 (PhCH2), 129.1 (CH, C-6'),
128.5 (PhCH2), 128.1 (CH, C-5''), 128.0 (CH, C-5'''), 127.8 (PhCH2), 127.2 (PhCH2), 121.6
(CH, C-4''), 120.6 (C, C-3), 115.6 (CH, C-4'''), 114.5 (C, C-5'), 112.2 (C, C-1'), 106.2 (C,
C-4a), 105.5 (C, C-6), 101.8 (CH, C-3'), 94.8 (CH, C-8), 77.9 (C, C-6'''), 76.8 (C, C-6''),
70.8 (CH2, PhCH2),  28.3 (2  CH3, C-7''' and C-8'''), 28.2 (2  CH3, C-7'' and C-8''); (Plate
15b)
HR-ESIMS m/z [M + Na]+ 531.1782 (Calcd. for C32H28NaO6 531.1784).
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BCl3 (0.5 mL, 1M in heptane) was added to a solution of 116 (50.0 mg, 0.0983 mmol) in
CH2Cl2 (5 mL) cooled to -80
oC. The mixture was stirred under N2 at the temperature
below -68 oC for 30 min. The reaction was quenched with H2O and extracted with CH2Cl2.
The combined organic extracts were washed with H2O, brine, and dried over anhydrous
MgSO4. Evaporation of the solvent gave a yellow oil which was purified by chromatotron
using CH2Cl2 to give 1.1 (24 mg, 69%) as a yellow solid. The solid was recrystallized from
Hex:CH3OH (4:1).
mp 186-188 oC  (Lit. 185-187 oC);
IR (KBr) vmax 3336, 2975, 2872, 1649, 1615, 1460, 1132, 773 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 12.55 (1H, s, OH-5), 8.27 (1H, s, OH-2'), 7.73 (1H, s, H-2),
6.75 (1H, s, H-6'), 6.74 (1H, d, J = 10.0 Hz, H-4'''), 6.53 (1H, s, H-3'), 6.40 (1H, s, H-8),
6.28 (1H, d, J = 9.8 Hz, H-4''), 5.65 (1H, d, J = 10.0 Hz, H-5'''), 5.52 (1H, d, J = 9.8 Hz, H-
5''), 1.49 (6H, s, H-7''' and H-8'''), 1.44 (6H, s, H-7'' and H-8'');  (Plate 9a)
13C NMR (CDCl3, 100 MHz) δ 182.0 (C, C-4), 160.4 (C, C-7), 157.2 (C, C-2'), 157.1 (C-
8a), 156.4 (C, C-5), 155.7 (C, C-4'), 154.7 (CH, C-2), 128.8 (CH, C-5''), 128.6 (CH, C-5'''),
127.1 (CH, C-6'), 123.1 (C, C-3), 121.3 (CH, C-4''), 115.28 (CH and C, C-4''' and C-5'),
112.1 (C, C-1'), 107.3 (CH, C-3'), 106.1 (C, C-6), 105.5 (C, C-4a), 95.0 (CH, C-8), 78.5
(C, C-6'''), 77.2 (C, C-6''), 28.4 (2  CH3, C-7''' and C-8'''), 28.2 (2  CH3, C-7'' and C-8'');
(Plate 9b)






Compound 121 was prepared from 33 (6.00 g, 31.3 mmol) according to the procedure
given in 4.5.4. The title compound was obtained as a white solid (6.5 g, 88%) after
purication by silica gel column chromatography using Hex:EtOAc (7:3) solvent system.
IR (neat) vmax 3097, 2970, 2929, 1672, 1605, 1256, 1149, 998, 967 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 7.73 (1H, d, J = 8.8 Hz, H-5), 6.56 (1H, dd, J = 2.3 and 8.8
Hz, H-6), 6.24 (1H, d, J = 2.3 Hz, H-8), 5.12 (2H, s, OCH2O),  3.40 (3H, s, OCH3), 2.59
(2H, s, H-3), 1.38 (6H, s, 2   CH3);
13C NMR (CDCl3, 100 MHz) δ 190.8 (C, C-4), 163.5 (C, C-7), 161.5 (C, C-8a), 128.0 (CH,
C-5), 114.8 (C, C-4a), 110.0 (CH, C-6), 103.7 (CH, C-8), 93.9 (CH2, OCH2O), 79.3 (C, C-
2), 56.1 (CH3, OCH3), 48.4 (CH2, C-3), 26.5 (2  CH3);






Compound 121 (5.00 g, 21.2 mmol) was iodinated according to the procedure given in
4.5.10 to give 6-iodochromanone 122 (6.5 g, 85%) as a white solid after flash
chromatography with Hex:EtOAc (7:3).
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IR (neat) vmax 2948, 1678, 1585, 1152 cm
1;
1H NMR (CDCl3, 400 MHz) δ 8.25 (1H, s, H-5), 6.60 (1H, s, H-8), 5.25 (2H, s, OCH2O),
3.50 (3H, s, OCH3), 2.67 (2H, s, H-3), 1.44 (6H, s, 2  CH3);
13C NMR (CDCl3, 100 MHz) δ 190.0 (C, C-4), 161.7 (C, C-7), 161.5 (C, C-8a), 137.3 (CH,
C-5), 116.6 (C, C-4a), 103.2 (CH, C-8), 94.9 (CH2, OCH2), 80.0 (C, C-2), 77.2 (C, C-6),
56.7 (CH3, OCH3), 48.3 (CH2, C-3), 26.6 (2  CH3);






Iodochromanone 122 (5.00 g, 13.8 mmol) was reduced following the procedure given in
4.5.11 to afford chromanol 123 as a colourless oil (4.0 g, 80%) after flash chromatography
with Hex:EtOAc (1:1).
IR (neat) vmax 3377, 2974, 1704, 1602, 1568, 1478, 1151, 1013 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 7.80 (1H, s, H-5), 6.55 (1H, s, H-8), 5.18 (2H, s, OCH2O),
4.78 (1H, dd, J = 6.2 and 8.5 Hz, H-4), 3.49 (3H, s, OCH3), 2.12 (1H, dd, J = 6.2 and 13.6
Hz, H-3b), 1.81 (1H, dd, J = 8.5 and 13.6 Hz, H-3a), 1.79 (1H, brs, OH-4), 1.43 (3H, s,
CH3), 1.30 (3H, s, CH3);
13C NMR (CDCl3, 100 MHz) δ 157.8 (C, C-7), 154.9 (C, C-8a), 138.0 (CH, C-5), 119.5
(C, C-4a), 101.8 (CH, C-8), 94.9 (CH2, OCH2), 76.2 (C, C-2), 75.2 (C, C-6), 62.9 (C, C-
4), 56.7 (CH3, OCH3), 42.6 (CH, C-3), 28.8 (CH3), 25.9 (CH3);





Dimethylchromene 124 was synthesised by dehydration of chromanol 123 (3.80 g, 10.4
mmol) according to the procedure in 4.5.12. The title compound was obtained as a
colourless oil (2.6 g, 72%) after purification with column chromatography using
Hex:EtOAc (8:2) as eluent.
IR (neat) vmax 2973, 2931, 1713, 1600, 1481, 1353, 1147, 1009 cm
-1;
1H NMR (CDCl3, 400 MHz) δ  7.33 (1H, s, H-5), 6.58 (1H, s, H-8), 6.20 (1H, d, J = 9.9
Hz, H-4), 5.49 (1H, d, J = 9.9 Hz, H-3), 5.17 (2H, s, OCH2O), 3.49 (3H, s, OCH3), 1.41
(6H, s, 2  CH3);
13C NMR (CDCl3, 100 MHz) δ 156.3 (C, C-7), 154.4 (C, C-8a), 135.6 (CH, C-5), 129.1
(CH, C-3), 120.7 (CH, C-4), 117.7 (C, C-4a), 103.9 (CH, C-8), 94.9 (CH2, OCH2O), 76.7
(C, C-2), 75.1 (C, C-6), 56.3 (CH3, OCH3), 28.0 (2  CH3);
HR-ESIMS m/z [M + Na]+  368.991 (Calcd. for C13H15INaO3 368.9964).
4.5.21 7-Methoxymethoxy-2,2-dimethylchromene-6-boronic acid (125)
OMOMO
(HO)2B
Compound 125 was prepared from iodochromene 124 (2.30 g, 6.64 mmol) according to the
procedure given in 4.5.5. Pure 125 was obtained in 79% (1.32 g, white solid) after
purification with column chromatography using Hex:EtOAc (7:3).
IR (neat) vmax 3380, 2945, 1644, 1609, 1569, 1448, 1014, 979 cm
-1;
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1H NMR (CDCl3, 400 MHz) δ 7.45 (1H, s, H-5), 6.58 (1H, s, H-8), 6.31 (1H, d, J = 9.9 Hz,
H-4), 5.63 (2H, s, B(OH)2),  5.50 (1H, d, J = 9.9 Hz, H-3), 5.24 (2H, s, OCH2O), 3.50 (3H,
s, OCH3), 1.43 (6H, s, 2  CH3); (Plate 16a)
13C NMR (CDCl3, 100 MHz) δ 165.6 (C, C-7), 157.2 (C, C-8a), 134.5 (C, C-6), 128.3 (C,
C-3), 121.7(CH, C-4), 115.6 (C, C-4a), 102.0 (CH, C-8), 94.8 (CH2, OCH2O), 77.1 (C, C-
2), 56.5 (CH3, OCH3), 28.3 (2  CH3), (C-6 signal not observed); (Plate 16b)







Boronic acid 125 (1.30 g, 4.92 mmol), K2CO3 (1.32 g, 9.33 mmol), and catalytic 10% Pd/C
were added to a solution of 3-iodochromone 90 (1.29 g, 3.28 mmol) in DME (10 mL) and
H2O (10 mL). The resulting mixture was stirred at 40-45
oC for 12 h. The catalyst was
filtered and washed with H2O and Et2O. The mixture was extracted with Et2O, washed
with water and brine. The solvent was evaporated and the crude product was purified by
column chromatography using Hex:EtOAc (7:3) to give compound 126 (1.2 g, 76%) as a
yellow oil.
IR (neat) vmax 3450, 2974, 2932, 1645, 1611, 1271, 1138, 1029 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 7.75 (1H, s, H-2), 6.93 (1H, s, H-6'), 6.73 (1H, d, J = 2.2
Hz, H-8), 6.72 (1H, d, J = 2.2 Hz, H-6), 6.63 (1H, s, H-3'), 6.24 (1H, d, J = 9.8 Hz, H-4''),
5.47 (1H, d, J = 9.8 Hz, H-5''), 5.28 (2H, s, OCH2O), 5.21 (2H, s, OCH2O), 5.06 (2H, s,
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OCH2O), 3.51 (3H, s, OCH3), 3.48 (3H, s, OCH3),  3.38 (3H, s, OCH3), 1.41 (6H, s, H-7''
and H-8''); (Plate 17a)
13C NMR (CDCl3, 100 MHz) δ 175.2 (C, C-4), 161.0 (C, C-7), 159.3 (C, C-5), 158.4 (C,
C-8a), 155.9 (C, C-2'), 154.1 (C, C-4'), 152.1 (CH, C-2),  129.2 (CH, C-6'), 128.3 (CH, C-
5''), 122.9 (CH, C-4''), 121.6 (C, C-3), 115.1 (C, C-5'), 113.6 (C, C-1'), 111.4 (C, C-4a),
103.5 (CH, C-3'), 101.9 (CH, C-6), 97.1 (CH, C-8), 95.4 (CH2, OCH2O), 95.0 (CH2,
OCH2O), 94.2 (CH2, OCH2O), 76.5 (C, C-6''), 56.4 (CH3, OCH3), 56.3 (CH3, OCH3), 56.0
(CH3, OCH3), 28.2 (2  CH3, C-7'' and C-8''); (Plate 17b)








Compound 115 (10 mg, 0.023 mmol) was debenzylated under similar conditions to those
in  procedure 4.5.16 and the product was purified on a chromatotron to give 17 as a yellow
solid (6 mg, 75%).
Method B
To a solution of 126 (1.0 g, 2.06 mmol) in CH3OH (25 ml) was added HCl (3 M, 10 mL).
The resulting solution was refluxed for 20 min, then CH3OH was evaporated and the
reaction mixture was diluted with EtOAc and water. The two phases were partitioned and
the organic layer was washed with water, brine and dried over anhydrous MgSO4. The
solvent was evaporated and the crude product was purified by column chromatography
using Hex:EtOAc (7:3) to afford eriosemaone D (17) as a yellow solid (0.56 g, 78%).
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1H NMR (CD3OD, 400 MHz) δ 8.04 (1H, s, H-2), 6.92 (1H, s, H-6'), 6.39 (1H, d, J = 2.3
Hz, H-8), 6.36 (1H, s, H-3'), 6.33 (1H, d, J = 10.0 Hz, H-4''), 6.27 (1H, d, J = 2.3 Hz, H-6),
5.55 (1H, d, J = 9.8 Hz, H-5''), 1.43 (6H, s, H-7'' and H-8''); (Plate 18a)
13C NMR (CD3OD, 100 MHz) δ 182.8 (C, C-4), 166.2 (C, C-7), 163.9 (C, C-5), 160.0 (C,
C-2'), 158.0 (C, C-8a), 157.1 (C, C-4'), 156.2 (CH, C-2),  130.5 (CH, C-6'), 129.1 (CH, C-
5''), 123.1 (CH, C-4''), 122.4 (C, C-3), 115.6 (C, C-5'), 112.2 (C, C-1'), 106.6 (C, C-4a),
105.3 (CH, C-3'), 100.5 (CH, C-6), 95.2 (CH, C-8), 77.8 (C, C-6''), 28.6 (2  CH3, C-7''
and C-8''); (Plate 18b)





Chromone 99 (50 mg, 0.188 mmol) was deprotected according to the procedure in 4.5.23
to afford 51 (27 mg, 80%) as a cream white solid after column chromatographic
purification with Hex:EtOAc (4:6).
1H NMR (CD3OD, 400 MHz) δ 7.97 (1H, d, J = 6.0 Hz, H-2), 6.34 (1H, d, J = 2.2 Hz, H-
8), 6.22 (1H, d, J = 2.2 Hz, H-6), 6.20 (1H, d, J = 6.0 Hz, H-3);
13C NMR (CD3OD, 100 MHz) δ 182.0 (C, C-4), 164.7 (C, C-7), 162.0 (C, C-5), 158.5 (C,























Citral (0.1 mL, 0.58 mmol) was added under an N2 atmosphere to a stirred mixture of
Ca(OH)2 (16.6 mg, 0.0.225 mmol) and chromone 51 (20 mg, 0.112 mmol) in CH3OH (5
mL). The mixture was stirred for 3 days at room temperature. CH3OH was evaporated and
the reaction mixture was diluted with EtOAc and H2O. The two phases were partitioned
and the aqueous phase was extracted with EtOAc. The organic layers were combined,
washed with 1M HCl, H2O, brine, and dried over anhydrous MgSO4. Evaporation of the
solvent followed by column chromatography gave racemic 127 as a yellow oil (22 mg,
64%).
1H NMR (CDCl3, 400 MHz) δ 12.86 (1H, s, OH-5), 7.70 (1H, d, J = 6.0 Hz, H-2), 6.75
(1H, d, J = 10.0 Hz, H-4'), 6.31 (1H, s, H-8), 6.19 (1H, d, J = 6.0 Hz, H-3), 5.57 (1H, d, J =
10.0 Hz, H-5'),  5.10 (1H, t, J = 7.2 Hz, H-10'), 2.09 (2H, dd, J = 16.1 and 8.0, H-9'),
1.75-1.81 (1H, m, H-8'b), 1.62-1.69 (4H, m, H-8'a and H-12' or 13'), 1.57 (3H, s, H-12' or
13'), 1.43 (3H, s, H-7'); (Plate 19a)
13C NMR (CDCl3, 100 MHz) δ 181.8 (C, C-4), 159.9 (C, C-7), 157.5 (C, C-8a), 156.4 (C,
C-5), 155.3 (CH, C-2), 132.0 (C, C-11'), 127.1 (CH, C-5'), 123.7 (CH, C-10'), 115.9 (CH,
C-4'), 111.3 (CH, C-3), 106.5 (C, C-6), 105.5 (C, C-4a), 94.8 (CH, C-8), 80.6 (C, C-6'),
41.7 (CH2, C-8'), 27.1 (CH3, C-12' or 13'), 25.6 (CH3, C-7'), 22.6 (CH2, C-9'), 17.6 (CH3,









The title compound was prepared in 68% yield (40 mg, yellow oil) from 115 (45.0 mg,
0.102 mmol) under similar reaction conditions to those in procedure 4.5.25.
1H NMR (CDCl3, 400 MHz) δ 13.22 (1H, s, OH-5), 7.79 (1H, s, H-2), 7.27-7.33 (5H, m,
PhCH2), 6.96 (1H, s, H-6'), 6.77 (1H, d, J = 10.0 Hz, H-4'''), 6.52 (1H, s, H-3'), 6.31 (1H, s,
H-8), 6.28 (1H, d, J = 9.8 Hz, H-4''), 5.59 (1H, d, J = 10.0 Hz, H-5'''), 5.49 (1H, d, J = 9.8
Hz, H-5''), 5.09 (1H, t, J = 7.2 Hz, H-10'''), 5.02 (2H, s, PhCH2), 2.10 (2H, dd, J = 16.0 and
8.3, H-9'''), 1.76-1.81 (1H, m, H-8'''b), 1.66-1.70 (4H, m, H-8'''a, H-12''' or 13'''),  1.59 (3H,
s, H-12''' or 13'''), 1.44 (6H, s, H-7'' and H-8''), 1.43 (3H, s, H-7'''); (Plate 20a)
13C NMR (CDCl3,100 MHz) δ 180.9 (C, C-4), 159.7 (C, C-7), 157.5 (CH, C-2'), 157.4 (C,
C-8a), 156.9 (C, C-5), 154.7 (C, C-4'), 154.3 (CH, C-2), 136.8 (PhCH2), 129.2 (CH, C-6'),
128.5 (PhCH2), 128.1 (CH, C-5''), 127.8 (PhCH2), 127.2 (PhCH2), 126.8 (CH, C-5'''), 123.8
(CH, C-10'''), 121.6 (CH, C-4''), 120.6 (C, C-3), 115.6 (CH, C-4'''), 114.5 (C, C-5'), 112.2
(C, C-1'), 106.2 (C, C-4a), 105.5 (C, C-6), 101.8 (CH, C-3'), 94.8 (CH, C-8), 80.4 (C, C-
6'''), 76.8 (C, C-6''), 70.8 (CH2, PhCH2), 41.7 (CH2, C-8'''), 28.3 (2  CH3, C-7'' and C-8'');
27.1 (CH3, C-12''' or 13'''), 25.6 (CH3, C-7'), 22.6 (CH2, C-9'''), 17.7 (CH3, C-12''' or 13''').
(Plate 20b)









Compound 89 as a racemic mixture was prepared from 128 (25 mg, 0.0433 mmol)
according to the procedure in 4.5.16. The title compound was obtained as a yellow oil (13
mg, 61%) after purification on a chromatotron.
12.54 (1H, s, OH-5), 8.29 (1H, brs, OH-2'), 7.93 (1H, s, H-2), 6.77 (1H, d, J = 10.0 Hz,
H-4'''), 6.75 (1H, s, H-6'), 6.53 (1H, s, H-3'), 6.38 (1H, s, H-8), 6.28 (1H, d, J = 9.8 Hz,
H-4''), 5.60 (1H, d, J = 10.0 Hz, H-5'''), 5.52 (1H, d, J = 9.8 Hz, H-5''),  5.09 (1H, t, J = 7.0
Hz, H-10'''), 2.11 (2H, dd, J = 15.8 and 7.9, H-9'''), 1.84 (1H, m, H-8'''b), 1.66-1.70 (4H, m,
H-8'''a, H-12''' or 13'''), 1.57 (3H, s, H-12''' or 13'''), 1.45 (3H, s, H-7'''), 1.44 (6H, s, H-7''
and H-8''); (Plate 21)
HR-ESIMS m/z [M + Na]+ 509.1934 (Calcd. for C30H30 NaO6 509.1940.
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CHAPTER 5
TOTAL SYNTHESIS OF THE PYRANOCOUMARONOCHROMONE
LUPINALBIN H
5.1 INTRODUCTION
Coumaronochromones are a subclass of isoflavonoids with general stucture 129.1 They
have been isolated from different plant genera, mostly of the Leguminosae,1-5 although a
few coumaronochromones have been reported from non-leguminous plants.6-8 The striking
feature of most naturally-occurring coumaronochromones is the presence of prenyl side
chains, which in most instances are cyclised to adjacent hydroxy groups to give pyrano or
furano rings.1-3,5,7,9,10 Most pyranocoumaronochromones exhibit important biological
activities such as anthelminthic, oestrogenic, neuroprotective, antiplatelet aggregation,
anti-HIV, immunosuppressive activities, as well as cytotoxicity against certain cancer cell










In continuation of our studies on the regioselective synthesis of pyranoisoflavonoids,14 this
Chapter reports the first total synthesis of lupinalbin H (130). With this synthesis, we
further demonstrate the usefulness of the Suzuki-Miyaura reaction in the synthesis of
isoflavonoids. A review on the methods for the synthesis of coumaronochromones and the
total syntheses of individual pyranocoumaronochromones is given in the beginning
sections of this Chapter, followed by discussions on the total synthesis of lupinalbin H
(130), and finally the conclusions and experimental procedures.
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5.2 METHODS FOR THE SYNTHESIS OF COUMARONOCHROMONES - AN
OVERVIEW
Coumaronochromones are commonly known to co-exist with structurally-similar 2'-
hydroxyisoflavones,1,15 thus 2'-hydroxyisoflavones, although not yet proven, are proposed
to be biosynthetic precursors of coumaronochromones.1,15,16 However, in 2008, Lawson
and co-workers isolated two new coumaronochromones along with the closely related
rotenoids dehydrodeguelin and dehydrorotenone.17 Therefore, they proposed the rotenoids
to be probable biosynthetic precursors of the coumaronochromones.17 These prospective
precursors have been chemically transformed into the corresponding coumaronochromones
under oxidative conditions.1,16,18
Chubachi and Hamada reported the synthesis of a coumaronochromone 132 by photo-
oxidative ring contraction of rotenoid 131 (Scheme 5.1).18 In their experiment, they
irradiated a solution of 131 in pyridine with a high pressure mercury lamp in the presence
of oxygen. This gave a mixture of products, whereby 3% of the coumaronochromone 132
was isolated, and the major product was rotenonone 133 obtained in 25% yield.18 Although
this method was developed four decades ago, it has received scant acceptance due to poor




















131 132 3% 133    25%
Pyridine
O2,hυ
Scheme 5.1. Synthesis of coumaronochromones from rotenoids
The most commonly employed procedure for the synthesis of coumaronochromones is
oxidative cyclisation of 2'-hydroxyisoflavones. Metal salts such as K3FeCN6, Ag2CO3,
Pb(OAc)4 and Mn(OAc)3.2H2O were initially employed to facilitate this
cyclodehydrogenation albeit in low yields.1,16,19 The major drawback with Pb(OAc)4 and
Mn(OAc)3.2H2O was the formation of the acetylated by-product 136 along with the
127
targeted coumaronochromone 135 when the reaction was conducted at low temperatures
(Scheme 5.2).19 In 1983, the method was greatly improved by using SeO2 as an oxidising
agent and later (2001) by using quinone-based oxidants such as DDQ and chloranil.20,21
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Scheme 5.2. Preparation of coumaronochromones from 2'-hydroxyisoflavones
5.3 TOTAL SYNTHESES OF PYRANOCOUMARONOCHROMONES – AN
OVERVIEW
Although coumaronochromones with dimethylpyran scaffolds continue to be reported as
new compounds with interesting biological properties, there are only a few reports on their
syntheses. Currently, there are two reports on the total synthesis of
pyranocoumarochromones.21,22 The first report was on the unnatural compound 141
prepared by Tsukayama and co-workers (Scheme 5.3).21 In their synthetic strategy, the
coumaronochromone nucleus was assembled by cyclodehydrogenation of 2'-
hydroxyisoflavone 140 with DDQ. The isoflavone 140 was prepared by TTN oxidative
rearrangement of chalcone 139, which was in turn prepared by the Claisen-Schmidt
condensation of acetophenone 137 and aldehyde 138, bearing the dimethyldihydropyran
scaffold. The dimethyldihydropyran moiety was introduced in the early stages of the
synthesis by condensation of benzaldehyde with 2-methyl-3-buten-2-ol in the presence of






































Scheme 5.3. Synthesis of the pyranocoumaronochromone 141
The second synthesis targeted the immunossuppresive agent, hirtellanine A (147) shown in
Scheme 5.4.22 The synthesis was based on the Suzuki-Miyaura reaction for the
construction of the isoflavone nucleus.22 The main precursors were 3-iodochromone
bearing a dimethylchromene scaffold 142 and boronic acid 143. The 3-iodochromone 142
was prepared in a sequence of steps, which involved regioselective formation the
chromene scaffold by a Tom-Harfenist rearrangement of the propagyl ether, prepared by
O-alkylation of the 7-hydroxy group of chromone 51 with 3-chloro-3-methylbut-1-yne.
Iodination of the resulting pyranochromone 52 at C-3 following Gammill’s protocol
rendered 142. The boronic acid 143 was prepared in three steps from trihydroxybenzene
144. The Suzuki coupling of 143 with 142 and subsequent oxidative cleavage of the p-
methoxybenzyl protecting groups gave a quinone 146, which upon treatment with acetic






















146 90.5% over three steps








































Scheme 5.4. Synthesis of hirtellanine A (147)
5.4 RESULTS AND DISCUSSION
5.4.1 Introduction
Lupinalbin H (130) was isolated together with other flavonoids from the methanolic extract
of the roots of yellow lupin (Lupinus luteus cv Topaz) by Tahara et al.23 The assignment of
the structure of 130 was based mainly on comparison of its 1H NMR signals with those of
related compounds. The 13C NMR data was not reported. Furthermore, the accompanying
flavonoids were reported to exhibit antifungal activity; however, 130 was not assayed for
its activity. The lack of detailed structural characterisation and bioactivity studies of
lupinalbin H (130) can be attributed to the low quantity obtained from the plant source.23
Therefore, our aim was to develop a synthetic route that can readily give access to 130 in a
good yield, to confirm its structure unambiguously, and provide material for future
biological studies.
Scheme 5.5 shows the retrosynthetic analysis for lupinalbin H (130). Lupinalbin H (130)
was planned to be synthesised by the regiospecific condensation of lupinalbin A (148)15,24
with prenal.  Compound 148 could be prepared by oxidative cyclisation of 2'-
hydroxygenistein (149),25,26 which could readily be accessed by the Suzuki-Miyaura
reaction of 3-iodochromone 150 and boronic acid 151. The synthesis of the penultimate
130
precursor 148 from 2'-hydroxyisoflavones has been reported previously.21,27 However, the
former syntheses were based on the deoxybenzoin and the chalcone routes for the
construction of the isoflavone core.21,27 Unlike the previous synthetic routes on
pyranocoumaronochromones,21,22 the current synthetic pathway was designed to give



























Scheme 5.5. Retrosynthetic route for lupinalbin H (130)
5.4.2 Optimisation of Conditions for the Synthesis of 3-Iodochromone Precursor
As seen from the retrosynthetic route (Scheme 5.5), the main precursors were 3-
iodochromone 150 and boronic acid 151. In Chapter 4, we reported the synthesis of the
dimethoxymethyl protected 3-iodochromone 90. However, the product was obtained in
poor overall yield, resulting from two low-yielding steps, which were the protection of the
phloroacetophenone 92 with MOMCl, and the iodine-mediated cyclisation of an
enaminoketone 93 into 3-iodochromone 90. Therefore, we decided to investigate other
protecting groups for the synthesis of 3-iodochromone 150.
Esters (acetyl and benzoyl) were initially employed for this protection. However, they were
immediately abandoned due to poor regioselectivity, which led to the formation of four
products identified as the tri-, di- and two monoprotected phloroacetophenones. Secondly,
condensation of either the O-diacetyl or O-dibenzoyl protected phloroacetophenone with
DMF-DMA failed to give the target enaminoketone.
131
From the literature, good regioselectivity and high yields of the diprotected
phloroacetophenone have been reported when TBDMS was employed for protection of the
2'- and 4'-hydroxy groups of 92.28 Motivated by these reports, phloroacetophenone (92)
was then protected with TBDMS to give 152 in 80% yield (Scheme 5.6). Encouraged by
the good yield, 152 was subsequently condensed with DMF-DMA.29 The reaction gave an
orange oil, which on TLC indicated complete consumption of the starting material.
However, the product could not be isolated as it trailed on TLC. DMF-DMA was then
evaporated under reduced pressure and the crude product reacted with iodine in the
presence of pyridine.30 Upon completion of the reaction, the targeted product 153 could not
be obtained from the reaction mixture; instead the diformylated enaminoketone 154 was
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Scheme 5.6. Attempted synthesis of TBDMS protected 3-iodochromone 153
The structure of 154 was deduced from the 1H NMR spectrum (Plate 22a), which showed
characteristic signals of the dimethylenaminoketone, in the form of two three-proton
singlets at δH 3.04 and 3.29, and two olefinic doublets at δH 6.45 and 8.10 (J = 12.0 Hz, H-
2 and H-3, respectively). The signals for the aromatic protons and the TBDMS groups
were not observed. Instead, two one-proton singlets appeared at δH 10.02 and 10.11,
indicative of two formyl groups. Furthermore, two hydrogen-bonded hydroxy protons at δH
14.19 and 15.26 were also observed in the spectrum of 154. The presence of formyl
132
functional groups was further confirmed by the 13C NMR spectrum, which displayed two
signals at δC 191.2 and 193.3 in addition to the 11 other carbon resonances (Plate 22b).
DMF-DMA is known to exist in equilibrium with its iminium counterpart, thereby
releasing methoxide ions as shown in Scheme 5.7.31 It is therefore deduced that the
generated methoxide ions led to cleavage of the TBDMS protecting groups, and hence
activated the phloroglucinol moiety for formylation. However, there are currently no
reports on formylation of electron-rich aromatic rings with DMF-DMA. The reaction is
proposed to proceed via electrophilic aromatic substitution of 155 to give 156, followed by
elimination of CH3OH to give an iminium intermediate 157, which upon hydrolysis with
water, gives the aldehyde 158 as shown in Scheme 5.7.
Scheme 5.7. Proposed mechanism for formylation with DMF-DMA
Failure to obtain the target intermediate from the TBDMS-protected phloroacetophenone,
prompted the investigation of other protecting groups. The choice of the protecting group
was motivated by its stability under basic conditions, especially resistance to the
methoxide ions which are generated from DMF-DMA.31 Therefore, we planned to prepare
3-iodochromone from 2'-hydoxy-4',6'-dimethoxyacetophenone (159). The reaction was
previously reported by Watanabe et al.32 and Vassseline et al.33 who independently
prepared 3-iodo-5,7-dimethoxychromone (161) from the corresponding enaminoketone














































performed in CH3OH, which partially dissolves propenone 160. Therefore, the solution had

















Scheme 5.8. Preparation of 3-iodochromone 161 by Watanabe et al. and Vasseline et
al.32,33
We envisaged that using CHCl3, which readily dissolves the enaminoketone 160, and
addition of pyridine to the reaction mixture, would improve the results. Pyridine and other
nitrogen-containing bases have been reported to prevent conversion of an enaminoketone
into the non-iodinated chromone, which is often formed as a major side product.30
As illustrated in Scheme 5.9, we prepared 3-iodo-5,7-dimethoxychromone (161) from
1,3,5-trimethoxybenzene (162). Friedel-Crafts acylation of 162 with Ac2O and ZnCl2 gave
acetophenone 163 in a 90% yield. Selective cleavage of the ortho-methoxy group of 163
was initially attempted by treatment of a CH3CN solution of 163 with AlCl3 and NaI.
34
This gave 159 in unsatisfactory yields and a diacylated by-product. Changing the solvent to
CH2Cl2 cleanly rendered 159 in 89%. It was therefore deduced that CH3CN promoted the
double acylation via a Houben-Hoesch-type reaction. Condensation of 159 with DMF-
DMA gave the enaminoketone 160 (92%),29 which was subsequently converted into 3-
iodochromone 161 (23%) by treatment with pyridine and I2 in CHCl3.
30
The 1H NMR spectrum of 161 displayed two singlets intergrating for three protons at δH
3.91 and 3.87 for the methoxy groups, two meta-coupled doublets at δH 6.41 and 6.37, for
the aromatic protons and a one-proton singlet at δH 8.06 (H-2) (Plate 23a). The HRMS
gave an m/z peak of 354.9442 [M + Na]+, in agreement with the calculated pseudo






































Scheme 5.9. Preparation of 3-iodochromone
Although the steps that preceded the formation 3-iodochromone 161 gave good yields, the
low yield obtained for 161 from iodine-mediated cyclisation of enaminoketone 160
prompted us to reconsider MOM protecting groups for the synthesis of the 3-
iodochromone. Previously, we obtained the MOM-protected iodochromone 90 in a
moderate yield of 58% (Chapter 4, Section 4.4.2), which is much better than the 23%
obtained for the dimethoxy-protected 3-iodochromone 161. However, the regioselective
protection of the phloroacetophenone 92 gave 50% of 2'-hydroxy-4',6'-
dimethoxymethoxyacetophenone (94). Denis et al. recently reported high yields of 94
when DIEA was used as a base.35 Motivated by these reports, we also used DIEA instead
of DIA for the regioselective protection of the 4'- and 6'-hydroxy groups of 92. This gave
the expected product 94 in 79% yield (Scheme 5.10). Having improved the yields of 94,
the next step was to optimise the reaction conditions for the iodine-mediated cyclisation of
enaminoketone into 3-iodochromone 90. The reaction was performed under different















Scheme 5.10. Protection of phloroacetophenone with MOMCl
135
5.4.3 Preparation of Boronic Acid Precursor
As seen from the retrosynthetic Scheme 5.5, the second precursor for the synthesis of
lupinalbin H (130) was the boronic acid 151. The synthesis of the boronic acid coupling
partner commenced with protection of the hydroxy groups of resorcinol (32) with
MOMCl.36 This rendered the methoxymethyl ether 162 in 60% yield. The MOM protecting
groups were used in the present case as they would be removed simultaneously after the
Suzuki-Miyaura coupling reaction with 3-iodochromome 90. Regioselective iodination of
162 at C-4 by I2 in the presence of CH3CO2Ag  gave an aryl iodide 163 in 95% yield.
37 In
our earlier investigation, we demonstrated the successful regioselective iodination of a
chromanone containing a resorcinol moiety using CF3CO2Ag and I2 (Chapter 4, section
4.4.4).
14 CH3CO2Ag gave comparable results in the present case. Other readily available
silver salts (AgNO3 and Ag2SO4) were tested for C-4 iodination of 162, but afforded 163 in
low yields when CHCl3 was used as the solvent and in moderate yields in EtOH (Table
1).38,39














Silver Salt Solvent Time (h) Yieldsb (%)
AgNO3 CHCl3 5 40
Ag2SO4c CHCl3 5 35
AgNO3 EtOH 1 62
Ag2SO4c EtOH 1 58
CH3CO2Ag CHCl3 5 95
a1.2 equiv silver salt, 1.1 equiv I2
b Isolated yields
c 0.6 equiv Ag2SO4, 1.1 equiv I2
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The 1H NMR spectrum of 163 displayed an ABX spin system at δH 7.62 (1H, d,
J = 8.5 Hz, H-6), 6.80 (1H, d, J = 2.5 Hz, H-3), 6.53 (1H, dd, J = 2.5 and 8.5 Hz, H-5),
confirming substitution at C-4 of 162, and the signals for the methoxymethyl ether were
displayed at δH 5.21 (2H, s, OCH2O), 5.13 (2H, s, OCH2O),  3.50 (3H, s, OCH3), 3.46 (3H,
s, OCH3). The presence of iodine was further confirmed by an up-field resonance at δC 77.4
for the carbon ipso to iodine. The HRMS gave an mz of 354.9442 [M + Na]+, which
corresponded with the calculated pseudo molecular mass of 354.9443 for C11H9INaO4.
The aryl iodide 163 was converted into boronic acid 164 by lithium-iodine exchange,
followed by the immediate in situ nucleophilic attack of the generated aryl lithium species
on triisopropyl borate and hydrolysis of the resulting boronate ester with NH4Cl in a one
pot reaction (Scheme 5.11).40,41 The substitution of iodine by a boronic acid was proven by
a down-field shift of the aromatic proton signals in the 1H NMR spectrum of 164 and the
disappearance of iodine-bearing carbon signal at δC 77.4 in the 13C NMR spectrum of 164.














Scheme 5.11. Synthesis of boronic acid 164
5.4.4 Synthesis of 2'-Hydroxygenistein, Lupinalbin A and Lupinalbin H
Having successfully synthesised the boronic acid 164, the next step involved coupling of
164 with 3-iodochromone 90 in the presence of 10% Pd(C) to give the isoflavone 165
(Scheme 5.12).42 Cleavage of the MOM protecting groups of 165 under acidic conditions
and subsequent oxidative cyclisation of 2'-hydroxygenistein (149) with DDQ afforded the



































148    66%
Scheme 5.12. Preparation of 2'-hydroxygenistein (149) and lupinalbin A (148)
The last step was the regioselective introduction of the dimethylpyran scaffold to the
phloroglucinol moiety of lupinalbin A (148) to give lupinalbin H (130) as shown in
Scheme 5.13. This was planned to be achieved by base-catalysed coupling of 148 with
prenal, which proceeds via an aldol-type reaction and a 6π-electrocylisation.43 Thus,
treatment of the methanolic solution of 148 with Ca(OH)2 and prenal (2.5 equiv) gave
lupinalbin H (130) in 40% yield and 35% of 148 was recovered.44 Addition of a large
excess of prenal (5 equiv) effected complete consumption of 148 as observed on TLC but
required tedious chromatographic isolation of the targeted product from the reaction
























Scheme 5.13. Synthesis of lupinalbin H (130)
138
Lupinalbin A (148) has four nucleophilic sites at positions 6, 8, 3' and 5', which can
condense with prenal to give multiple products. As anticipated, the reaction favoured the
more nucleophilic phloroglucinol moiety (A-ring) rather than the resorcinol moiety (B-
ring). Nevertheless, three possible regioisomers can result from condensation of prenal













From the 1H NMR results, it could be readily deduced that the isomer 167 was not formed
due to the presence of a signal characteristic for a hydrogen-bonded OH at δH 13.38 (1H,
OH-5). Furthermore, signals for four aromatic protons, comprising an ABX spin system
for the B-ring protons at δH 7.82 (1H, d, J = 8.3 Hz, H-6'), 7.14 (1H, d, J = 2.0 Hz, H-3'),
7.02 (1H, dd, J = 2.0 and 8.3 Hz, H-5'), and a one-proton singlet for the A-ring proton at δH
6.54 (H-8) were present in the 1H NMR spectrum (Plate 26a). The dimethylpyran protons
occurred as a singlet integrating for six protons at δH 1.48 (2  CH3) and two one-proton
doublets for the olefinic protons at δH 6.70 (J = 10.0 Hz, H-4'') and 5.79 (1H, d, J = 10.0
Hz, H-5''). These 1H NMR results were in agreement with those reported for 130.23 The 13C
NMR spectrum displayed 19 carbon resonances (Plate 26b), which were identified as two
methyl carbons overlapping at δC 27.3, six methine carbons at δc 128.6, 121.3, 114.6,
113.6, 98.5 and 95.3 and twelve quaternary carbons at δC 178.6, 164.7, 158.5, 157.0, 156.4,































Figure 5.1. Key HMBC Correlations of (130)
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To distinguish between the linear and angular isomers, it was crucial to assign the oxygen-
bonded aromatic carbons attached to the A-ring unambiguously using the HMBC
experiment. As shown in Figure 5.1, a two-bond HMBC correlation was established
between the hydroxy proton at δH 13.38 (OH-5) and the aromatic carbon at δC 157.0 (C, C-
5). The olefinic proton at δH 6.70 (H-4'') showed correlations to carbon signals at δC 80.0
(C, C-6''), 105.9 (C, C-6), 157.0 (C, C-5) and 158.5 (C, C-7) and the aromatic proton at  δH
6.54 (H-8) showed connections to carbon resonances at δC 104.0 (C, C-4a), 105.9 (C, C-6),
154.0 (C, C-8a) and 158.5 (C, C-7) (Figure 5.1). From these correlations, it was confirmed
that the dimethylpyran ring was attached to C-6 and OH-7, giving the targeted product 130
and not the angular isomer 166. The assignments of the quaternary carbons on the B-ring
were also based on HMBC correlations. The proton at δH 7.82 (H-6') displayed correlations
to carbon signals at 97.5 (C, C-3), 150.4 (C, C-2') and 156.4 (C, C-4'), whereas H-5' (δH
7.02) showed correlations to carbons at δC 114.0 (C, C-1') and 156.4 (C, C-4'), and the
proton at δH 7.14 (H-3') showed correlations to signals at δC 114.0 (C, C-1'), 150.4 (C, C-
2') and 156.4 (C, C-4') (Figure 5.1). The structure of 130 was confirmed by HRMS, which
gave an m/z peak of 349.0710 [M-H]-, in agreement with the calculated pseudo molecular
weight of 349.0712 for C20H13O.
5.5 CONCLUSION
In conclusion, lupinalbin H (130) has been successfully synthesised by a highly convergent
route.  The synthesis featured the Suzuki-Miyaura coupling reaction for the construction of
the isoflavone nucleus in good yields, and a highly regioselective introduction of the
dimethylpyran scaffold to the coumaronochromone core. Furthermore, it gave access to
other naturally-occurring phytoestrogens, 2'-hydroxygenistein (149) and lupinalbin A
(148). Owing to the potential pharmacological properties of the
pyranocoumaronochromones, the development of the practical synthetic route described
herein for lupinalbin H (130) represents a significant advance towards the synthesis of
other structurally related compounds and exploration of their biological properties.
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5.6 EXPERIMENTAL PROCEDURES





To a round bottom flask cooled in an ice bath, was added 1,3,5-trimethoxybenzene (162)
(5.00 g, 29.7 mmol), ZnCl2 (4.05 g, 29.7 mmol) and Ac2O (20 mL). The resulting mixture
was stirred for 1 h, quenched with H2O and stirred for an additional 30 min. A white solid
precipitated. It was filtered by suction and washed with H2O to give 2',4',6'-
trimethoxyacetophenone (163) as a white solid (5.9 g, 95%). The solid was recrystallised
from EtOH to give 163 as white needles.
mp 103.4 – 104.5 oC  (Lit.45 mp 93.5 – 104 oC);
IR (neat) vmax 2954, 1688, 1583, 1417, 1158, 1122, 822 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 6.08 (2H, s, H-3' and H-5'), 3.79 (3H, s, OCH3), 3.76 (6H, s,
2  OCH3), 2.43 (3H, s, COCH3);
13C NMR (CDCl3, 100 MHz) δ 201.6 (C, C-1), 162.3 (C, C-4'), 158.3 (2  C, C-2' and C,
C-6'), 113.6 (C, C-1'), 90.5 (2  CH, C-3' and C-5'), 55.7 (2  CH3, 2  OCH3), 55.3 (CH3,
OCH3), 32.4 (CH3, -COCH3);






To an ice cold mixture of 163 (5.00 g, 23.7 mmol) and NaI (1.80 g, 11.8 mmol) in CH2Cl2
50 mL), was added AlCl3 (15.8 g, 0.237 mol) in small portions with stirring. The mixture
was stirred in an ice bath for additional 10 min and then heated to 40 oC for 24 h. The
reaction mixture was cooled in an ice bath and HCl (1 M, 40 mL) was added slowly with
stirring. The organic and the aqueous phases were partitioned. The aqueous phase was
extracted with CH2Cl2. The combined organic extracts were washed with H2O, brine and
dried over anhydrous MgSO4. The solvent was evaporated to give a yellow solid, which
was purified by silica gel column chromatography using Hex:EtOAc (7:3) to give 159 as a
white solid (4.1 g, 89%). Recrystallisation of the compound from EtOH gave colourless
crystals.
mp 83.6 – 85.4 oC  (Lit.46 mp 84 - 85 oC);
1H NMR (CDCl3, 400 MHz) δ 13.96 (1H, s, OH), 5.99 (1H, d, J = 2.4 Hz, H-3'), 5.86 (1H,
d, J = 2.4 Hz, H-5'), 3.80 (3H, s, OCH3), 3.77 (3H, s, OCH3), 2.55 (3H, s, COCH3);
13C NMR (CDCl3, 100 MHz) δ 202.9 (C, C-1), 167.4 (C, C-2'), 166.0 (C, C-4'), 162.8 (C,
C-6'), 105.8 (C, C-1'), 97.4 (CH, C- 3'), 90.4 (CH, C-5'), 55.3 (CH3, OCH3), 55.2 (CH3,







DMF-DMA (13.1 mL, 0.1 mol) was added to 159 (4.0 g, 20.0 mmol) at 95 oC. The mixture
was stirred at the same temperature for 12 h to give an orange solid. The volatiles were
evaporated on a rotary evaporator and the solid was recrystallised from CH3OH to give 160
as yellow needles (4.6 g, 92%).
mp 152.6 – 154.5 oC
IR (neat) vmax 3171, 2920, 1582, 1539, 1412, 1359, 1207, 1115, 889 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 15.59 (1H, s, OH-2'), 7.88 (1H, d, J = 12.4 Hz, H-3), 6.23
(1H, d, J = 12.4 Hz, H-2), 6.04 (1H, d, J = 2.4 Hz, H-3'), 5.89 (1H, d, J = 2.4 Hz, H-5'),
3.81 (3H, s, OCH3), 3.76 (3H, s, OCH3), 3.09 (3H, br s, N(CH3)2), 2.92 (3H, br s,
N(CH3)2);
13C NMR (CDCl3, 100 MHz) δ 189.9 (C, C-1), 167.7 (C, C-2'), 163.9 (C, C-4'), 161.6 (C,
C-6'), 154.2 (CH, C-3), 105.3 (C, C-1'), 96.7 (CH, C-2), 93.9 (CH, C-3'), 90.5 (CH, C-5'),
55.6 (CH3, OCH3), 55.2 (CH3, OCH3), 45.0 (CH3, N(CH3)2), 37.2 (CH3, N(CH3)2);







To a solution of propenone 160 (4.50 g, 17.9 mmol) in CHCl3 (100 mL) was added
pyridine (2.90 mL, 35.8 mmol) followed by I2 (9.09 g, 35.8 mmol). The resulting solution
was stirred at rt for 12 h. The reaction was quenched with saturated Na2S2O3 solution and
the two phases partitioned. The aqueous phase was extracted with CH2Cl2. The organic
layers were combined, washed with H2O, brine and dried over anhydrous MgSO4. The
solvent was evaporated to give a yellow solid. The crude product was purified by silica gel
column chromatography using Hex:EtOAc (1:1) as eluent. The solvent was evaporated to
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afford 161 (1.4 g, 23%) as a white solid, which was recrystallised from EtOH to give white
fluffy crystals.
mp 157.6 – 159.8 oC  (Lit.47 mp 157 - 159 oC);
IR (neat) vmax 2938, 1644, 1622, 1597, 1548, 1217, 1154, 1068, 831 cm
1;
1H NMR (CDCl3, 400 MHz) δ 8.06 (1H, s, H-2), 6.41 (1H, d, J = 2.3 Hz, H-8), 6.37 (1H,
d, J = 2.3 Hz, H-6), 3.91 (3H, s, OCH3), 3.87 (3H, s, OCH3); (Plate 23a)
13C NMR (CDCl3, 100 MHz) δ 171.1 (C, C-4), 164.1 (C, C-7), 160.8 (C, C-5), 159.6 (C,
C-8a), 155.3 (CH, C-2), 107.3 (C, C-4a), 96.5 (CH, C-6), 92.3 (CH, C-8), 89.6 (C, C-3),
56.3 (CH3, OCH3), 55.7 (CH3, OCH3); (Plate 23b)




ZnBr2 (10.25 mg, 0.045 mmol) was dissolved in dimethoxymethane (16.0 mL, 0.182 mol)
under an N2 atmosphere, and then AcCl (12.9 mL, 0.182 mol) was added dropwise to the
stirred solution. The solution was stirred for an additional 2 h at rt and then transferred via
a cannula to an ice-cold solution of resorcinol (32) (5.00 g, 45.4 mmol) and DIEA (23.3
mL, 0.136 mol) in CH2Cl2 (100 mL) under an N2 atmosphere. The mixture was stirred for
3 h, diluted with saturated NH4Cl solution and stirred for an additional 15 min. The two
phases were partitioned and the aqueous phase was extracted with CH2Cl2. The combined
organic extracts were washed with brine and dried over anhydrous MgSO4. The solvent
was evaporated to give a yellow oil, which was purified by column chromatography using
Hex:EtOAc (9:1) to give 162 as a colorless oil (5.4 g, 60%).
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IR (neat) vmax 2955, 2902, 2827, 1768, 1591, 1487, 1219, 1138, 1004, 772 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 7.19 (1H, t, J = 8.3 Hz, H-5), 6.75 (1H, t, J = 2.3 Hz, H-2),
6.71 (2H, dd, J = 2.3 and 8.3 Hz, H-4 and H-6), 5.16 (4H, s, 2  OCH2O), 3.48 (6H, s, 2 
OCH3);
13C NMR (CDCl3, 100 MHz) δ 158.3 (2  C, C-1 and C-3), 129.9 (CH, C-5), 109.6 (2 
CH, C-4 and C-6), 105.0 (CH, C-2), 94.5 (2  OCH2O), 55.9 (2  OCH3);





 CH3CO2Ag (5.10 g, 30.3 mmol) was added to a solution of 162 (5.00 g, 25.2 mmol) in
CHCl3 (50 mL). The mixture was stirred for 5 min, and then a solution of I2 (7.04 g, 27.7
mmol) in CHCl3 (150 mL) was added dropwise to the stirred suspension. The resulting
mixture was stirred at rt for 5 h and filtered to remove the AgI. The filtrate was washed
with 10% Na2S2O3 solution, 5% NaHCO3 solution, H2O and brine. The organic phase was
dried over anhydrous MgSO4 and the solvent evaporated to give a colourless oil. The oil
was purified by flash chromatography using Hex:EtOAc (9:1) to afford the iodinated
compound 163 as a colorless oil (7.76 g, 95%).
IR (neat) vmax 2956, 2902, 2826, 1716, 1577, 1567, 1474, 1219, 1149, 982, 772 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 7.62 (1H, d, J = 8.5 Hz, H-6), 6.80 (1H, d, J = 2.5 Hz, H-3),
6.53 (1H, dd, J = 2.5 and 8.5 Hz, H-5), 5.21 (2H, s, OCH2O), 5.13 (2H, s, OCH2O),  3.50
(3H, s, OCH3), 3.46 (3H, s, OCH3);
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13C NMR (CDCl3, 100 MHz) δ 158.7 (C, C-4), 156.7 (C, C-2), 139.2 (CH, C-6), 111.4
(CH, C-5), 104.4 (CH, C-3), 95.0 (CH2, OCH2O), 94.5 (CH2, OCH2O), 77.4 (C, C-1), 56.4
(CH3, OCH3), 56.0 (CH3, OCH3);
HR-ESIMS m/z [M + Na]+ 346.9754 (Calcd. for C10H13INaO4 346.9756).




 Triisopropyl borate (10.7 mL, 46.3 mmol) was added to the stirred solution of aryl iodide
163 (5.00 g, 15.4 mmol) in THF:Et2O (1:2, 100 mL) under N2. The solution was cooled to
-100 oC using liquid N2 and a CH3OH bath, and then n-BuLi (14.5 mL of a 1.6 M solution
in hexanes) was added slowly with stirring. After 1 h of stirring at a temperature below -78
oC, a saturated NH4Cl solution was added. The solution was stirred for an additional 1 h at
rt and the two phases partitioned. The aqueous phase was extracted with Et2O. The
combined organic phases were washed with H2O and brine, and dried over anhydrous
MgSO4. The solvent was evaporated under reduced pressure to give an orange oil.
Purification of the oil by column chromatography (8:2 Hex:EtOAc) and evaporation of the
solvent afforded the boronic acid 164 as an orange solid (2.76 g, 74%).
IR (neat) vmax 3385, 2957, 1726, 1603, 1142, 993 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 7.79 (1H, d, J = 8.4 Hz, H-6), 6.80 (1H, d, J = 2.0 Hz, H-3),
6.76 (1H, dd, J = 2.0 and 8.4 Hz, H-5), 6.68 (2H, br s, B(OH)2), 5.27 (2H, s, OCH2O), 5.19
(2H, s, OCH2O),  3.50 (3H, s, OCH3), 3.47 (3H, s, OCH3);
13C NMR (CDCl3, 100 MHz) δ 163.5 (C, C-2), 160.9 (C, C-4), 137.8 (CH, C-6), 109.3
(CH, C-5), 102.1 (CH, C-3), 94.6 (OCH2O), 94.0 (OCH2O), 56.4 (OCH3), 56.0 (OCH3),
(C-1 signal not observed);
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11B NMR (CDCl3, 128 MHz) δB 28.55.
5.6.8 2',4',5,7-Tetramethoxymethoxyisoflavone (165)
To a solution of 3-iodochromone 90 (1.20 g, 3.06 mmol) in 1:1 DME:H2O (50 mL)  were
added 10% Pd/C (0.160 g, 5 mol%),  Na2CO3 (0.970 g, 9.18 mmol), and phenylboronic
acid 164 (1.11 g, 4.59 mmol). The resulting mixture was stirred at 40-45 oC overnight. The
catalyst was filtered and washed with H2O and EtOAc. The aqueous phase was extracted
with EtOAc, and the combined organic layers were washed with H2O, brine and dried over
anhydrous MgSO4. The solvent was evaporated and the crude product was purified by
silica gel column chromatography using Hex:EtOAc (7:3) to afford the isoflavone 168 (1.1
g, 78%) as a yellow oil:
IR (neat) vmax  2905, 2828, 1647, 1609, 1570, 1256, 1150, 999, 918 cm
-1;
1H NMR (CDCl3, 400 MHz) δ 7.75 (1H, s, H-2), 7.22 (1H, d, J = 8.5 Hz, H-6'), 6.88 (1H,
d, J = 2.3 Hz, H-3'), 6.76-6.72 (3H, m, H-6, H-8, H-5'), 5.27 (2H, s, OCH2O), 5.23 (2H, s,
OCH2O), 5.17 (2H, s, OCH2O), 5.10 (2H, s, OCH2O),  3.52 (3H, s, OCH3), 3.50 (3H, s,
OCH3), 3.47 (3H, s, OCH3), 3.41 (3H, s, OCH3);
13C NMR (CDCl3, 100 MHz) δ 174.9 (C, C-4), 160.9 (C, C-7), 159.4 (C, C-8a), 158.5 (C,
C-5), 158.4 (C, C-4'), 156.2 (C, C-2'), 151.8 (CH, C-2),  132.4 (CH, C-6'), 123.1 (C, C-3),
115.5 (C, C-1'), 111.5 (C, C-4a), 108.9 (CH, C-5'), 104.1 (CH, C-3'), 102.4 (CH, C-6), 97.3
(CH, C-8), 95.8 (CH2, OCH2O), 95.1 (CH2, OCH2O), 94.5 (CH2, OCH2O), 94.3 (CH2,
OCH2O), 56.5 (CH3, OCH3), 56.4 (CH3, OCH3), 56.1 (CH3, OCH3), 56.0 (CH3, OCH3);















HCl (3M, 15 mL) was added to a solution of 165 (1.00 g, 2.16 mmol) in CH3OH (30 mL)
and stirred at 50 oC for 12 h. CH3OH was evaporated and the reaction mixture was
extracted with EtOAc.  The combined organic phases were washed with H2O and brine.
The organic layer was dried over anhydrous MgSO4 and the solvent evaporated under
reduced pressure to give a yellow solid. Purification of the solid by column
chromatography using Hex:EtOAc (1:1) afforded 149 as a pale yellow solid (0.45 g, 73%).
Recrystallisation of 149 from Hex:EtOAc (1:4) gave pale yellow needles.
mp 268.4 - 270.1 oC  (Lit.26 mp 272.0 oC);
IR (neat) vmax 3319, 1652, 1613, 1502, 1254, 1171 cm
-1;
1H NMR (CD3OD, 400 MHz) δ 8.00 (1H, s, H-2), 7.04 (1H, d, J = 8.2 Hz, H-6'), 6.40 (1H,
d, J = 2.3 Hz, H-3'), 6.37 (1H, dd, J = 2.3 and 8.2 Hz, H-5'), 6.36 (1H, d, J = 2.3 Hz, H-8),
6.23 (1H, d, J = 2.3 Hz, H-6); (Plate 24a)
13C NMR (CD3OD, 100 MHz) δ 182.7 (C, C-4), 166.2 (C, C-7), 163.7 (C, C-5), 160.2 (C,
C-4'), 159.8 (C, C-8a), 157.8 (C, C-2'), 156.7 (CH, C-2),  133.2 (CH, C-6'), 122.6 (C, C-3),
110.9 (C, C-1'), 108.2 (CH, C-5'), 106.2 (C, C-4a), 104.4 (CH, C-3'), 100.3 (CH, C-6), 94.9
(CH, C-8); (Plate 24b)
HR-ESIMS m/z [M - H]- 285.0399 (Calcd. for C15H9O6 285.0399).
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DDQ (79.0 mg, 0.349 mmol) was added under N2 to a solution of 149 (100 mg, 0.350
mmol) in THF (20 mL). The reaction mixture was heated to 60 oC with stirring for 15 min.
Additional DDQ (79.0 mg, 0.349 mmol) was added and stirring was continued at the same
temperature for 30 min. The solvent was evaporated and the crude mixture purified by
column chromatography using Hex:EtOAc as eluent to give coumaronochromone 148 (66
mg, 66%) as a white solid. 148 was recrystallised from Hex:EtOAc (1:4) to afford white
needle-like crystals, which decomposed at 278.4 - 280.0 oC  (Lit.21 mp > 300 oC);
IR (neat) vmax  3327, 3101, 2922, 1622, 1436, 1029, 822 cm
-1;
1H NMR (CD3OD, 400 MHz) δ 7.75 (1H, d, J = 8.4 Hz, H-6'), 6.99 (1H, d, J = 1.9 Hz, H-
3'), 6.89 (1H, dd, J = 1.9 and 8.4 Hz, H-5'), 6.46 (1H, d, J = 2.0 Hz, H-8), 6.27 (1H, d, J =
2.0 Hz, H-6); (Plate 25a)
13C NMR (CD3OD, 100 MHz) δ 180.0 (C, C-4), 166.2 (C, C-2), 165.2 (C, C-7), 164.0 (C,
C-5), 157.8 (C, C-4'), 156.6 (C, C-8a), 151.9 (C, C-2'), 122.5 (CH, C-6'), 115.2 (CH, C-5'),
114.7 (C, C-1'), 104.5 (C, C-4a), 100.9 (CH, C-6), 99.5 (C, C-3),  98.7 (CH, C-3'), 95.8
(CH, C-8); (Plate 25b)
HR-ESIMS m/z [M - H]- 283.0239 (Calcd for C15H7O6 283.0243).








To a solution of 148 (40 mg, 0.141 mmol) in CH3OH (15 mL) was added Ca(OH)2  (21.0
mg, 0.282 mmol) followed by prenal (0.03 mL, 0.353 mmol). The mixture was stirred
under an N2 atmosphere for 3 days at rt. The CH3OH was evaporated and the reaction
mixture was diluted with EtOAc and 1 M HCl. The two phases were partitioned and the
aqueous phase was extracted with EtOAc. The combined organic extracts were washed
with H2O and brine and dried over anhydrous MgSO4. The solvent was evaporated and the
crude product purified by column chromatography using Hex:EtOAc:acetone (6:1:1),
followed by chromatotron using CH2Cl2 to give 130 as a cream white solid (20 mg, 40%)
and lupinalbin A (148) (14 mg, 35%) was recovered. Recrystallisation of 130 from CH3OH
gave cream white crystals, which decomposed at 245.5-247.2 oC  (Lit.23 mp 248.0-250.0
oC);
IR (neat) vmax  3501, 3230, 2923,  2853, 1729, 1640, 1594, 1456, 1393, 1116, 811 cm
-1;
1H NMR (acetone-d6), 500 MHz) δ 13.38 (1H, s, OH-5), 8.98 (1H, brs, OH-4'), 7.82 (1H,
d, J = 8.3 Hz, H-6'), 7.14 (1H, d, J = 2.0 Hz, H-3'), 7.02 (1H, dd, J = 2.0 and 8.3 Hz, H-5'),
6.70 (1H, d, J = 10.0 Hz, H-4''), 6.54 (1H, s, H-8), 5.79 (1H, d, J = 10.0 Hz, H-5''), 1.48
(6H, s, H-7'' and H-8''); (Plate 26a)
13C NMR (acetone-d6), 125 MHz) δ 178.6 (C, C-4), 164.7 (C, C-2), 158.5 (C, C-7), 157.0
(C, C-5), 156.4 (C, C-4'), 154.0 (C, C-8a), 150.4 (C, C-2'), 128.6 (CH, C-5''), 121.3 (CH,
C-6'), 114.6 (CH, C-4''), 114.0 (C, C-1'), 113.6 (CH, C-5'), 105.9 (C, C-6), 104.0 (C, C-4a),
98.5 (CH, C-3'), 97.5 (C, C-3),  95.3 (CH, C-8), 80.0 (C, C-6''), 27.3 (2  CH3, C-7'' and C-
8''); (Plate 26b)
HR-ESIMS m/z [M - H]- 349.0710 (Calcd for C20H13O6 349.0712).
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The main aims of this investigation were to develop an HPLC method for the analysis of
Eriosema plants used for the treatment of male impotence and  to develop methods for the
synthesis of kraussianone 1 (1) and related isoflavonoids. Six plants from different sources,
which were grouped as E. kraussianum, uqonsi and ubangalala were analysed by reversed-
phase HPLC-PDA. Three plants, i.e., the two authentic E. kraussianum plants from the
Drakensberg and Pietermaritzburg, and uqonsi from the herbal shop in Pietermaritzburg
showed similar chemical profiles. However, there were variations in the relative amounts of
the metabolites within each plant. In all the three plants, kraussianone 1 (1) occurred in
relatively low concentrations, while kraussianone 2 (2) was one of the major constituents in
the plant extracts. Other plant extracts contained different components from those found in E.
kraussianum. This may suggest that the active ingredients in these plants are different
compounds from those found in E. kraussianum. However, further chemical and biological
investigations are required to reveal the active components in these plants.
The synthesis of kraussianone 1 (1) was accomplished both by a semi-synthetic route and a
total synthetic strategy. Two routes were explored for the semi-synthesis of kraussianone 1 (1)
from kraussianone 2 (2). The key step in the two semi-synthetic strategies was the conversion
of the prenyl side chain of kraussianone 2 (2) into a dimethylchromene scaffold fused to OH-
7. The formation of the dimethylchromene ring in the first route was based on acid-catalysed
cyclisation of the prenyl group to give the dimethylchroman ring and subsequent
dehydrogenation. This route was abandoned due to poor regioselectivity of the acid-catalysed
cycloaddition reaction and the difficulty of oxidising the chroman fused to phloroglucinol
moiety into a chromene. The best results were obtained from the second route, which was
based on selective protection of the 2'-hydroxy group and oxidative cyclisation of the prenyl
154
side chain to OH-7 of kraussianone 2 (2) to give the dimethylpyran scaffold. Following this
route, kraussianone 1 (1) was prepared in a 54% overall yield over five steps.
Although kraussianone 1 (1) could be prepared in good yields by the semi-synthetic route,
there are several limitations inherent with semi-syntheses in general. Firstly, semi-synthetic
routes depend on natural compounds as starting materials; this may increase the demand of the
plant material and lead to illegal and unsustainable harvesting of the plant. Secondly, isolation
of the pure material from the plant may be difficult and costly. Furthermore, the application of
semi-synthetic strategies is narrow, especially in the preparation of diverse structural
analogues.
The total synthesis of kraussianone 1 (1) and related isoflavonoids featured the Suzuki-
Miyaura coupling reaction for the construction of the isoflavone nucleus and two methods for
the regioselective introduction of the dimethylpyran scaffolds to the A- and B-rings. This route
has advantages over the semi-synthetic one in that it allowed for the preparation of compounds
structurally related to kraussianone 1 (1) by modifications of rings A, B and C. Following this
protocol, six more isoflavonoids, eriosemaone D (17), genistein (103), geranylated
isoflavonoid 89, 2'-hydroxygenistein (149), lupinalbin A (148) and lupinalbin H (130), as well
as two pyranochromones 52 and 127 were prepared in good to excellent yields by structural
modifications of rings A, B and C (Figure 6.1).
The developed synthetic routes for kraussianone 1 (1) and related compounds provide us with
material to conduct biological activity studies. Therefore, future work will involve
investigations that will lead to the revelation of the mode of action of 1 for the erectile
dysfunction activity. Furthermore, prenylated isoflavonoids are reported to exhibit many










































Figure 6.1. Synthesised isoflavonoids and chromones
APPENDIX I
COPIES OF NMR SPECTRA
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Plate 1a. 1H NMR spectrum of 2',5-dihydroxy-[6'',6''-dimethylpyrano(2'',3'':4',5')][4''',5'''-

















































































Plate 1b. 13C NMR spectrum of 2',5-dihydroxy-[6'',6''-dimethylpyrano(2'',3'':4',5')][4''',5'''-






































































































































Plate 2a. 1H NMR Spectra of 2',7-dihydroxy-[6'',6''-dimethylpyrano(2'',3'':4',5')][4''',5'''-








































































Plate 2b. 13C NMR Spectra of 2',7-dihydroxy-[6'',6''-dimethylpyrano(2'',3'':4',5')][4''',5'''-
dihydro-6''',6'''-dimethylpyrano(2''',3''':5,6)]isoflavone (39) in DMSO-d6





































































































































Plate 3a. 1H NMR spectrum of 2',7-diacetoxy-[6'',6''-dimethylpyrano(2'',3'':4',5')][4''',5'''-


























































































Plate 3b. 13C NMR spectrum of 2',7-diacetoxy-[6'',6''-dimethylpyrano(2'',3'':4',5')][4''',5'''-


















































































































































Plate 4a. 1H NMR spectrum of 7-tert-butyldimethylsiloloxy-2',5-dihydroxy-6-prenyl-

































































































Plate 4b. 13C NMR spectrum of 7-tert-butyldimethylsiloloxy-2',5-dihydroxy-6-prenyl-
[6'',6''-dimethylpyrano(2'',3'':4',5')]isoflavone (59) in CDCl3



























































































































































Plate 5a. 1H NMR spectrum of 7-tert-butyldiphenylsilyloxy-2',5-dihydroxy-6-











































































































Plate 5b. 13C NMR spectrum of 7-tert-butyldiphenylsilyloxy-2',5-dihydroxy-6-









































































































































































Plate 6a. 1H NMR spectrum of 2'-acetoxy-7-tert-butyldiphenylsilyloxy-5-hydroxy-6-

















































































































Plate 6b. 13C NMR spectrum of 2'-acetoxy-7-tert-butyldiphenylsilyloxy-5-hydroxy-6-


























































































































































































Plate 7a. 1H NMR spectrum of 2'-acetoxy-5,7-dihydroxy-6-prenyl[6'',6''-dimethylpyrano





























































































Plate 7b. 13C NMR spectrum of 2'-acetoxy-5,7-dihydroxy-6-prenyl[6'',6''-dimethylpyrano
























































































































































Plate 8a. 1H NMR spectrum of 2'-acetoxy-5-hydroxy-[6'',6''-


























































































Plate 8b. 13C NMR spectrum of 2'-acetoxy-5-hydroxy-[6'',6''-



























































































































































































































































































































































Plate 10a. 1H NMR spectrum of 3-(N,N-dimethylamino)-1-(2'-hydroxy-4',6'-




























































7.88.0 ppm 6.16.26.3 ppm
Plate 10b. 13C NMR spectrum of 3-(N,N-dimethylamino)-1-(2'-hydroxy-4',6'-






































































































































* impurities of 95




























































































































6.87.07.27.4 ppm 6.26.36.4 ppm
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Plate 14a. 1H NMR spectrum of 2'-benzyloxy-5,7-dihydroxy-6'',6''-












































































6.2 ppm 5.5 ppm
Plate 14b. 13C NMR spectrum of 2'-benzyloxy-5,7-dihydroxy-6'',6''-













































































































































































































































































































































































































Plate 16a. 1H NMR spectrum of 7-methoxymethoxy-2,2-dimethylchromene-6-boronic




















































Plate 16b. 13C NMR spectrum of 7-methoxymethoxy-2,2-dimethylchromene-6-boronic

































































Plate 17a. 1H NMR spectrum of 2',5,7-trimethoxymethoxy-6'',6''-


























































































Plate 17b. 13C NMR spectrum of 2',5,7-trimethoxymethoxy-6'',6''-

























































































































































































































































































































Plate 19a. 1H NMR spectrum of rac-5-hydroxy-[6'-methyl-6'-(4-methylpent-3-










































































































Plate 19b. 13C NMR spectrum of rac-5-Hydroxy-[6'-methyl-6'-(4-methylpent-3-
enyl)pyrano]-2',3':7,6-chromone (127) in CDCl3












































































































































































































































































































































































































































Plate 21. 1H NMR spectrum of rac-2',5-dihydroxy-[(6'',6''-dimethylpyrano(2'',3'':4',5')]



































































































































































































































































































































































































































































































































































































































































































































































































































Total Synthesis of the Pyranoisoflavone Kraussianone 1 and Related Isoflavones
Mamoalosi A. Selepe, Siegfried E. Drewes, and Fanie R. van Heerden*
School of Chemistry, UniVersity of KwaZulu-Natal, PriVate Bag X01, ScottsVille 3209, Pietermaritzburg, South Africa
ReceiVed June 22, 2010
The first total synthesis of the pyranoisoflavone kraussianone 1 (1) is described. The key steps involved the
Suzuki-Miyaura reaction for the construction of the isoflavone core and the regioselective formation of the dimethylpyran
scaffolds to the phloroglucinol (ring A) and resorcinol (ring B) moieties of kraussianone 1 (1). This route also provided
access to the related isoflavones eriosemaone D (2) and genistein (3) via simple structural modifications.
Kraussianone 1 (1) is a pyranoisoflavone that was isolated from
the bark of Eriosema kraussianum Meisn. (Fabaceae), a plant used
traditionally for the treatment of male impotence and urinary
complaints in KwaZulu-Natal, South Africa.1 Preliminary studies
on the biological activity of the compounds isolated from E.
kraussianum revealed 1 to be the most potent metabolite for the
relaxation of carvenosal smooth muscle, an assay used to evaluate
drugs for erectile dysfunction. In this assay, 1 showed an activity
of 85% compared to sildenafil (Viagra) at 78 ng/mL.1,2 Compound
1 further demonstrated significant hypoglycemic and secondary
vasorelaxant effects.3 Therefore, 1 serves as an ideal lead compound
for the development of drugs to combat erectile dysfunction and
related disorders. However, 1 awaits in-depth biochemical studies
to reveal its molecular basis of action for these activities. This has
been hampered by the limited supply of the compound from E.
kraussianum, its sole natural source to date. In order to provide
access to sufficient quantities of 1 for further pharmacological
studies, we have developed a convenient synthetic route for the
preparation of 1 and related compounds, based on the Suzuki-
Miyaura reaction for the construction of the isoflavone core.4 While
the application of the Suzuki-Miyaura reaction in the synthesis of
isoflavones was demonstrated more than two decades ago,4 there
are not many reports on the synthesis of isoflavones with naturally
occurring substitution patterns by this method, especially those with
ring A possessing a phloroglucinol moiety.5,6 Except for the
pyranoisoflavone recently synthesized as a precursor to hirtellanine
A,6 no natural pyranoisoflavones have been reported by this method.
The previous synthetic procedures for pyranoisoflavones were based
on the deoxybenzoin or the chalcone route, which often suffered
from poor regioselectivity in the introduction of the dimethylpyran
ring to the isoflavone skeleton.7-13 We herein report the first
regioselective total synthesis of kraussianone 1 (1), employing the
Suzuki-Miyaura reaction as the key step for the construction of
the isoflavone nucleus.4 This route also gave access to a structurally
related antifungal pyranoisoflavone, eriosemaone D (2),14,15 whose
synthesis has not been disclosed, and to an important phytoestrogen,
genistein (3).
Results and Discussion
The retrosynthetic analysis of kraussianone 1 (1) is shown in
Scheme 1. We envisaged that the regioselective aldol-type con-
densation of the pyranoisoflavone 4 with prenal and the subsequent
6π electrocyclization would give the dimethylpyran ring fused to
ring A of kraussianone 1 (1). The isoflavone 4 would in turn be
synthesized by the Suzuki-Miyaura cross-coupling of 3-iodoch-
romone 5 and the boronic acid derivate 6, with the requisite
dimethylpyran scaffold. The latter would be prepared from readily
available resorcinol (8) and the former from phloroacetophenone
(7). Following this route, a number of related isoflavones can be
synthesized from the same key building blocks. This has been
demonstrated by the synthesis of eriosemaone D (2) from the
kraussianone 1 precursor 4 and by the synthesis of genistein (3)
from the 3-iodochromone 5 (Vide infra).
As illustrated in Scheme 2, the synthesis of the intermediate 5
commenced with regioselective protection of the hydroxy groups
of phloroacetophenone (7) by MOMCl generated from the reaction
of dimethoxymethane, AcCl, and catalytic ZnBr2
16 to give 9 in
50% yield. Condensation of 9 with DMF-DMA gave the enami-
noketone 10 (68%), which was cyclized in the presence of pyridine
and I2 to afford an inseparable mixture of 5 and 11 in the ratio of
50:7 (by 1H NMR), giving 58% and 6% overall yields, respecti-
vely.17-19 3-Iodochromone 5 is thus appropriately functionalized
for the ultimate conversion to an isoflavone via C-C bond
formation by the Suzuki-Miyaura reaction.
Having synthesized the first key building block, 5, the next step
was to prepare its boronic acid partner, 6. This was achieved in a
sequence of steps starting from resorcinol (8) (Scheme 3). Thus,
condensation of 8 with 3-methyl-2-butenoic acid gave chromanone
12 in 92% yield.20 Iodination of 12 with I2 and HIO3 in CH3OH/
H2O
21 gave a mixture of the targeted 6-iodochromanone 13 as the
major component in 65% yield together with 8-iodochromanone
14 as a minor component. These compounds were inseparable by
silica gel column chromatography. However, their purification could
be effected by their different solubility properties. The 6-iodoch-
romanone 13 was insoluble in CH2Cl2 and CHCl3, whereas
compound 14 readily dissolved in these solvents. Although
compound 13 was initially obtained in moderate yields under these
conditions, this method was not reproducible on a larger scale.
Therefore, alternative iodinating reagents, KIO3/KI, HIO4/I2, and
ICl, were screened for the regioselective C-6 iodination of chro-
manone 12 under different conditions,22-25 but these mostly gave
the 8-iodo isomer 14 and 7-hydroxy-6,8-diiodo-2,2-dimethyl-4-
chromanone (15). Benzyl protection of the 7-hydoxy group of
* To whom correspondence should be addressed. Tel: +27 33 2605886.
Fax: +27 33 2605009. E-mail: vanheerdenf@ukzn.ac.za.
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chromanone 12 and subsequent iodination of the resulting benzy-
loxychromanone 16 with HIO3/I221 resulted in the formation of
7-benzyloxy-3-iodo-2,2-dimethyl-4-chromanone (17).
Eventually, the targeted C-6-iodinated chromanone was success-
fully synthesized by treatment of the CHCl3 solution of 7-benzy-
loxy-2,2-dimethyl-4-chromanone (16) with CF3CO2Ag and I2 at
room temperature.26 This reaction gave 7-benzyloxy-6-iodo-2,2-
dimethyl-4-chromanone (18) as the sole product in 94% yield.
Reduction of 18 with NaBH4 and subsequent dehydration proceeded
smoothly to afford the iodochromene 20 in 96% overall yield.27,28
We envisioned that the boronic acid 6 could be synthesized from
20 by lithium-iodine exchange with n-BuLi, followed by treatment
of the phenyllithium with triisopropyl borate and hydrolysis of the
resulting boronate ester.29 The viability of this method was tested
on p-methoxymethylphenyl iodide (21) (Scheme 4), synthesized
by protection of the hydroxy group of p-iodophenol as the
methoxymethyl ether.16 A solution of phenyl iodide 21 in THF
was therefore sequentially treated with n-BuLi, triisopropyl borate,
and NH4Cl in one pot. Following this procedure, a small amount
of the targeted boronic acid 22 was obtained plus appreciable
quantities of the deiodinated material. It was evident from these
results that the lithium-iodine exchange occurred rapidly as
expected and that the generated aryllithium was very unstable.
Optimum results were obtained by changing the solvent system
to THF/Et2O (1:2) and the sequence in which the reagents were
added, by employing the “in situ quench” procedure developed by
Li and co-workers.30 Accordingly, the boronic acid 22 was prepared
in a one-pot sequence that involved addition of n-BuLi to a solution
of aryl iodide 21 and triisopropyl borate in THF/Et2O (1:2), followed
by the hydrolysis of the boronate ester with an NH4Cl solution
(Scheme 4). The improvement observed with this procedure may
be attributed to the immediate in situ quench of the generated
phenyllithium with triisopropyl borate, thus preventing side reac-
tions of the phenyllithium.30 These optimized reaction conditions
were subsequently employed for the synthesis of the boronic acid
6 in 70% yield from iodochromene 20, as shown in Scheme 3.
The Suzuki-Miyaura cross-coupling of 3-iodochromone 5 with
boronic acid 6 using a heterogeneous Pd(C) catalyst19,31 and
subsequent cleavage of the MOM protecting groups with HCl
furnished the pyranoisoflavone 4 in 72% yield. Base-catalyzed
condensation of the pyranoisoflavone 4 with prenal32 gave the
benzyl derivative of kraussianone 1, 23 (74% yield), which was
finally deprotected with BCl3
13 to afford kraussianone 1 (1) in 69%
yield (Scheme 5).
Having successfully synthesized kraussianone 1 (1), we took
advantage of the available materials and the optimized reaction
conditions to synthesize genistein (3) and eriosemaone D (2).
Eriosemaone D (2) was isolated from E. tuberosum A.Rich,14,15
but its total synthesis has not been disclosed. The synthesis of
genistein (2) by the Suzuki-Miyaura reaction has also not been
published. As shown in Scheme 5, genistein (3) was synthesized
in 66% yield over two steps, by coupling the boronic acid 22 to
3-iodochromone 5,19,31 followed by removal of MOM protecting
groups under similar conditions to those employed for 4. Eriose-
maone D (2) on the other hand was synthesized by benzyl
deprotection of the pyranoisoflavone 4 with BCl3.13 The physical
properties and the spectroscopic data of all the synthesized
compounds were in agreement with those of the isolated natural
compounds. This represents the first total synthesis of kraussianone
1 (1) and eriosemaone D (2) and the first synthesis of genistein
using the Suzuki-Miyaura reaction.
In conclusion, kraussianone 1 (1) and the structurally related
isoflavones eriosemaone D (2) and genistein (3) have been
successfully synthesized by employing the Suzuki-Miyauara
reaction as the key step. The successful synthesis of kraussianone
1 (1), via a route that readily gives entry to analogues, will allow
for further investigations of its pharmacological properties and
structure-activity relationship studies.
Scheme 1. Retrosynthetic Analysis of Kraussianone 1 (1) Scheme 2. Synthesis of 3-Iodochromone 5
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Experimental Section
General Experimental Procedures. Abbreviations: DIA, diisopro-
pylamine; DMF-DMA, N,N-dimethylformamide dimethylacetal; Hex,
hexanes (bp 68-70 °C); p-TSA, p-toluenesulfonic acid. Hex used for
chromatographic purifications was distilled prior to use. Anhydrous
CH2Cl2, CH3CN, THF, and Et2O were obtained from Innovative
Technologies (Newburyport, MA) Pure-Solv 800 solvent purification
system. Reagents used for syntheses were purchased from Fluka, Sigma-
Aldrich, or Merck and were used without further purification unless
otherwise stated. 2′,4′,6′-Trihydroxyacetophenone monohydrate was
dried in an oven at 90 °C for 24 h prior to use. Reactions were
monitored by TLC. The TLC was performed on Merck silica gel plates
(60 F254) and visualized under UV light (254 nm). Alternatively,
detection of spots on the TLC was achieved by heating with a heat
gun after treatment with a solution of anisaldehyde in concentrated
H2SO4 and EtOH prepared in the volume ratio 1:1:18, respectively.
Column chromatography was performed using Merck Kieselgel 60
(230-400 mesh). Centrifugal chromatography was performed on a
Harrison Research Chromatotron model 7924T on glass plates coated
with Merck silica gel with particle size 0.040-0.063 mm, 2-4 mm
thick.
The melting points were measured on a Reichert electrothermal
melting point apparatus and are uncorrected. IR spectra were recorded
with a Perkin-Elmer spectrophotometer, and NMR spectra on a Bruker
AVANCE DPX400 spectrometer. 11B NMR spectra were referenced
against an external standard of neat BF3 ·OEt2 containing a capillary
tube of acetone-d6 for deuterium lock. The chemical shifts from 1H
NMR and 13C NMR spectra are reported in parts per million relative
to the residual protonated or deuterated solvents peaks (CDCl3: δH 7.26,
δC 77.0 and DMSO-d6: δH 2.50, δC 39.5). The spin multiplicities are
given as s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q
(quartet), br (broad), or m (multiplet). The mass spectra were recorded
on a Thermo Finnigan GC-MS ion trap using electron-impact ionization
or on a time-of-flight Waters LCT Premier MS using electrospray
ionization in the positive or negative mode.
2′-Hydroxy-4′,6′-dimethoxymethoxyacetophenone (9). Catalytic
ZnBr2 was dissolved in dimethoxymethane (2.62 mL, 29.74 mmol)
under an N2 atmosphere, and then AcCl (2.12 mL, 29.74 mmol) was
added dropwise to the stirred solution. The solution was stirred for an
additional 2 h at room temperature and transferred via a cannula to an
ice-cold solution of the predried phloroacetophenone (7) (2.0 g, 11.89
mmol) and DIA (3.6 mL, 23.59 mmol) in CH2Cl2 (100 mL) under an
N2 atmosphere. The mixture was stirred for 3 h, diluted with saturated
NH4Cl solution (40 mL), and stirred for an additional 15 min. The two
phases were partitioned, and the aqueous phase was extracted with
CH2Cl2 (2 × 30 mL). The combined organic extracts were washed
with brine (3 × 100 mL) and dried over anhydrous MgSO4. The solvent
was evaporated to give a yellow oil, which was purified by column
chromatography using Hex/EtOAc (7:3) as eluent to afford 9 as a
colorless oil (1.53 g, 50%): IR (neat) νmax 3100, 2925, 1618 cm-1; 1H
NMR (CDCl3, 400 MHz) δ 13.68 (1H, s, OH), 6.26 (1H, d, J ) 2.4
Hz, H-3′), 6.24 (1H, d, J ) 2.4 Hz, H-5′), 5.25 (2H, s, OCH2O), 5.16
(2H, s, OCH2O), 3.52 (3H, s, OCH3), 3.47 (3H, s, OCH3), 2.65 (3H, s,
COCH3); 13C NMR (CDCl3, 100 MHz) δ 203.1 (C, C-1), 167.3 (C,
C-2′), 163.3 (C, C-4′), 160.5 (C, C-6′), 107.3 (C, C-1′), 97.3 (CH, C-
3′), 94.5 (CH, C-5′), 94.0 (CH2, 2 × OCH2O), 56.7 (CH3, OCH3), 56.4
(CH3, OCH3), 32.9 (CH3, -COCH3); EIMS m/z 225 (10%), 209 (29),
207 (100), 191 (22), 44 (40), 40 (62).
3-(N,N-Dimethylamino)-1-(2′-hydroxy-4′,6′-dimethoxymethoxy-
phenyl)propenone (10). DMF-DMA (0.29 mL, 2.19 mmol) was added
to 9 (0.28 g, 1.09 mmol) at 95 °C. The mixture was stirred at the same
temperature for 1.5 h. The volatiles in the orange oil were evaporated
on a rotary evaporator, and the crude solid was subjected to flash
chromatography using Hex/EtOAc (1:1) as eluent. Evaporation of the
solvent gave 10 as a yellow oil, which solidified upon cooling (0.23 g,
68%). The solid was recrystallized to give yellow needle-like crystals
(1:1 Hex/Et2O): mp 85-86 °C; IR (KBr) νmax 3445, 3163, 2913, 1606,
1233 cm-1; 1H NMR (CDCl3, 400 MHz) δ 15.08 (1H, s, OH-2′), 7.92
(1H, d, J ) 12.0 Hz, H-3), 6.29 (1H, d, J ) 12.0 Hz, H-2), 6.26 (1H,
Scheme 3. Synthesis of Boronic Acid 6
Scheme 4. Model Reaction for Synthesis of Boronic Acid
Scheme 5. Synthesis of Kraussianone 1 (1), Eriosemaone D (2),
and Genistein (3)
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d, J ) 2.4 Hz, H-3′), 6.17 (1H, d, J ) 2.4 Hz, H-5′), 5.20 (2H, s,
OCH2O), 5.14 (2H, s, OCH2O), 3.51 (3H, s, OCH3), 3.46 (3H, s, OCH3),
3.13 (3H, brs, N(CH3)2), 2.94 (3H, brs, N(CH3)2); 13C NMR (CDCl3,
100 MHz) δ 190.6 (C, C-1), 166.9 (C, C-2′), 161.3 (C, C-4′), 158.9
(C, C-6′), 154.4 (CH, C-3), 107.1 (C, C-1′), 97.9 (CH, C-3′), 97.0 (CH,
C-2), 95.2 (CH2, OCH2O), 94.5(CH, C-5′), 94.1 (CH2, OCH2O), 56.7
(CH3, OCH3), 56.3 (CH3, OCH3), 45.5 (CH3, N(CH3)2), 37.2 (CH3,
N(CH3)2); HRMS-ES m/z [M + Na]+ 334.1267 (calcd for C15H21NO6Na
334.1267).
3-Iodo-5,7-dimethoxymethoxychromone (5). To a solution of
propenone 10 (0.12 g, 0.38 mmol) in CH2Cl2 (20 mL) was added
pyridine (0.06 mL, 0.74 mmol) followed by I2 (0.11 g, 0.44 mmol).
The resulting solution was stirred at room temperature for 12 h. The
reaction was quenched with a saturated Na2S2O3 solution (10 mL), and
the two phases were partitioned. The aqueous phase was extracted with
CH2Cl2 (2 × 20 mL). The organic layers were combined, washed with
H2O (15 mL) and brine (15 mL), and dried over anhydrous MgSO4.
The solvent was evaporated to give a yellow solid. The crude product
was purified on a chromatotron using Hex/EtOAc (7:3) as eluent. The
solvent was evaporated to afford a cream-white solid (94 mg), which
was identified (1H NMR) as a mixture of 5 and 11 in the ratio 50:7,
respectively. Therefore, the percentage yield of compound 5 was 58%:
IR (KBr) νmax 3179, 3099, 3058, 2958, 2904, 1622, 1445, 1275, 1140,
1036, 921, 844 cm1; 1H NMR (CDCl3, 400 MHz) δ 8.09 (1H, s, H-2),
6.75 (1H, d, J ) 2.3 Hz, H-8), 6.71 (1H, d, J ) 2.3 Hz, H-6), 5.29
(2H, s, OCH2O), 5.22 (2H, s, OCH2O), 3.54 (3H, s, OCH3), 3.49 (3H,
s, OCH3); 13C NMR (CDCl3, 100 MHz) δ 171.2 (C, C-4), 161.5 (C,
C-7), 159.2 (C, C-5), 158.3 (C, C-8a), 155.6 (CH, C-2), 108.8 (C, C-4a),
102.1 (CH, C-6), 96.8 (CH, C-8), 95.5 (CH2, OCH2O), 94.4 (CH2,
OCH2O), 89.4 (C, C-3), 56.7 (CH3, OCH3), 56.5 (CH3, OCH3); HRMS-
ES m/z [M + Na]+ 392.9834 (calcd for C13H14O6NaI 392.9835).
7-Hydroxy-2,2-dimethyl-4-chromanone (12). Resorcinol (8) (1.0
g, 9.1 mmol) and 3-methyl-2-butenoic acid (0.91 g, 9.1 mmol) were
added simultaneously under N2 to a stirred mixture of CH3SO3H (14.5
mL, 218.2 mmol) and P2O5 (0.7 g, 5.1 mmol) at 70 °C. The reaction
mixture was stirred at the same temperature for 30 min, cooled to room
temperature, and poured into ice-water (150 mL). The aqueous phase
was extracted with Et2O (3 × 25 mL), and the combined organic
extracts were washed with H2O (2 × 50 mL) and brine (25 mL) and
dried over anhydrous MgSO4. The solvent was evaporated to afford a
yellow solid. The solid was purified by flash chromatography using
Hex/EtOAc (3:2) as mobile phase to give chromanone 12 as a light
yellow solid (1.61 g, 92%). Recrystallization of the solid afforded white
crystals (9:1 CH2Cl2/Et2O): mp 170.0-171.5 °C (lit.20 172-174 °C);
IR (KBr) νmax 3129, 2967, 2837, 1578, 1252, 1169, 1126, 854 cm-1;
1H NMR (DMSO-d6, 400 MHz) δ 7.58 (1H, d, J ) 8.4 Hz, H-5), 6.43
(1H, dd, J ) 1.9 and 8.4 Hz, H-6), 6.24 (1H, d, J ) 1.9 Hz, H-8), 2.65
(2H, s, H-3), 1.36 (6H, s, 2 × CH3); 13C NMR (DMSO-d6, 100 MHz)
δ 190.1 (C, C-4), 164.7 (C, C-7), 161.4 (C, C-8a), 127.9 (CH, C-5),
112.8 (C, C-4a), 109.8 (CH, C-6), 102.8 (CH, C-8), 79.3 (C, C-2),
47.8 (CH2, C-3), 26.2 (2 × CH3); HRMS-ES m/z [M + Na]+ 215.0687
(calcd for C11H12O3Na 215.0684).
7-Hydroxy-6-iodo-2,2-dimethyl-4-chromanone (13). A solution of
chromanone 12 (0.15 g, 0.78 mmol), HIO3 (0.03 g, 0.17 mmol), and I2
(0.08 g, 0.32 mmol) in CH3OH/H2O (3:1, 10 mL) was heated to 85 °C
for 12 h. The CH3OH was evaporated to give a yellow residue, which
was diluted with EtOAc (20 mL) and H2O (25 mL). The two phases
were partitioned, and the aqueous phase was extracted with EtOAc (2
× 20 mL). The combined organic extracts were washed with saturated
Na2S2O3 solution (20 mL), H2O (40 mL), and brine (30 mL) and dried
over anhydrous MgSO4. Evaporation of solvent gave a yellow solid,
which was washed with hot CH2Cl2, cooled, and filtered. The residue
was recrystallized from CH2Cl2/EtOAc (8:2) to give pure 13 (0.16 g,
65%). The mother liquor, which contained mostly 7-hydroxy-8-iodo-
2,2-dimethyl-4-chromanone (14), was evaporated to give a yellow solid
(49 mg). Compound 13 had mp 195-197 °C; IR (KBr) νmax 2978,
2922, 2702, 1641, 1563, 1327, 1259, 849 cm1; 1H NMR (DMSO-d6,
400 MHz) δ 7.96 (1H, s, H-5), 6.40 (1H, s, H-8), 2.67 (2H, s, H-3),
1.36 (6H, s, 2 × CH3); 13C NMR (DMSO-d6, 100 MHz) δ 189.2 (C,
C-4), 163.1 (C, C-7), 161.1 (C, C-8a), 136.3 (CH, C-5), 114.9 (C, C-4a),
102.8 (CH, C-8), 79.8 (C, C-2), 76.4 (C, C-6), 47.4 (CH2, C-3), 26.1
(2 × CH3); HRMS-ES m/z [M + Na]+ 340.9656 (calcd for C11H11O3NaI
340.9651).
7-Benzyloxy-2,2-dimethyl-4-chromanone (16). K2CO3 (2.16 g,
15.63 mmol) and BnBr (1.2 mL, 10.42 mmol) were added under N2 to
a stirred solution of chromanone 12 (1.00 g, 5.21 mmol) in dry CH3CN
(30 mL). The reaction mixture was refluxed for 8 h under N2. The
mixture was cooled to room temperature, acidified with 2 M HCl (40
mL), and extracted with EtOAc (3 × 20 mL). The organic extracts
were combined and washed with H2O (25 mL) and brine (25 mL),
then dried over anhydrous MgSO4. The solvent was removed with a
rotary evaporator and the crude product purified on a chromatotron
using a Hex/EtOAc (7:3) solvent mixture. The product 16 was obtained
as white crystals after evaporation of the solvent and recrystallization
from Hex (1.30 g, 88%): mp 55-56 °C; IR (KBr) νmax 3324, 2982,
2964, 2890, 1672, 1604, 1441, 1319, 1258, 1164, 1000, 988, 840 cm-1;
1H NMR (CDCl3, 400 MHz) δ 7.81 (1H, d, J ) 8.4 Hz, H-5),
7.32-7.43 (5H, m, PhCH2), 6.62 (1H, dd, J ) 1.9 and 8.4 Hz, H-6),
6.46 (1H, d, J ) 1.9 Hz, H-8), 5.08 (2H, s, PhCH2), 2.66 (2H, s, H-3),
1.45 (6H, s, 2 × CH3); 13C NMR (CDCl3, 100 MHz) δ 191.2 (C, C-4),
165.7 (C, C-7), 161.8 (C, C-8a), 136.2 (PhCH2), 128.7 (PhCH2), 128.3
(CH, C-5), 128.2 (PhCH2), 127.5 (PhCH2), 113.1 (C, C-4a), 109.8 (CH,
C-6), 102.2 (CH, C-8), 79.6 (C, C-2), 70.2 (CH2, PhCH2), 48.6 (CH2,
C-3), 26.7 (2 × CH3); HRMS-ES m/z [M + Na]+ 305.1149 (calcd for
C18H18O3Na 305.1154).
7-Benzyloxy-6-iodo-2,2-dimethyl-4-chromanone (18). CF3CO2Ag
(94 mg, 0.426 mmol) was added to a solution of 16 (100 mg, 0.355
mmol) in CHCl3 (10 mL). The mixture was stirred for 5 min, and then
a solution of I2 (90 mg, 0.355 mmol) in CHCl3 (20 mL) was added
dropwise to the stirred suspension. The resulting mixture was stirred
at room temperature for 12 h. The solution was filtered to remove the
AgI, and the filtrate was washed with Na2S2O3 solution (10%, 30 mL),
NaHCO3 solution (5%, 30 mL), H2O (50 mL), and brine (30 mL). The
organic phase was dried over anhydrous MgSO4, and the solvent was
evaporated to give a cream-white solid. The solid was purified by flash
chromatography using Hex/EtOAc (6:4) as eluent to afford iodochro-
manone 18 as a white solid (136 mg, 94%). Recrystallization of the
solid from CH3OH gave colorless needles: mp 128-130 °C; IR (KBr)
νmax 2983, 1661, 1583, 1262 cm1; 1H NMR (CDCl3, 400 MHz) δ 8.28
(1H, s, H-5), 7.48 (2H, d, J ) 7.5 Hz, PhCH2), 7.41 (2H, t, J ) 7.5
Hz, PhCH2), 7.34 (1H, t, J ) 7.3 Hz, PhCH2), 6.40 (1H, s, H-8), 5.14
(2H, s, PhCH2), 2.65 (2H, s, H-3), 1.44 (6H, s, 2 × CH3); 13C NMR
(CDCl3, 100 MHz) δ 194.2 (C, C-4), 162.8 (C, C-7), 162.1 (C, C-8a),
137.3 (CH, C-5), 135.6 (PhCH2), 128.7 (PhCH2), 128.2 (PhCH2), 127.0
(PhCH2), 116.0 (C, C-4a), 101.3 (CH, C-8), 80.1 (C, C-2), 77.2 (C,
C-6), 71.1 (CH2, PhCH2), 48.2 (CH2, C-3), 26.6 (2 × CH3); HRMS-
ES m/z [M + Na]+ 431.0118 (calcd for C18H17O3NaI 431.0120).
7-Benzyloxy-6-iodo-2,2-dimethyl-4-chromanol (19). To a solution
of 18 (0.295 g, 1.05 mmol) in THF (5 mL) was added NaBH4 (0.20 g,
5.25 mmol) in EtOH (20 mL). The resulting solution was refluxed for
3 h. The reaction mixture was cooled to room temperature, quenched
with saturated NH4Cl solution (40 mL), and extracted with EtOAc (3
× 20 mL). The organic phases were combined, washed with saturated
NaHCO3 solution (20 mL), brine (20 mL), and H2O (20 mL), and dried
over anhydrous MgSO4. The organic layer was concentrated, and the
product was purified by flash chromatography using a Hex/EtOAc (1:
1) solvent system to afford chromanol 19 as a colorless oil (0.282 g,
95%), which eventually solidified. The solid was recrystallized from
Hex/Et2O (3:2) to give white crystals: mp 90-92 °C; IR (KBr) νmax
3782, 3467, 2982, 2929, 1579, 1460, 1278, 1163, 1129, 1035 cm-1;
1H NMR (CDCl3, 400 MHz) δ 7.83 (1H, s, H-5), 7.49 (2H, d, J ) 7.5
Hz, PhCH2), 7.39 (2H, t, J ) 7.6 Hz, PhCH2), 7.32 (1H, t, J ) 7.3 Hz,
PhCH2), 6.36 (1H, s, H-8), 5.07 (2H, s, PhCH2), 4.75 (1H, brq, J )
7.5 Hz, H-4), 2.17 (1H, brd, J ) 7.3 Hz, OH-4), 2.10 (1H, dd, J ) 6.0
and 13.6 Hz, H-3b), 1.80 (1H, dd, J ) 8.5 and 13.6 Hz, H-3a), 1.43
(3H, s, CH3), 1.30 (3H, s, CH3); 13C NMR (CDCl3, 100 MHz) δ 157.8
(C, C-7), 154.9 (C, C-8a), 138.0 (CH, C-5), 136.6 (PhCH2), 128.5
(PhCH2), 127.9 (PhCH2), 127.0 (PhCH2), 119.5 (C, C-4a), 101.8 (CH,
C-8), 76.2 (C, C-2), 75.2 (C, C-6), 70.8 (CH2, PhCH2), 62.9 (C, C-4),
42.6 (CH, C-3), 28.8 (CH3), 25.9 (CH3); HRMS-ES m/z [M + Na]+
433.0280 (calcd for C18H19O3NaI 433.0277).
7-Benzyloxy-6-iodo-2,2-dimethylchromene (20). p-TSA (0.012 g,
0.058 mmol) was added to a solution of chromanol 19 (0.12 g, 0.29
mmol) in THF (15 mL) under N2. The resulting solution was refluxed
under N2 for 2 h. A NaOH solution (10%, 15 mL) was added to the
cooled reaction mixture, and the mixture was extracted with Et2O (3
× 15 mL). The combined organic extracts were washed with H2O (40
mL) and brine solution (30 mL) and dried over anhydrous MgSO4.
Evaporation of the solvent afforded a colorless oil, which solidified
upon cooling. The solid was successively recrystallized from Hex and
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CH3OH to give iodochromene 20 as white fluffy crystals (0.112 g,
97%): mp 63-65 °C; IR (KBr) νmax 3032, 2972, 2924, 1713, 1602,
1480, 1454, 1358, 1158, 736 cm-1; 1H NMR (CDCl3, 400 MHz) δ
7.49 (2H, d, J ) 7.3 Hz, PhCH2), 7.40 (2H, t, J ) 7.3 Hz, PhCH2),
7.37 (1H, s, H-5), 7.32 (1H, t, J ) 7.2 Hz, PhCH2), 6.41 (1H, s, H-8),
6.22 (1H, d, J ) 9.9 Hz, H-4), 5.48 (1H, d, J ) 9.9 Hz, H-3), 5.10
(2H, s, PhCH2), 1.42 (6H, s, 2 × CH3); 13C NMR (CDCl3,100 MHz)
δ 157.9 (C, C-7), 154.6 (C, C-8a), 136.5 (PhCH2), 136.0 (CH, C-5),
128.7 (CH, C-3), 128.5 (PhCH2), 127.9 (PhCH2), 127.0 (PhCH2), 120.9
(CH, C-4), 117.0 (C, C-4a), 102.0 (CH, C-8), 76.8 (C, C-2), 74.8 (C,
C-6), 70.9 (CH2, PhCH2), 28.0 (2 × CH3); HRMS-ES m/z [M + Na]+
415.0176 (calcd for C18H17O2NaI 415.0171).
7-Benzyloxy-2,2-dimethylchromene-6-boronic acid (6). Triiso-
propyl borate (1.8 mL, 7.65 mmol) was added to a stirred solution of
20 (1.0 g, 2.55 mmol) in THF/Et2O (1:2, 75 mL) under N2. The solution
was cooled to -100 °C using a liquid N2 and CH3OH bath, and then
n-BuLi (2.4 mL of a 1.6 M solution in hexanes) was added slowly
with stirring. After 1 h of stirring at a temperature below -78 °C,
saturated NH4Cl solution was added (50 mL). The solution was stirred
for an additional 1 h at room temperature, and the aqueous phase was
extracted with Et2O (3 × 30 mL). The combined organic phases were
washed with H2O (2 × 60 mL) and brine (60 mL) and dried over
anhydrous MgSO4. The solvent was evaporated to give a white solid,
which was purified by column chromatography using Hex/EtOAc (4:
1) as the mobile phase. Evaporation of the solvent gave boronic acid
6 as a fluffy white solid (0.55 g, 70%): IR (KBr) νmax 3367, 3027,
2969, 2928, 1643, 1607, 1567, 1449 cm-1; 1H NMR (CDCl3, 400 MHz)
δ 7.47 (1H, s, H-5), 7.36-7.42 (5H, m, PhCH2), 6.46 (1H, s, H-8),
6.32 (1H, d, J ) 10.1 Hz, H-4), 5.54 (2H, s, B(OH)2), 5.49 (1H, d, J
) 10.1 Hz, H-3), 5.08 (2H, s, PhCH2), 1.44 (6H, s, 2 × CH3); 13C
NMR (CDCl3,100 MHz) δ 165.6 (C, C-7), 157.4 (C, C-8a), 135.8
(PhCH2), 134.8 (CH, C-5), 128.9 (PhCH2), 128.6 (PhCH2), 127.9 (C,
C-3), 127.8 (PhCH2), 121.8 (CH, C-4), 114.9 (C, C-4a), 100.1 (CH,
C-8), 77.1 (C, C-2), 70.9 (CH2, PhCH2), 28.3 (2 × CH3) (C-6 signal
not observed); 11B NMR (CDCl3, 128 MHz) δB 28.74.
2′-Benzyloxy-5,7-dihydroxy-6′′,6′′-dimethylpyrano[2′′,3′′:4′,5′]isofla-
vone (4). To a solution of 5 (0.5 g, 1.28 mmol) in DME/H2O (1:1, 60
mL) were added K2CO3 (0.52 g, 3.82 mmol), boronic acid 6 (0.55 g,
1.77 mmol), and 10% Pd(0)/C (68 mg, 5 mol %). The reaction mixture
was stirred at 40-45 °C for 12 h. The catalyst was filtered and washed
with Et2O and H2O. The organic solvents were evaporated, and the
crude product was diluted with CH3OH (25 mL) and HCl (3 M, 10
mL). The resulting solution was stirred at 50 °C for 18 h. CH3OH was
evaporated, and the reaction mixture was diluted with CH2Cl2 (15 mL)
and H2O (10 mL). The two phases were partitioned, and the aqueous
phase was extracted with CH2Cl2 (2 × 15 mL). The combined organic
phases were washed with NaHCO3 solution (10%, 50 mL), H2O (50
mL), and brine (50 mL). The organic layer was dried over anhydrous
MgSO4. Evaporation of the solvent with a rotary evaporator gave a
yellow oil, which was subjected to column chromatography using Hex/
EtOAc (3:2) as eluent. The solvent was evaporated to give 4 as a
yellowish oil, which solidified upon cooling (0.41 g, 72%). Recrystal-
lization of the solid from Hex/Et2O (1:1) gave white crystals: mp 93-95
°C; IR (KBr) νmax 3255, 2974, 2929, 1650, 1615, 1497, 1277, 1151,
1038, 832, 699 cm-1; 1H NMR (CDCl3, 400 MHz) δ 12.79 (1H, s,
OH-5), 7.77 (1H, s, H-2), 7.22-7.34 (5H, m, PhCH2), 6.92 (1H, s,
H-6′), 6.50 (1H, s, H-3′), 6.23 (1H, d, J ) 9.8 Hz, H-4′′), 6.21 (1H, d,
J ) 2.2 Hz, H-8), 6.19 (1H, d, J ) 2.2 Hz, H-6), 5.44 (1H, d, J ) 9.8
Hz, H-5′′), 5.03 (2H, s, PhCH2), 1.40 (6H, s, H-7′′ and H-8′′); 13C
NMR (CDCl3,100 MHz) δ 181.0 (C, C-4), 163.0 (C, C-7), 162.5 (C,
C-5), 158.0 (C, C-8a), 157.5 (C, C-2′), 154.8 (C, C-4′), 154.6 (CH,
C-2), 136.6 (PhCH2), 129.2 (CH, C-6′), 128.5 (PhCH2), 128.2 (CH,
C-5′′), 127.9 (PhCH2), 127.3 (PhCH2), 121.5 (CH, C-4′′), 120.8 (C,
C-3), 114.6 (C, C-5′), 112.0 (C, C-1′), 105.8 (C, C-4a), 101.8 (CH,
C-3′), 99.6 (CH, C-6), 94.1 (CH, C-8), 76.8 (C, C-6′′), 70.9 (CH2,
PhCH2), 28.2 (2 × CH3, C-7′′ and C-8′′); HRMS-ES m/z [M + Na]+
465.1312 (calcd for C27H22O6Na 465.1314).
2′-O-Benzylkraussianone 1 (23). 3-Methyl-2-butenal (0.18 mL, 1.85
mmol) was added under an N2 atmosphere to a stirred mixture of
Ca(OH)2 (55 mg, 0.74 mmol) and 4 (82 mg, 0.185 mmol) in CH3OH
(10 mL). The mixture was stirred for 3 days at room temperature.
CH3OH was evaporated, and the reaction mixture was diluted with
EtOAc (15 mL) and H2O (20 mL). The two phases were partitioned,
and the aqueous phase was extracted with EtOAc (2 × 15 mL). The
organic layers were combined, washed with 1 M HCl (40 mL), H2O
(40 mL), and brine (40 mL), and dried over anhydrous MgSO4.
Evaporation of the solvent followed by column chromatography gave
23 as a yellowish oil (70 mg, 74%): IR (KBr) νmax 3422, 3034, 2974,
2927, 1651,1615, 1496, 1463, 1287, 1146, 1058, 828, 696 cm-1; 1H
NMR (CDCl3, 400 MHz) δ 13.22 (1H, s, OH-5), 7.79 (1H, s, H-2),
7.27-7.34 (5H, m, PhCH2), 6.96 (1H, s, H-6′), 6.73 (1H, d, J ) 10.0
Hz, H-4′′′), 6.52 (1H, s, H-3′), 6.31 (1H, s, H-8), 6.28 (1H, d, J ) 9.8
Hz, H-4′′), 5.61 (1H, d, J ) 10.0 Hz, H-5′′′), 5.49 (1H, d, J ) 9.8 Hz,
H-5′′), 5.04 (2H, s, PhCH2), 1.47 (6H, s, H-7′′′ and H-8′′′), 1.44 (6H,
s, H-7′′ and H-8′′); 13C NMR (CDCl3,100 MHz) δ 180.9 (C, C-4), 159.3
(C, C-7), 157.5 (CH, C-2′), 157.3 (C, C-8a), 156.9 (C, C-5), 154.7 (C,
C-4′), 154.4 (CH, C-2), 136.8 (PhCH2), 129.1 (CH, C-6′), 128.5
(PhCH2), 128.1 (CH, C-5′′), 128.0 (CH, C-5′′′), 127.8 (PhCH2), 127.2
(PhCH2), 121.6 (CH, C-4′′), 120.6 (C, C-3), 115.6 (CH, C-4′′′), 114.5
(C, C-5′), 112.2 (C, C-1′), 106.2 (C, C-4a), 105.5 (C, C-6), 101.8 (CH,
C-3′), 94.8 (CH, C-8), 77.9 (C, C-6′′′), 76.8 (C, C-6′′), 70.8 (CH2,
PhCH2), 28.3 (2 × CH3, C-7′′′ and C-8′′′), 28.2 (2 × CH3, C-7′′ and
C-8′′); HRMS-ES m/z [M + Na]+ 531.1782 (calcd for C32H28O6Na
531.1784).
Kraussianone 1 (1). BCl3 (0.5 mL, 1 M in heptane) was added to
a solution of 23 (50 mg, 0.1 mmol) in CH2Cl2 (5 mL) cooled to -80
°C. The mixture was stirred under N2 at a temperature below -68 °C
for 30 min. The reaction was quenched with H2O and extracted with
CH2Cl2 (2 × 15 mL). The combined organic extracts were washed
with H2O (20 mL) and brine (20 mL) and dried over anhydrous MgSO4.
Evaporation of the solvent gave a yellow oil, which was purified on a
chromatotron using CH2Cl2 to give 1 (24 mg, 69%) as a yellow solid.
The solid was recrystallized from Hex/CH3OH (4:1): mp 186-188 °C
(lit.1 185-187 °C); IR (KBr) νmax 3336, 2975, 2872, 1649, 1615, 1460,
1132, 773 cm-1; 1H NMR (CDCl3, 400 MHz) δ 12.55 (1H, s, OH-5),
8.27 (1H, s, OH-2′), 7.73 (1H, s, H-2), 6.75 (1H, s, H-6′), 6.74 (1H, d,
J ) 10.0 Hz, H-4′′′), 6.53 (1H, s, H-3′), 6.40 (1H, s, H-8), 6.28 (1H,
d, J ) 9.8 Hz, H-4′′), 5.65 (1H, d, J ) 10.0 Hz, H-5′′′), 5.52 (1H, d,
J ) 9.8 Hz, H-5′′), 1.49 (6H, s, H-7′′′ and H-8′′′), 1.44 (6H, s, H-7′′
and H-8′′); 13C NMR (CDCl3,100 MHz) δ 182.0 (C, C-4), 160.4 (C,
C-7), 157.2 (CH, C-2′), 157.1 (C-8a), 156.4 (C, C-5), 155.7 (C, C-4′),
154.7 (CH, C-2), 128.8 (CH, C-5′′), 128.6 (CH, C-5′′′), 127.1 (CH,
C-6′), 123.1 (C, C-3), 121.3 (CH, C-4′′), 115.28 (CH and C, C-4′′′ and
C-5′), 112.1 (C, C-1′), 107.3 (CH, C-3′), 106.1 (C, C-6), 105.5 (C,
C-4a), 95.0 (CH, C-8), 78.5 (C, C-6′′′), 77.2 (C, C-6′′), 28.4 (2 × CH3,
C-7′′′ and C-8′′′), 28.2 (2 × CH3, C-7′′ and C-8′′); HRMS-ES m/z [M
+ Na]+ 441.1317 (calcd for C25H22O6Na 441.1314).
Eriosemaone D (2). Compound 4 (10 mg, 0.023 mmol) was
debenzylated under similar conditions to those applied for 1, and the
product was purified on a chromatotron to give 2 as a yellow solid (6
mg, 75%): 1H NMR (CDCl3, 400 MHz) δ 12.32 (1H, s, OH-5), 8.21
(1H, brs, OH-7 or OH-2), 7.96 (1H, s, H-2), 6.76 (1H, s, H-6′), 6.53
(1H, s, H-3′), 6.44 (1H, d, J ) 2.3 Hz, H-8), 6.37 (1H, d, J ) 2.3 Hz,
H-6), 6.27 (1H, d, J ) 9.8 Hz, H-4′′), 5.53 (1H, d, J ) 9.8 Hz, H-5′′),
1.44 (6H, s, H-7′′ and H-8′′); LRMS-ES m/z [M - H]+ 351.0.
4-Methoxymethoxy-1-iodobenzene (21). AcCl (1.94 mL, 27.27
mmol) was added dropwise to the stirred solution of dimethoxymethane
(2.40 mL, 27.27 mmol) and catalytic ZnBr2 under N2. The solution
was stirred for an additional 2 h at room temperature and transferred
via a cannula to an ice-cold solution of 4-iodophenol (2.0 g, 9.09 mmol)
and DIA (4.16 mL, 27.27 mmol) in CH2Cl2 (100 mL) under an N2
atmosphere. The mixture was stirred for 4 h, diluted with saturated
NH4Cl solution (40 mL), and stirred for an additional 15 min. The two
phases were partitioned, and the aqueous phase was extracted with
CH2Cl2 (2 × 30 mL). The combined organic extracts were washed
with brine (3 × 100 mL) and dried over anhydrous MgSO4. The solvent
was evaporated, and the product was purified with column chroma-
tography using Hex/EtOAc (8:2) to afford 21 as a colorless oil (1.8 g,
75%): IR (neat) νmax 2954, 2901, 2825, 1585, 1483, 1231, 1147, 987,
818 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.56 (2H, d, J ) 9.0 Hz,
H-2 and H-6), 6.82 (2H, d, J ) 9.0 Hz, H-3 and H-5), 5.14 (2H, s,
OCH2O), 3.46 (3H, OCH3); 13C NMR (CDCl3, 100 MHz) δ 157.0 (C,
C-4), 138.2 (CH, C-2 and C-6), 118.5 (CH, C-3 and C-5), 94.3 (CH2,
OCH2O), 84.3 (C, C-1), 55.9 (CH3, OCH3).
4-Methoxymethoxyphenylboronic acid (22). Triisopropyl borate
(2.21 mL, 9.47 mmol) was added in one portion to the stirred solution
of iodobenzene 21 (1.0 g, 3.79 mmol) in THF/Et2O (60 mL, 1:2) under
N2. The solution was cooled to -100 °C using a liquid N2 and CH3OH
bath, and then n-BuLi (3.79 mL of a 1.5 M solution in hexanes) was
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added with stirring over 5 min. After 1 h of stirring at a temperature
below -78 °C, a saturated NH4Cl (30 mL) solution was added. The
mixture was stirred for an additional 1 h, and the two phases were
partitioned. The aqueous phase was extracted with Et2O (2 × 20 mL).
The organic phases were combined, washed with H2O (40 mL) and
brine (40 mL), and dried over anhydrous MgSO4. The solvent was
evaporated to give a white solid, which was subjected to column
chromatography using Hex/EtOAc (4:1) as the mobile phase. The
solvent was evaporated to give boronic acid 22 as a white solid (0.59
g, 85%): IR (KBr) νmax 3436, 3359, 1651, 1606, 1235, 1016, 773 cm-1;
1H NMR (CDCl3, 400 MHz) δ 8.16 (2H, d, J ) 8.6 Hz, H-2 and H-6),
7.15 (2H, d, J ) 8.6 Hz, H-3 and H-5), 5.27 (2H, s, OCH2O), 3.52
(3H, OCH3); 13C NMR (CDCl3, 100 MHz) δ 160.9 (C, C-4), 137.5
(CH, C-2 and C-6), 115.6 (CH, C-3 and C-5), 94.1 (CH2, OCH2O),
56.1 (CH3, OCH3) (C-1 signal not observed); 11B NMR (128 MHz,
CDCl3) δ 28.52.
Genistein (3). 4-Methoxymethoxyphenylboronic acid (22) (42 mg,
0.23 mmol), K2CO3 (51 mg, 0.37 mmol), and catalytic 10% Pd/C were
added to a solution of 3-iodochromone 5 (50 mg, 0.13 mmol) in DME
(2 mL) and H2O (2 mL). The resulting mixture was stirred at 40-45
°C for 12 h. The catalyst was filtered and washed with H2O and Et2O.
The organic solvents were evaporated, and the crude product was diluted
in CH3OH (10 mL) and HCl (3 M, 5 mL). The resulting solution was
refluxed for 30 min. CH3OH was evaporated, and the aqueous phase
was extracted with EtOAc (3 × 15 mL). The combined organic layers
were washed with H2O (30 mL) and brine (30 mL) and dried over
anhydrous MgSO4. The solvent was evaporated, and the crude product
was purified by column chromatography using Hex/EtOAc (3:2) and
recrystallized from EtOH to give the isoflavone 3 as a yellow solid
(23 mg, 66%): mp 300-303 °C (lit.33 301-302 °C); IR (KBr) νmax
3434, 3181, 3069, 2922, 1652, 1621, 1176, 809, 784 cm-1; 1H NMR
(DMSO-d6, 400 MHz) δ 12.93 (1H, s, OH-5), 9.65 (1H, brs, OH-4′),
8.29 (1H, s, H-2), 7.36 (2H, d, J ) 8.8 Hz, H-2′ and H-6′), 6.81 (2H,
d, J ) 8.8 Hz, H-3′ and H-5′), 6.38 (1H, d, J ) 2.1 Hz, H-6), 6.22
(1H, d, J ) 2.1 Hz, H-8); 13C NMR (DMSO-d6, 100 MHz,) δ 182.3
(C, C-4), 166.0 (C, C-7), 163.9 (C, C-5), 159.8 (C, C-4′), 158.9 (C,
C-8a), 154.8 (CH, C-2), 131.2 (CH, C-2′ and C-6′), 124.8 (C, C-1′),
123.3 (C, C-3), 116.8 (CH, C-3′ and C-5′), 106.3 (C, C-4a), 100.1 (CH,
C-6), 94.8 (CH, C-8); HRMS-ES (m/z) [M - H]- 269.0452 (calcd for
C15H9O5 269.0450).
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The pyranocoumaronochromone lupinalbin H was synthesized in three major steps, which involved
preparation of 20-hydroxygenistein by the SuzukieMiyaura reaction, followed by oxidative cyclo-
dehydrogenation into lupinalbin A. The final step was the regiospecific introduction of the dimethylpyran
moiety to ring A of lupinalbin A via an aldol-type condensation with 3-methyl-2-butenal and 6p-
electrocyclization.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
Coumaronochromones are a subclass of isoflavonoids with gen-
eral structure1.1 They have been isolated fromdifferent plant genera,
mostlyof the Leguminosae,1e5 althougha fewcoumaronochromones
have been reported from non-leguminous plants.6e8 The striking
feature of most naturally-occurring coumaronochromones is the
presence of prenyl side chains, which in most instances are cyclized
to adjacent hydroxy groups to give pyrano or furano rings.1e3,5,7,9,10
Most pyranocoumaronochromones exhibit important biological ac-
tivities, such as anthelminthic, oestrogenic, neuroprotective, anti-
platelet aggregation, anti-HIV, immunosuppressive activities as well
as cytotoxicity against certain cancer cell lines.2,3,5,9e13 Despite their
biological importance, the synthesis of these compounds has re-
ceived little attention. Methods, which have been employed for the
synthesis of the coumaronochromone nucleus are photochemical
contraction of rotenoids and oxidative cyclization of 20-hydroxyiso-
flavones, the latter being the strategy employed mostly.14e16 The
dimethylpyran scaffold, on the other hand, can be accessed via sev-
eral synthetic approaches, which involve cycloaddition reactions of
C-prenylated phenols, aldol-type condensation of phenols with
prenal (3-methyl-2-butenal) or prenal acetal, dehydration of chro-
manols, HarfenisteThom rearrangement of propargyl ethers and
one-pot Wittig reactions of o-naphthoquinones with allyl-
triphenylphosphonium salts and subsequent electrocyclization.17e20x: þ27 33 2605009; e-mail
All rights reserved.Despite the numerous synthetic procedures that have been de-
veloped for the dimethylpyran moiety, the regioselective in-
troduction of the dimethylpyran system to the synthetic precursors




























In continuation of our studies on the regioselective synthesis of
pyranoisoflavonoids,21 the present paper reports the first total
synthesis of lupinalbin H (2) and confirmation of its structure on
the basis of 1D and 2D NMR techniques. Lupinalbin H (2) was iso-
lated together with other flavonoids from the methanolic extract of
the roots of yellow lupin (Lupinus luteus cv Topaz) by Tahara et al.22
The assignment of the structure of 2 was based mainly on com-
parison of its 1H NMR signals with those of related compounds and
the 13C NMR data was not reported. Furthermore, the other flavo-
noids isolated along with it were reported to exhibit antifungal
activity; however, 2 was not assayed for its activity. The lack of
detailed structural characterization and bioactivity studies of
lupinalbin H (2) can be attributed to the low quantity obtained from
M.A. Selepe et al. / Tetrahedron 67 (2011) 8654e8658 8655the plant source.22 Therefore, our aim was to develop a synthetic
route that can readily give access to 2 in a good yield, to confirm its
structure unambiguously and provide material for future biological
studies.
With this synthesis we hope to demonstrate the usefulness of
the SuzukieMiyaura reaction in the synthesis of isoflavonoids.
Previous methods for the synthesis of this class of compounds were
based mainly on chalcones and deoxybenzoins as in-
termediates.14,16 However, the chalcone route depends on the use
of the highly toxic thallium trinitrate whereas the deoxybenzoin
route employs harsh reaction conditions.Table 1
Preparation of aryl iodide 9 by iodination of 8 with I2 and silver saltsa
Silver salt Solvent Time (h) Yieldsb (%)
AgNO3 CHCl3 5 402. Results and discussion
Scheme 1 shows the retrosynthetic analysis of lupinalbin H (2).
Lupinalbin H (2) was planned to be synthesized by the regiospecific
condensation of lupinalbin A (3)23,24 with prenal. Compound 3
could be prepared by oxidative cyclization of 20-hydroxygenistein
(4),25,26 which could readily be accessed by the SuzukieMiyaura
reaction of 3-iodochromone 521 and boronic acid 6.27 The synthesis
of the penultimate precursor 3 from 20-hydroxyisoflavones has
been reported previously.14,16 However, the former syntheses were
based on the deoxybenzoin and the chalcone routes for the con-























Scheme 1. Retrosynthetic analysis of lupinalbin H (2).
Ag2SO4c CHCl3 5 35
AgNO3 EtOH 1 62
Ag2SO4c EtOH 1 58
CH3CO2Ag CHCl3 5 95
a Silver salt (1.2 equiv), 1.1 equiv I2.
b Isolated yields.
c Ag2SO4 (0.6 equiv), 1.1 equiv I2.The synthesis of intermediate 5 was described in a previous
paper.21 Vasselin et al.28 reported that with the widely used benzyl











Scheme 2. Synthesis oprepared and therefore we opted for methoxymethyl as protecting
group in the synthesis of 5. Boronic acid 627 was prepared from
commercially available resorcinol (7), as illustrated in Scheme 2.
Protection of 7 with MOMCl, prepared in situ from the readily
available dimethoxymethane and acetyl chloride,29 rendered
methoxymethyl ether 8 (60%),30 which was regioselectively io-
dinated at C-4 by I2 in the presence of CH3CO2Ag to give an aryl
iodide 9 in 95% yield.31 In our previous investigation, we dem-
onstrated the successful regioselective iodination of a chromanone
containing resorcinol moiety using CF3CO2Ag and I2.21 CH3CO2Ag
gave comparable results in the present case. Other readily avail-
able silver salts (AgNO3 and Ag2SO4) were tested for C-4 iodination
of 8, but rendered 9 in low yields when CHCl3 was used as the
solvent and in moderate yields in EtOH (Table 1).32,33 The aryl
iodide 9 was converted into boronic acid 6 by lithiumeiodine
exchange, followed by immediate in situ nucleophilic attack of the
generated aryl lithium species on triisopropyl borate and hydro-
lysis of the resulting boronate ester with NH4Cl in a one-pot
reaction.34,35Having successfully synthesized the boronic acid 6, the next step
involved coupling of 6 with 3-iodochromone 521 in the presence of
10% Pd(C) to give an isoflavone 10 (Scheme 3).36 Cleavage of the
MOM protecting groups of 10 under acidic conditions and sub-
sequent oxidation of 20-hydroxygenistein (4) with DDQ afforded
the phytoestrogen lupinalbin A (3)16 in a 66% yield.14 The last step
was regioselective introduction of the dimethylpyran scaffold to
the phloroglucinol moiety of lupinalbin A (3) to give lupinalbin H
(2). This was planned to be achieved by base-catalyzed coupling of
3 with prenal, which proceeds via aldol-type reaction and 6p-
electrocylization.18 Thus, treatment of the methanolic solution of 3
with Ca(OH)2 and prenal (2.5 equiv) rendered lupinalbin H (2) in
40% yield and 35% of 3was recovered.37 Addition of a large excess of
prenal (5 equiv) effected complete consumption of 3 as observed on
TLC but required tedious chromatographic isolation of the targeted
product from the reaction mixture due to side products resulting
from the polymerization of prenal.
Lupinalbin A (3) has four nucleophilic sites at positions 6, 8, 30
and 50, which can condense with prenal to give multiple products.
As anticipated, the reaction favoured the more nucleophilic
phloroglucinol moiety (ring A) rather than the resorcinol moiety
(ring B). Nevertheless, three possible regioisomers can result from
condensation of prenal with ring A of 3, i.e., the targeted linear
isomer 2 and two angular isomers 11 and 12. From the 1H NMR
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Scheme 3. Total synthesis of lupinalbin H (2).
M.A. Selepe et al. / Tetrahedron 67 (2011) 8654e86588656formed due to the appearance of a signal characteristic for a hy-
drogen-bonded OH at dH 13.38 (1H, OH-5). Furthermore, in the
1H NMR spectrum was present four aromatic protons, which gave
an ABX spin system for ring B protons at dH 7.82 (1H, d, J¼8.3 Hz,
H-60), 7.14 (1H, d, J¼2.0 Hz, H-30), 7.02 (1H, dd, J¼2.0 and 8.3 Hz, H-
50),and a one-proton singlet for the ring A proton at dH 6.54 (H-8).
The dimethylpyran protons displayed a singlet integrating for six
protons at dH 1.48 (2 CH3) and two one-proton doublets for the
olefinic protons at dH 6.70 (J¼10.0 Hz, H-400) and 5.79 (1H, d,
J¼10.0 Hz, H-500). These 1H NMR results were in agreement with
those reported in the literature for 2.22 The 13C NMR spectrum
displayed 19 carbon resonances, which were identified as two
methyl carbons overlapping at dC 27.3, six methine carbons at dc
128.6, 121.3, 114.6, 113.6, 98.5 and 95.3 and 12 quaternary carbons
at dC 178.6, 164.7, 158.5, 157.0, 156.4, 154.0, 150.4, 114.0, 105.9,
104.0, 97.5 and 80.0 by DEPT and HSQC experiments. From the
HMBC spectrum, the olefinic proton at dH 6.70 (H-400) displayed
correlations to carbon signals at dC 80.0 (C, C-600), 105.9 (C, C-6),
157.0 (C, C-5) and 158.5 (C, C-7) and the aromatic proton at dH 6.54
(H-8) showed connections to carbon resonances at dC 104.0 (C, C-
4a), 105.9 (C, C-6), 154.0 (C, C-8a) and 158.5 (C, C-7) (Fig. 1). From
these correlations, it was confirmed that the dimethylpyran ring
was attached to C-6 and OH-7, giving the targeted product 2 and
not the angular isomer 11. The assignments of the quaternary
carbons on ring B were also based on HMBC correlations. The
proton at dH 7.82 (H-60) displayed correlations to carbon signals at
dC 97.5 (C, C-3), 150.4 (C, C-20) and 156.4 (C, C-40), whereas H-50 (dH
7.02) showed correlations to carbons at dC 114.0 (C, C-10) and 156.4
(C, C-40), and the proton at dH 7.14 (H-30) showed correlations to
signals at dC 114.0 (C, C-10), 150.4 (C, C-20) and 156.4 (C, C-40)
(Fig. 1). The structure of 2 was confirmed by HRMS-ESI, which
gave an m/z peak of 349.0710 [MH], in agreement with the










































In conclusion, lupinalbin H (2) has been successfully synthesized
by a highly convergent route. The synthesis featured the Suzu-
kieMiyaura coupling reaction for the construction of the isoflavone
nucleus in good yields, and a highly regioselective introduction of
the dimethylpyran scaffold to the coumaronochromone core. Fur-
thermore, it gave access to other naturally-occurring phytoes-
trogens, 20-hydroxygenistein (4) and lupinabin A (3). Owing to the
potential pharmacological properties of the pyranocoumar-
onochromones, the development of the practical synthetic route
described herein for lupinalbin H (2) represents a significant ad-
vance towards the synthesis of other structurally related com-
pounds and exploration of their biological properties.
4. Experimental procedures
4.1. General
All moisture-sensitive reactions were performed using dried
anhydrous solvents in oven-dried glassware under an atmosphere
of N2. Hexanes (Hex) used for chromatographic purifications was
distilled prior to use. Reactions were monitored by TLC, performed
on silica gel plates (60 F254) and visualized under UV light. Alter-
natively, detection of spots on the TLC was achieved by heating
with a heat gun after treatment with a solution of anisaldehyde in
concentrated H2SO4 and EtOH prepared in volume ratios 1:1:18,
respectively. Column chromatographic purifications were effected
using silica gel (60 Ǻ, 230e400 mesh). Centrifugal chromatogra-
phy (chromatotron) was performed on glass plates coated with
silica gel with particle size 0.040e0.063 mm, 2e4 mm thick. 1H,
11B, 13C NMR spectra were recorded on 400 or 500 MHz spec-
trometer. DEPT and 2D NMR (COSY, HSQC and HMBC) were used
for assignments of individual protons and carbons resonances. 11B
NMR spectra were referenced against an external standard of neat
BF3.OEt2 containing a capillary tube of acetone-d6 for deuterium
M.A. Selepe et al. / Tetrahedron 67 (2011) 8654e8658 8657lock. The chemical shifts from 1H NMR and 13C NMR spectra are
reported in parts per million relative to the residual protonated or
deuterated solvents peaks (CDCl3: dH 7.26, dc 77.0; CD3OD: dH 3.31,
dc 49.0 and acetone-d6: dH 2.05, dc 205.1). The mass spectra were
recorded on a time-of-flight mass spectrometer using electrospray
ionisation in the positive or negative mode. IR spectra were
recorded with FT-IR spectrophotometer.
4.2. Synthesis
4.2.1. 1,3-Dimethoxymethoxybenzene (8)30. Catalytic ZnBr2 was
dissolved in dimethoxymethane (16.0 mL, 0.182 mol) under nitro-
gen atmosphere, and then acetyl chloride (12.9 mL, 0.182 mol) was
added dropwise to the stirred solution. The solution was stirred for
an additional 2 h at rt then transferred via a cannula to the ice-cold
solution of resorcinol (7) (5.00 g, 45.4 mmol) and (i-Pr)2EtN
(23.3 mL, 0.136 mol) in CH2Cl2 (100 mL) under a nitrogen atmo-
sphere. The mixture was stirred for 3 h, diluted with saturated
NH4Cl solution and stirred for an additional 15 min. The two phases
were partitioned and the aqueous phasewas extractedwith CH2Cl2.
The combined organic extracts were washed with brine and dried
over anhydrous MgSO4. The solvent was evaporated to give a yel-
low oil, which was purified by column chromatography using Hex/
EtOAc (9:1) to give 8 as a colorless oil (5.4 g, 60%): IR (neat) nmax
2955, 2902, 2827, 1768, 1591, 1487, 1219, 1138, 1004, 772 cm1; 1H
NMR (CDCl3, 400 MHz) d 7.19 (1H, t, J¼8.3 Hz, H-5), 6.75 (1H, t,
J¼2.3 Hz, H-2), 6.71 (2H, dd, J¼2.3 and 8.3 Hz, H-4 and H-6), 5.16
(4H, s, 2 OCH2O), 3.48 (6H, s, 2 OCH3); 13C NMR (CDCl3,
100MHz) d 158.3 (2 C, C-1 and C-3), 129.9 (CH, C-5), 109.6 (2 CH,
C-4 and C-6), 105.0 (CH, C-2), 94.5 (2 OCH2O), 55.9 (2 OCH3);
LRMS-ESI m/z [M]þ 198.1.
4.2.2. 1-Iodo-2,4-dimethoxymethoxybenzene (9). CH3CO2Ag (5.10 g,
30.3 mmol) was added to a solution of 8 (5.00 g, 25.2 mmol) in
CHCl3 (50 mL). The mixture was stirred for 5 min, and then a so-
lution of I2 (7.04 g, 27.7 mmol) in CHCl3 (150 mL) was added
dropwise to the stirred suspension. The resulting mixture was
stirred at rt for 5 h and filtered to remove the AgI. The filtrate was
washed with 10% Na2S2O3 solution, 5% NaHCO3 solution, H2O and
brine. The organic phase was dried over anhydrous MgSO4 and the
solvent evaporated to give a colourless oil. The oil was purified by
flash chromatography using Hex/EtOAc (9:1) to afford the iodin-
ated compound 9 as a colorless oil (7.76 g, 95%): IR (neat) nmax
2956, 2902, 2826, 1716, 1577, 1567, 1474, 1219, 1149, 982,
772 cm1; 1H NMR (CDCl3, 400 MHz) d 7.62 (1H, d, J¼8.5 Hz, H-6),
6.80 (1H, d, J¼2.5 Hz, H-3), 6.53 (1H, dd, J¼2.5 and 8.5 Hz, H-5),
5.21 (2H, s, OCH2O), 5.13 (2H, s, OCH2O), 3.50 (3H, s, OCH3), 3.46
(3H, s, OCH3); 13C NMR (CDCl3, 100 MHz) d 158.7 (C, C-4), 156.7 (C,
C-2), 139.2 (CH, C-6), 111.4 (CH, C-5), 104.4 (CH, C-3), 95.0 (CH2,
OCH2O), 94.5 (CH2, OCH2O), 77.4 (C, C-1), 56.4 (CH3, OCH3), 56.0
(CH3, OCH3); HRMS-ESI m/z [MþNa]þ calcd for C10H13INaO4
346.9756, found 346.9754.
4.2.3. 2,4-Dimethoxymethoxyphenylboronic acid (6)27. Triisopropyl
borate (10.7 mL, 46.3 mmol) was added to the stirred solution of
aryl iodide 9 (5.00 g, 15.4 mmol) in THF/Et2O (1:2, 100 mL) under
N2. The solution was cooled to 100 C using liquid N2 and CH3OH
bath, and then n-BuLi (14.5 mL of a 1.6 M solution in hexanes,
23.2 mmol) was added slowly with stirring. After 1 h of stirring at
the temperature below 78 C, saturated NH4Cl solution was
added. The solution was stirred for an additional 1 h at rt and the
two phases partitioned. The aqueous phase was extracted with
Et2O. The combined organic phases were washed with H2O and
brine, and dried over anhydrous MgSO4. The solvent was evapo-
rated under reduced pressure to give an orange oil. Purification of
the oil by column chromatography (8:2 Hex/EtOAc) andevaporation of the solvent afforded the boronic acid 6 as an orange
soild (2.76 g, 74%): IR (neat) nmax 3385, 2957, 1726, 1603, 1142,
993 cm1; 1H NMR (CDCl3, 400 MHz) d 7.79 (1H, d, J¼8.4 Hz, H-6),
6.80 (1H, d, J¼2.0 Hz, H-3), 6.76 (1H, dd, J¼2.0 and 8.4 Hz, H-5),
6.68 (2H, br s, B(OH)2), 5.27 (2H, s, OCH2O), 5.19 (2H, s, OCH2O),
3.50 (3H, s, OCH3), 3.47 (3H, s, OCH3); 13C NMR (CDCl3, 100 MHz)
d 163.5 (C, C-2), 160.9 (C, C-4), 137.8 (CH, C-6), 109.3 (CH, C-5),
102.1 (CH, C-3), 94.6 (OCH2O), 94.0 (OCH2O), 56.4 (OCH3), 56.0
(OCH3), (C-1 signal not observed); 11B NMR (CDCl3, 128 MHz) dB
28.55.
4.2.4. 20,40,5,7-Tetramethoxymethoxyisoflavone (10). To a solution of
3-iodochromone 5 (1.20 g, 3.06 mmol) in 1:1 DME/H2O (50 mL)
were added 10% Pd/C (0.160 g, 5 mol %), Na2CO3 (0.970 g,
9.18 mmol) and phenylboronic acid 6 (1.11 g, 4.59 mmol). The
resulting mixture was stirred at 40e45 C overnight. The catalyst
was filtered and washed with water and EtOAc. The aqueous phase
was extracted with EtOAc, and the combined organic layers were
washed with water, brine and dried over anhydrous MgSO4. The
solvent was evaporated and the crude product was purified by silica
gel column chromatography using Hex/EtOAc (7:3) to afford an
isoflavone 10 (1.1 g, 78%) as a yellow oil: IR (neat) nmax 2905, 2828,
1647, 1609, 1570, 1256, 1150, 999, 918 cm1; 1H NMR (CDCl3,
400MHz) d 7.75 (1H, s, H-2), 7.22 (1H, d, J¼8.5 Hz, H-60), 6.88 (1H, d,
J¼2.3 Hz, H-30), 6.76e6.72 (3H, m, H-6, H-8, H-50), 5.27 (2H, s,
OCH2O), 5.23 (2H, s, OCH2O), 5.17 (2H, s, OCH2O), 5.10 (2H, s,
OCH2O), 3.52 (3H, s, OCH3), 3.50 (3H, s, OCH3), 3.47 (3H, s, OCH3),
3.41 (3H, s, OCH3); 13C NMR (CDCl3, 100 MHz) d 174.9 (C, C-4), 160.9
(C, C-7), 159.4 (C, C-8a), 158.5 (C, C-5), 158.4 (C, C-40), 156.2 (C, C-20),
151.8 (CH, C-2), 132.4 (CH, C-60), 123.1 (C, C-3), 115.5 (C, C-10), 111.5
(C, C-4a), 108.9 (CH, C-50), 104.1 (CH, C-30), 102.4 (CH, C-6), 97.3 (CH,
C-8), 95.8 (CH2, OCH2O), 95.1 (CH2, OCH2O), 94.5 (CH2, OCH2O), 94.3
(CH2, OCH2O), 56.5 (CH3, OCH3), 56.4 (CH3, OCH3), 56.1 (CH3, OCH3),
56.0 (CH3, OCH3); HRMS-ESI m/z [MþNa]þ calcd for C23H26NaO10
485.1424, found 485.1415.
4.2.5. 20,40,5,7-Tetrahydroxyisoflavone (4)25,26. HCl (3 M, 15 mL)
was added to a solution of 10 (1.00 g, 2.16 mmol) in CH3OH
(30 mL) and stirred at 50 C for 12 h. CH3OH was evaporated and
the reaction mixture was extracted with EtOAc. The combined
organic phases were washed with H2O and brine. The organic
layer was dried over anhydrous MgSO4 and the solvent evaporated
under reduced pressure to give a yellow solid. Purification of the
solid by column chromatography using Hex/EtOAc (1:1) afforded 4
as a pale yellow solid (0.45 g, 73%): recrystallization of 4 from Hex/
EtOAc (1:4) gave pale yellow needles. Mp 268.4e270.1 C (lit.26
mp 272.0 C); IR (neat) nmax 3319, 1652, 1613, 1502, 1254,
1171 cm1; 1H NMR (CD3OD, 400 MHz) d 8.00 (1H, s, H-2), 7.04
(1H, d, J¼8.2 Hz, H-60), 6.40 (1H, d, J¼2.3 Hz, H-30), 6.37 (1H, dd,
J¼2.3 and 8.2 Hz, H-50), 6.36 (1H, d, J¼2.3 Hz, H-8), 6.23 (1H, d,
J¼2.3 Hz, H-6); 13C NMR (CD3OD, 100 MHz) d 182.7 (C, C-4), 166.2
(C, C-7), 163.7 (C, C-5), 160.2 (C, C-40), 159.8 (C, C-8a), 157.8 (C, C-
20), 156.7 (CH, C-2), 133.2 (CH, C-60), 122.6 (C, C-3), 110.9 (C, C-10),
108.2 (CH, C-50), 106.2 (C, C-4a), 104.4 (CH, C-30), 100.3 (CH, C-6),
94.9 (CH, C-8), HRMS-ESI m/z [MH] calcd for C15H9O6 285.0399,
found 285.0399.
4.2.6. Lupinalbin A (3)23. DDQ (79.0 mg, 0.349 mmol) was added
under N2 to a solution of 4 (100 mg, 0.35mmol) in THF (20mL). The
reaction mixture was heated to 60 C with stirring for 15 min.
Additional DDQ (79.0 mg, 0.349 mmol) was added to the mixture
and stirringwas continued at the same temperature for 30min. The
solvent was evaporated and the crude mixture purified by column
chromatography using Hex/EtOAc as eluent to give coumar-
onochromone 3 (66 mg, 66%) as a white solid: 3 was recrystallized
from Hex/EtOAc (1:4) to afford white needle-like crystals, which
M.A. Selepe et al. / Tetrahedron 67 (2011) 8654e86588658decomposed at 278.4e280.0 C (lit.14 mp >300 C); IR (neat) nmax
3327, 3101, 2922, 1622, 1436, 1029, 822 cm1; 1H NMR (CD3OD,
400 MHz) d 7.75 (1H, d, J¼8.4 Hz, H-60), 6.99 (1H, d, J¼1.9 Hz, H-30),
6.89 (1H, dd, J¼1.9 and 8.4 Hz, H-50), 6.46 (1H, d, J¼2.0 Hz, H-8),
6.27 (1H, d, J¼2.0 Hz, H-6); 13C NMR (CD3OD, 100 MHz) d 180.0 (C,
C-4),166.2 (C, C-2),165.2 (C, C-7),164.0 (C, C-5),157.8 (C, C-40),156.6
(C, C-8a), 151.9 (C, C-20), 122.5 (CH, C-60), 115.2 (CH, C-50), 114.7 (C, C-
10), 104.5 (C, C-4a), 100.9 (CH, C-6), 99.5 (C, C-3), 98.7 (CH, C-30),
95.8 (CH, C-8); HRMS-ESI m/z [MH] calcd for C15H7O6 283.0243,
found 283.0239.
4.2.7. Lupinalbin H (2)22. To a solution of 3 (40.0 mg, 0.141 mmol)
in CH3OH (15 mL) was added Ca(OH)2 (21.0 mg, 0.282 mmol) fol-
lowed by prenal (0.03 mL, 0.353 mmol). The mixture was stirred
under an N2 atmosphere for 3 days at rt. CH3OH was evaporated
and the reaction mixture was diluted with EtOAc and 1 M HCl. The
two phases were partitioned and the aqueous phase was back-
extracted with EtOAc. The combined organic extracts were
washed with H2O and brine and dried over anhydrous MgSO4. The
solvent was evaporated and the crude product purified by column
chromatography using Hex/EtOAc/acetone (6:1:1), followed by
centrifugal chromatography using CH2Cl2 to give 2 as a creamwhite
solid (20 mg, 40%) and lupinalbin A (3) (14 mg, 35%) was recovered.
Recrystalization of 2 from CH3OH gave creamwhite crystals, which
decomposed at 245.5e247.2 C (lit.22 mp 248e250 C); IR (neat)
nmax 3501, 3230, 2923, 2853, 1729, 1640, 1594, 1456, 1393, 1116,
811 cm1; 1H NMR (acetone-d6, 500 MHz) d 13.38 (1H, s, OH-5),
8.98 (1H, br s, OH-40), 7.82 (1H, d, J¼8.3 Hz, H-60), 7.14 (1H, d,
J¼2.0 Hz, H-30), 7.02 (1H, dd, J¼2.0 and 8.3 Hz, H-50), 6.70 (1H, d,
J¼10.0 Hz, H-400), 6.54 (1H, s, H-8), 5.79 (1H, d, J¼10.0 Hz, H-500), 1.48
(6H, s, H-700 and H-800); 13C NMR (acetone-d6, 125 MHz) d 178.6 (C,
C-4),164.7 (C, C-2),158.5 (C, C-7),157.0 (C, C-5),156.4 (C, C-40), 154.0
(C, C-8a), 150.4 (C, C-20), 128.6 (CH, C-500), 121.3 (CH, C-60), 114.6 (CH,
C-400), 114.0 (C, C-10), 113.6 (CH, C-50), 105.9 (C, C-6), 104.0 (C, C-4a),
98.5 (CH, C-30), 97.5 (C, C-3), 95.3 (CH, C-8), 80.0 (C, C-600), 27.3 (2
CH3, C-700 and C-800); HRMS-ESI m/z [MH] calcd for C20H13O6
349.0712, found 349.0710.
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